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7I. Introduction  
1. Physiopathologie d’otospongiose 
L'otospongiose est une dystrophie osseuse limitée à la capsule otique et responsable de 
surdité. Cette surdité est d'abord une surdité de transmission (mécanique, liée au blocage de 
l'étrier empêchant ainsi la progression de l'onde sonore vers la cochlée et  les cellules 
sensorielles). Elle évolue par la suite vers une surdité mixte avec une composante 
neurosensorielle liée à l'atteinte de l'oreille interne. Les foyers d’otospongiose sont composés 
de zones actives hypercellulaires et basophiles avec des signes d’inflammation et des foyers 
de résorption osseuse appelées otospongiose, et des zones inactives ou cicatricielles denses et 
peu cellulaires appelées également otosclérose. Les zones d’otospongiose et  d’otosclérose 
sont juxtaposées au sein d’un même tissu avec une disposition en mosaïque.  Dans les zones 
actives, il existe de nombreux ostéoclastes multi-nucléés, cellules ostéocytes et la 
prolifération des cellules endothéliales dans les espaces pseudo vasculaire des foyers actifs 
otospongiose. Généralement, CD8+, les lymphocytes T cytotoxiques et des ostéoclastes 
activés se trouvent dans la zone périphérique des foyers actifs. Des études antérieures ont 
suggéré différents types de cytokines pro inflammatoires jouent un rôle dans la 
physiopathologie de l'otospongiose. Plusieurs facteurs étiologiques ont été évoqués pour 
expliquer le déséquilibre de la résorption/formation osseuse: auto-immunité, micro-
organismes (virus de la rougeole), facteurs génétiques et hormonaux (incidence plus élevée 
chez la femme et  aggravation au décours des grossesses). Le traitement de l'otospongiose 
repose sur la correction de la surdité par la prothèse auditive ou par le remplacement 
chirurgical de l'étrier atteint, aucun traitement étiologique ne peut être proposé. L'utilisation 
de fluor ou, plus récemment des biphosphonates (inhibiteurs de l'activité ostéoclastique) a été 
proposée afin de ralentir l'évolution de la maladie. Aujourd'hui, le traitement chirurgical 
8(platinotomie calibrée au laser) reste la meilleure option de traitement pour otospongiose. 
L'otospongiose est essentiellement une maladie touchant les caucasiens et fortement liée à 
leur répartition géographique dans le monde. Sa prévalence est estimée à 0,3%. L'âge moyen 
au moment du diagnostic est de 33 ans. Des rapports récents montrent un passage de cet âge à 
40-50 ans. Le sexe ratio (hommes/femmes) est  de 1:2 et il a été signalé que la progression de 
l’otospongiose serait plus rapide chez les femmes que les hommes. Environ 60% des patients 
ont des antécédents familiaux d'otospongiose. Les 40% restants sont soit des cas liés à une 
transmission autosomique dominante avec absence pénétrance chez les autres membres de la 
famille, soit de nouvelles mutations, ou enfin des cas ou les cas familiaux existant n’ont pas 
été détectés.
2. Le système rénine-angiotensine-aldostérone 
Le système rénine-angiotensine-aldostérone (SRAA) est un régulateur physiologique majeur 
de la pression artérielle et de l'équilibre hydro-électrolytique. Ce système est  également 
considéré non seulement comme un système endocrinien, mais aussi comme un modulateur 
autocrine / paracrine des fonctions tissulaires de différents organes comme le cœur, les 
vaisseaux sanguins, le rein, le cerveau et les glandes endocrines. Il y a trois éléments 
importants de ce système: 1) la rénine, 2) l'angiotensine, et 3) l'aldostérone. Néanmoins, 
l'angiotensine II (Ang II) est à plusieurs titres l’agent central du SRAA. 
Ang II qui est un octa-peptide bioactif, joue un rôle clé dans la régulation de l'homéostasie 
cardiovasculaire. Ang II peut également fonctionner comme une hormone paracrine/autocrine 
induisant la croissance et la prolifération cellulaire. Les études pharmacologiques ont montré 
plusieurs types de récepteurs de l’Ang II. Des récepteurs de type 1 (AT1) régulent deux voies 
de signalisations distinctes qui impliquent des protéines G. Une des voies implique 
l'activation de la phospholipase C et la production de l'inositol 1,4,5-triphosphate, et l'autre 
9voie concerne la régulation d'AMPc via l'activation ou l'inhibition de l'adénylate-cyclase. La 
voie de signalisation des récepteurs de type 2 (AT2) reste à être élucidée. Plus récemment, le 
type 4 (AT4) a été décrit dans le système nerveux central. Ce récepteur semble être impliqué 
dans l'acquisition et la mémoire. 
La plupart des effets connus de l'Ang II sont médiés par le récepteur AT1. Des études in vitro 
et in vivo suggèrent que le récepteur AT2 a un effet antagoniste sur AT1. L’activation de l’AT2 
entraîne une inactivation des MAPK, a un effet anti-prolifératif, favorise l'apoptose, la 
différenciation cellulaire, la régénération, l'ouverture de canaux K + lents et la fermeture des 
canaux de Ca2 + de type T. Ce récepteur AT2 est exprimé dans les tissus cibles dans diverses 
maladies et semble donc impliqué dans leur physiolpâthologie. Comme le récepteur AT2, le 
récepteur AT4 s'oppose également aux effets déclenchés par l’activation du récepteur AT1. 
Il existe des antagonistes non peptidiques des récepteurs AT1 (Sartans) et AT2 (PD123317 et 
PD123319). 
Ang II active plusieurs facteurs de transcription nucléaires, comprenant le récepteur et 
activateur des facteurs de transcription (STAT), protéine activatrice 1 (AP-1), NF-kB et 
l'adénosine monophosphate cyclique (AMPc) et CERB. Ang II est également connu pour 
activer la famille des protéine-kinases activées par les mitogènes (MAPK), comprenant ERK 
1/2, c-jun N-terminal kinase (JNK, également connu sous le nom SAPKs), et MAPK 
(p38MAPKs). Les MAPK sont des protéines régulatrices qui contrôlent la réponse cellulaire 
aux signaux de croissance, l'apoptose et le stress. 
L'angiotensine II est connue pour moduler le remodelage osseux. Nous avons récemment mis 
en évidence que plusieurs polymorphismes génétiques liés à une activation du SRAA 
(M235T, ACE I/D) étaient associés à l'otospongiose. Par ailleurs, l'angiotensine II stimule la 
production d’une cytokine pro-inflammatoire (interleukine 6) et diminue l'activité de la 
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phosphatase alcaline dans des cultures primaires d'os otospongieux, contrairement aux 
cultures d'étriers témoin.
3. Le stress oxydatif 
Le stress oxydatif a lieu dans les tissus sous l'effet d'agents toxiques, l'inflammation, 
l'ischémie ou un traumatisme physique. Ces situations peuvent conduire à une formation 
excessive d'espèces réactives de l'oxygène (DRO) et un déséquilibre entre la formation et 
l'élimination des DRO. Ce stress peut être provoqué dans diverses pathologies aiguës comme 
les maladies cardiovasculaires, les maladies neuro-dégénératives et les tumeurs malignes. 
Avec une quantité excessive de DRO dans l'environnement cellulaire, les lipides 
membranaires sont peroxydés et les constituants lipidiques des cellules sont endommagés. Ce 
processus aboutit  à la production d'aldéhydes très réactifs, qui sont appelés des seconds 
messagers du stress oxydatif. Contrairement aux DRO, les aldéhydes réactifs sont 
relativement stables dans le temps. Par conséquent, ils pourraient diffuser à partir du site de 
leur production et attaquer des cibles éloignées intracellulaire ou extracellulaire. Parmi de 
nombreux aldéhydes réactifs, les plus étudiés sont malondi-aldéhyde, l'acroléine et de la 
famille 4-hydroxyalkenal, en particulier le 4-hydroxynonénal (HNE). 
HNE est également considéré comme le principal produit de la peroxydation lipidique des 
acides gras polyinsaturés ω-6.
Cet aldéhyde réactif est un composant cytotoxique et mutagène, mais aussi une molécule de 
signalisation, avec possibilité de modifier la prolifération cellulaire, la différenciation et 
l'apoptose. L'importance de la HNE a été démontrée dans la physiopathologie de plusieurs 
maladies telles que celles impliquant une inflammation chronique, les maladies neuro-
dégénératives, les états d’ischémie-reperfusion, le syndrome de détresse respiratoire aiguë, 
l'athérogenèse et le diabète. HNE est également détectable dans des conditions 
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physiologiques dans de nombreux tissus humains et animaux. Son rôle physiologique reste 
encore à être clarifié, mais il est probable que HNE ait  un rôle important  dans la régulation de 
la croissance cellulaire.
Contrairement aux radicaux libres, HNE a la particularité de rester stable pendant plusieurs 
heures et se lie aux macromolécules avec une réactivité élevée, en particulier aux protéines, 
entraînant la modification de leur structure tertiaire et leur fonction. Les conjugués HNE-
protéine peuvent être détectés par des anticorps monoclonaux. HNE réagit  le plus souvent 
avec les peptides et les protéines par leurs groupes SH. Ce type de réaction entre HNE et le 
glutathion (GSH) représente le mécanisme le plus important de détoxification de cet aldéhyde 
réactif.
4. L'objectif de l'étude 
La phase active de l’otospongiose est accompagnée d’inflammation. L'origine ou le facteur 
déclenchant de cette inflammation n'est pas élucidée. La participation de microorganismes tels 
que bactéries, virus, champignons ou même le traumatisme causé par la mastication a été 
évoquée. Une autre question dans la physiopathologie de l'otospongiose est l’inflammation 
persistante pendant plusieurs années. Dans un modèle physiopathologique proposé pour le 
diabète sucré de type 1, un virus coxsackie est le facteur déclenchant de la destruction des 
îlots de Langerhans. L'inflammation est maintenue par une réaction auto-immune qui apparaît 
secondairement et  achève la destruction des tissus endocriniens. Ce modèle est une 
explication possible de l'inflammation chronique dans l'otospongiose et soutenu par plusieurs 
rapports sur la réaction auto-immune chez les patients présentant une otospongiose. 
Cependant, l'auto-immunité n'est pas constamment observée dans l’otospongiose. 
Afin d'élucider les facteurs qui peuvent participer à l'entretien de l'inflammation au cours de 
l’otospongiose, Ang II a été étudiée. En induisant ou en entretenant l'inflammation, Ang II 
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peut potentiellement induire un stress oxydatif dans l'otospongiose. Potentiellement, ce stress 
a des effets importants sur le remodelage osseux. Les DRO qui diffusent dans l'oreille interne 
pourraient également expliquer les lésions de l'oreille interne au cours de l'otospongiose. 
Le but de ce projet était d'étudier le rôle de l'Ang II et du stress oxydatif dans les os et en 
particulier dans l'otospongiose à travers 2 modèles expérimentaux : 
1  Etude de l'effet de l'Ang II sur les voies de l'inflammation dans des cultures primaires 
de cellules osseuses dans l'otospongiose et étrier normal 
2 Etude de la présence d’un messager du stress oxydatif  dans les étriers otospongieux 
(HNE) et de son interaction avec Ang II dans une lignée cellulaire de type ostéoblaste 
humaine (HOS)
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III. Etude de l'effet de l'Ang II sur les voies de l'inflammation 
dans des cultures primaires de cellules osseuses dans 
l'otospongiose et étrier normal
INTRODUCTION 
Les effets  de l’Ang II sur le remodelage tissulaire et de réparation ont été déjà étudiés chez 
l'homme et  les animaux. Ang II est impliquée dans les événements de l'inflammation et 
modifie la composition de la matrice extracellulaire par divers facteurs de croissance et 
cytokines. Dans la présente étude, nous avons cherché à étudier l'effet de l’Ang II sur la 
production de cytokines dans les cultures cellulaires primaires d’étriers otospongieux et 
normaux obtenu de patients. 
MATERIELS ET METHODES 
Des fragments d'os ont été prélevés chez des patients atteints d’otospongiose lors de la 
chirurgie de réhabilitation auditive et chez des patients subissant une chirurgie pour une 
tumeur angle ponto-cérébelleux par une voie transpétreuse. Les cultures cellulaires primaires 
ont été obtenues de ces deux types de prélèvement. Ces cultures avaient été déjà caractérisées 
lors des études précédentes. Elles présentent des cellules ostéoblastiques avec plusieurs 
marqueurs phénotypiques (récepteurs de PTH, sécrétion d’ostéocalcine, production de 
phosphatase alcaline, nodules de calcification).
Concentration des cytokines dans le milieu de culture
Les surnageants des cultures cellulaires d’otospongiose (n=6) et d’étriers témoins (n=6) ont 
été recueillis après 24h de traitement par Ang II (10-7M, 24H) ou le diluant pour l'analyse par 
des biopuces à anticorps (RayBio ® Human Inflammation G3 réseau d'anticorps, RayBiotech, 
Norcross, GA). Cette technique a permis d’analyser les surnageants pour 40 cytokines et  de 
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chémiokines. La concentration de chaque molécule a été déterminée par une mesure semi-
quantitative. 
Expression de l'ARNm des cytokines pro inflammatoires
L'ARN total a été extrait de 3 cultures de cellules primaires parmi les 6 dans chaque groupe 
(otospongiose, témoin). Après synthèse et  purification, l'ARNc marqué à la biotine a été 
hybridé sur des membranes de biopuce a ARN pour la détéction et la mesure semi-
quantitative de l’expression ARNm de 126 gènes codant pour les cytokines et les molécules 
impliquées dans l’inflammation (Oligo GEArray ® cytokines inflammatoires de l'homme et 
des récepteurs de biopuces, EHS-011, SA Biosciences, Frederick, MD). 
Quantification de l'expression ARNm de BCL-6 par la RT-PCR quantitative
L'ARN total de 4 cultures de cellules primaires parmi les 6 dans chaque groupe 
(otospongiose, contrôle) a été utilisé dans ces expériences. Tous les échantillons utilisés dans 
les tests de biopuce à ARN ont été inclus dans l'évaluation par une transcription inverse suivie 
d’une réaction de polymérase en chaîne quantitative (qRT-PCR). L'ADN complémentaire a 
été synthétisé par RT. Les paramètres de la qRT-PCR ont été déterminés dans des expériences 
préliminaires sur des lignées de cellules d'ostéosarcome (HOS, et SaOS, American Type 
Culture Collection, Molsheim, France). Seul l’ARNm de BCL-6 qui a montré une différence 
d’expression  entre otospongiose et témoin et une modification sous l’effet  d’Ang II lors des 
essais par la biopuce à ARN a été étudiée par la qRT-PCR. 
Immunocytochimie 
Quatre cultures cellulaires de chaque groupe ont été utilisées pour immunohistochimie afin de 
détecter des différences de population cellulaires entre les étriers témoins et les étriers 
otospongieux. Les anticorps primaires suivants ont été utilisés: pour des ostéoblastes, 
l’anticorps monoclonal de souris anti-humain CDH11, clone 4D10 (Sigma-Aldrich, France); 
15
pour des ostéoclastes, l’anticorps monoclonal de souris anti-CD61 humain, clone Y2/51 ; et 
enfin pour des macrophages, l’anticorps monoclonal de souris anti-CD68 humain, clone KP1 
(DakoCytomation, Glostrup, Danemark).
RÉSULTATS 
La libération de cytokines et des protéines liées aux cytokines dans le milieu de culture 
En condition basale, les concentrations d’IP-10 et  IL-1b étaient plus élevées dans 
l'otospongiose que dans l'étrier témoin (88 ± 6.9 versus 36 ± 4.7 unités arbitraires pour IP-10 
et 51 ± 6.9 versus 26  ± 5.1 unités arbitraires pour IL-1b respectivement, p<0,05, ANOVA, 
n=6). Cette observation était en accord avec une plus haute activité de leucocytes ou des 
ostéoclastes (IL-1b), et  une augmentation de l'activité angiogénique (IP-10) dans les cultures 
issues de l'étrier otospongiose. En outre, une concentration plus faible de l’inhibiteur de 
métalloprotéases TIMP-2 a été détectée dans des conditions basales dans des cultures 
cellulaires otospongiose (11296 ± 1705.7 versus 21410 ± 3278.2 unités arbitraires, p<0,05, 
ANOVA, n=6). Cette observation était également compatible avec une remodelage osseux 
plus important détecté dans l’otospongiose et rapporté dans d’autres études. L'expression 
d'autres protéines ne différaient pas entre les échantillons d’otospongiose et témoins en 
condition basale. 
Ang II a stimulé la libération d'IFN-γ dans le milieu de culture dans l’otospongiose et les 
témoins (99 ± 27 versus 136 ± 9.1 unités arbitraires pour l’otospongiose et 90 ± 25.3 versus 
141 ± 27 unités arbitraires pour les témoins, p<0,05, ANOVA, n=6). Ang II a également 
augmenté la concentration d'IL-10 dans les milieux de culture otospongiose (70 ± 7.2 versus 
116 ± 12.5 unités arbitraires, p<0,05, ANOVA, n=6). Il a inhibé la protéine inflammatoire des 
macrophages, MIP-1a, (22 ± 6.7 versus 9 ± 3.8 unités arbitraires, p<0,05, ANOVA, n=6) et 
l'interleukine 11, IL-11, (124 ± 7.3 versus 98 ± 8 unités arbitraires, p<0,05, ANOVA, n=6) 
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seulement dans les étriers témoins. Ang II a réduit la concentration de sTNFRII dans les 
milieux de culture otospongiose (18330 ± 2991.9 versus 11547 ± 2130.6 unités arbitraires, 
p<0,05, ANOVA, n=6) sans modifier le facteur de nécrose tumorale alpha (TNF-α).
Expression de l’ARNm des cytokines 
Au total, 126 gènes impliqués dans la réponse inflammatoire ont été analysés par biopuces à 
ARN. Expression de l'ARNm de 15 cytokines ou des molécules liées aux cytokines a pu être 
détectée par cette technique. Une importante variation inter-individuelle a été observée. En 
condition basale, l'expression d'ARNm de BCL-6 était plus élevée dans l'otospongiose que 
chez les témoins (328 ± 39,7 unités arbitraires dans le groupe otospongiose contre 48 ± 21,7 
dans les témoins, n = 3, p <0,05, test-t non pairé). L’Ang II a réduit l'expression de l'ARNm 
du BCL-6 dans l'otospongiose seulement (424 ± 63,3 en condition basale versus 105 ± 64,7 
après Ang II, n=3, p  <0,05, test-t pairé). La qRT-PCR après normalisation par l’expression du 
gène codant pour une protéine ribosomique S14 a confirmé des niveaux plus élevés de BCL-6 
dans l'otospongiose par rapport aux témoins en condition basale. Toutefois, la réduction de 
l'expression d'ARNm du BCL-6 après Ang II dans l'otospongiose observée par puces à ARN 
n'a pu être confirmée par qRT-PCR. Des résultats similaires ont été obtenus après qRT-PCR 
après normalisation par le gène de référence GAPDH. 
Immunocytochimie
Les cultures témoins et  otospongiose ont  montré un marquage positif avec des anticorps 
spécifiques pour des ostéoblastes, des ostéoclastes et des macrophages. Il n'y avait pas de 
différence de marquage entre le groupe otospongiose et des cultures témoins (n=3). Cette 
observation suggère que la différence de la production de cytokines pro-inflammatoires n'était 
pas liée à des différences quantitatives de sous-populations cellulaires entre les cultures 
otospongiose et témoin. 
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CONCLUSION 
Ces données soutiennent l'hypothèse que l’Ang II est  impliquée dans l'inflammation et la 
régulation du remodelage osseux dans l'otospongiose, via différents facteurs de croissance et 
cytokines. Ils indiquent plusieurs cibles potentielles pour leurs actions anti-inflammatoires ou 
anti-cataboliques telles que l'IL-11 et  TIMP-2. Néanmoins d'autres investigations sont 
nécessaires pour clarifier le rôle de l 'Ang II dans la physiopathologie de l’otospongiose et le 
métabolisme osseux dans l'étrier. 
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III. L'intéraction entre angiotensine II et de 4-hydroxynonenal 
(HNE) en dans les l ignées cellulaires humaines 
ostéoblastiques et dans l’otospongiose 
INTRODUCTION
Le stress oxydatif et Ang II interagissent dans le remodelage des tissus par via les DRO. Ces 
dérivés interviennent dans de nombreuses voies de signalisation de l’Ang II. HNE qui 
représente un des DRO les plus étudiés se trouve dans de nombreux tissus humains en tant 
que second messager, mais ses rôles physiologiques ne sont pas encore entièrement compris. 
Des études récentes sur l'influence de la HNE sur les cellules osseuses ont démontré son effet 
inhibiteur sur la prolifération et la différenciation des cellules osseuses et son effet stimulateur 
sur l'apoptose.
L'objectif de la présente étude était  d’étudier l'interaction entre l'Ang II et la HNE dans la 
physiopathologie de l'otospongiose en étudiant le modèle in vitro des lignées cellulaires 
humaines ostéoblastiques et dans les étriers humains otospongieux.
MATERIELS ET METHODES 
La présence et la localisation de la HNE a été étudié dans les étriers humains otospongieux et 
témoins par immuno-histiochimie. Cette technique a été réalisée sur des échantillons de tissus 
prélevés chez 15 patients atteints d’otospongiose et 6 témoins (tumeurs de l’angle ponto-
cérébelleux opérées par voie transpétreuse). Un anticorps anti-HNE a été utilisé. Une lignée 
de cellules ostéblastiques humaines (HOS, Human Osteosarcoma) a été utilisée pour analyser 
l'effet de l’Ang II et de la HNE sur la prolifération (incorporation de 3H-thymidine), la 
différenciation (détection de l'activité phosphatase alcaline par un test  de NBT / BCIP, Roche) 
et l'induction de l'apoptose par la cytometrie de flux (marquage des cellules apoptotiques par 
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un kit de coloration annexine-V, Roche, Allemagne). Une analyse par immunoblot a été 
effectuée pour déterminer s'il existe une interaction directe entre l'Ang II et HNE. 
RESULTATS 
La détection immuno-histochimique des conjugués HNE-protéine a été positive à la fois dans 
le groupe otospongiose et les témoins. Cependant la distribution du marquage était différente 
entre les deux groupes : diffuse dans l’otospongiose et limitée à l’espace sous-périostée dans 
les étriers témoins. L’association de l'Ang II à une concentration de 0,1nM  à la HNE à 2,5 µM 
pendant 24 heures a stimulé la prolifération des cellules HOS (p <0,0002). La diminution de 
l'activité de la phosphatase alcaline (ALP) a été observée dans des cultures traitées par une 
concentration de 0,1 nM  Ang II associée à la HNE à une concentration de 1 ou 2,5 µM (p 
<0,01). Au contraire, HNE seul à 10 µM  (p  <0,05) ou en combinaison avec 0,1 ou 0,5 nM 
d’Ang II (p <0,01) augmente l'activité ALP. La diminution de l'apoptose a été également 
observée dans les cellules traitées par Ang II seule à 0,1 ou 0,5 nM (p <0.05). Au contraire, 
une augmentation de l'apoptose a été détectée dans les cultures traitées avec HNE à 10 µM 
seule ou en combinaison avec 0,1 ou 0,5 nM d’Ang II, (p  <0,01). Le traitement avec 0,5 nM 
d’Ang II et 1 µM  de HNE réduit le niveau de cellules nécrotiques (p  <0.05). L’augmentation 
de la nécrose a été observée dans toutes les conditions : HNE seule à 10 µM  (p  <0.01), en 
combinaison avec Ang II à 0,1 nM  (p  <0,02), 0.5 et 1 nM (p <0,002),  ainsi que la 
combinaison de HNE à 5 µM  avec Ang II à 0,1 0,5 (p  <0.05) ou 1 nM (p <0,003). L’analyse 
immunoblot a montré une liaison significative entre l'Ang II et la HNE.
CONCLUSION 
Nos résultats étayent l'hypothèse de l'implication des dérivés réactifs d’oxygène et notamment 
la HNE dans la physiopathologie de l'otospongiose. L’intéraction entre la HNE et l’Ang II 
peut expliquer la différence de réponse à l’Ang II observée entre les étriers otospongieux et 
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témoins. En outre, les résultats l'effet de l'Ang II et HNE sur la prolifération, la différenciation 
et l'apoptose des ostéoblastes, soutiennent leur rôle important dans le remodelage osseux au 
cours de l’otospongiose. 
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IV.  Conclusion générale  
Les résultats de ces 2 études fournissent un éclairage nouveau sur le rôle de l'Ang II et le 
stress oxydatif (DRO et ses seconds messagers) dans la physiopathologie du métabolisme 
étrier au cours de l’otospongiose. L’Ang II induit la sécrétion de différentes cytokines pro-
inflammatoires dans les cultures primaires de cellules otospongieux. Notre investigation sur 
les effets de l’Ang II et les messagers secondaires du DRO (HNE), montrent l'interaction de 
ces deux facteurs ainsi que l'influence positive sur la prolifération cellulaire humaine 
d’osteosarcome (HOS). La distribution hétérogène et diffuse des HNE dans l'os otospongieuse 
appuie le rôle possible du stress oxydatif dans la physiopathologie de la maladie. Enfin, les 
produits du stress oxydatif interagissent avec l’Ang II pour modifier la réponse des cellules 
osseuses à cette hormone. Comme indiqué par immunoblot, au moins une partie de cette 
interaction a lieu dans le milieu extracellulaire et avant la liaison aux récepteurs de l’Ang II. 
Dans des études antérieures, nous avons observé une différence de réponse à l'Ang II entre 
étrier otospongieux et normal. La présence des dérivés réactifs d’oxygène dans les foyers 
actifs d’otospongiose suite à l’inflammation est au moins l'une des explications de cette 
différence de réponse à l’Ang II.
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SAŽETAK 
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I. Uvod
1. Patofiziologija otoskleroze (bolesti stapesa)
Otoskleroza je bolest labirintne kapsule koja postupno zahvaća i osikularni lanac srednjega 
uha, točnije strukture stapesa. Osikularni lanac srednjega uha sastoji se od triju slušnih 
košćica (maleusa, inkusa i stapesa). Stapes (stremen) sastoji se od prednjeg i stražnjeg krusa 
(suprastruktura) i pločice kojim prijanja na ovalni prozorčić (fenestra ovalis). Patološke 
promjene koje ga zahvaćaju širenjem iz područja labirintne kapsule, obilježene su stalnim 
procesom koštane razgradnje i predgradnje. Rezultat toga je fiksacija stapesa i posljedično 
konduktivna nagluhost, što je jedna od prvih i glavnih karakteristika otoskleroze. Incidencija 
bolesti kreće se od 0,3 do 1% u različitim populacijama i obično se manifestira između 
drugoga i petoga desetljeća života. Bilateralni oblik bolesti prisutan je u 80% slučajeva. 
Histološki razlikujemo tri faze bolesti. Koštana resorpcija i pojačana vaskularizacija 
karakteriziraju prvu fazu. Kako sazreli kolagen nestaje, kost poprima spongiozni oblik (u 
francuskoj literaturi drugi naziv za bolest je otospongioza). Zadnju fazu bolesti obilježava 
čvrsta sklerotična kost, odakle i konačno ime otoskleroza. Otosklerotična kost pokazuje jaku 
koštanu pregradnju s dva jasno ograničena područja aktivnosti: inaktivno fibrozno područje i 
aktivno područje bogato osteoklastima, osteoblastima i krvnim žilama formiranima u 
zajednički mozaik. Etiologija bolesti još uvijek nije do kraja razjašnjena. U različitim 
istraživanjima predloženo je više potencijalnih etioloških faktora (inflamatorni, infektivni, 
genetski, autoimuni, hormonalni). Kliničku sliku karakterizira progresivan konduktivan 
gubitak sluha i šum. Neki pacijenti javljaju bolju razumljivost u bučnoj okolini, što je poznato 
kao fenomen Wilisi. Vestibularni simptomi su rijetki. Kliničkim pregledom ustanovi se 
normalan vanjski zvukovod i bubnjić. U određenoga broja bolesnika vidljivo je crvenilo iznad 
promontorija (Schwartzov znak), a rezultat je pojačane vaskularizacije kosti odmah ispod 
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periosta. Audiološka testiranja pokazuju umjerenu do jaku provodnu nagluhost, sa zračno-
koštanim gapom više izraženim u nižim frekvencijama. Senzoneuralni gubitak od 20dB na 
frekvenciji od 2000Hz (Carhartov znak) tipičan je audiološki nalaz. Medikamentozna terapija 
bolesti usmjerena je ka koštanom sazrijevanju i smanjenju otosklerotične aktivnosti. Upotreba 
natrij florida predložena je kao moguća terapija vezano za uspjeh iste kod osteoporoze. 
Upotreba bifosfonata koji inhibiraju aktivnost osteoklasta i antagoniste citokina koji inhibiraju 
koštanu resorpciju, drugi je izbor terapije. Ostali mogući oblici terapije uključuju upotrebu 
antioksidansa (koji blokiraju stimulatorni efekt slobodnih radikala na osteoklaste), inhibitora 
neuralne apoptoze, upotrebu kortikoida i konačno antagonista angiotenzina. Za sada ipak 
jedni je učinkovit oblik terapije kirurški postupak koji uključuje izvođenje stapedotomije 
(uklanjanje otosklerotično izmijenjene kosti i njezina zamjena posebno proizvedenom 
protezom).
2. Angiotenzin II  
Vaskularni sustav igra važnu ulogu u remodeliranju koštanoga tkiva bilo u fiziološkim bilo u 
patofiziološkim uvjetima. Zbog bliskoga anatomskoga odnosa, endotelijalne i koštane stanice 
izlučuju slične parakrine medijatore. Jedan od njih je i angiotenzin II koji se lokalno 
sintetizira upravo u endotelijalnim stanicama. Angiotenzin II glavni je izvršni peptid sustava 
angiotenzin-renin i kao takav poznati je regulator kardiovaskularnog sustava i sustava tjelesne 
homeostaze. Angiotenzin II nastaje konverzijom iz angiotenzina I pomoću angiotenzin 
konvertirajućeg enzima (ACE). Povezuje ga se s više različitih procesa koji uključuju 
kontrolu neuralne aktivnosti, staničnoga rasta i razvoja. Dokazani su njegovi stimulatorni 
utjecaji na sintezu DNA i sintezu kolagena na staničnim linijama osteoblasta i to preko 
receptora tipa 1, kao i stimulatorni učinak na ekspresiju receptora aktivatora NF-kB liganda 
25
(RANKL) u osteoblastima. Poznata su dva subtipa angiotenzin II receptora. Tip 1 (AT1) i tip 2 
(AT2) receptori. AT1 receptori reguliraju dva signalna puta koji uključuju G proteine. Jedan 
put uključuje aktivaciju fosfolipaze C, uz posljedičnu stimulaciju produkcije inozitol 1,4,5-
trifosfata, dok drugi uključuje regulaciju stupnja aktivnosti cAMP, bilo aktivacijom ili 
inhibicijom adenilat-ciklaze. Signalni put angiotenzin II receptora (AT2) još valja do kraja 
razjasniti. Specifični antagonisti peptida kao losartan i ostali sartani blokiraju AT1 receptore, 
dok ne-peptidne komponente kao PD123317 i PD123319 antagoniziraju AT2 receptore. 
Angiotenzin II upleten je i u patofiziološke procese povezane s vaskularnim ozljedama i 
oporavkom od njih, kao i s mehanizmima koji promovirajući oksidacijski stres u vaskularnom 
zidu vode do endotelijalne disfunkcije, stanične apoptoze i lipoproteinske peroksidacije. Kao 
takav povezuje se s medijatorima oksidacijskog signalnoga puta.
Angiotenzin II isto tako može aktivirati više nuklearnih transkripcijskih faktora, signalnih 
transdusera i aktivirajućih faktora kao STAT, AP-1, NF-kB i proteina ovisnih o sustavu 
ciklične adenozin monofosfataze (cAMP). Među njima osobito je zanimljiv NF-kB sustav, 
budući da je upravo on odgovoran u kontroli imunološki odgovornih gena, uključujući 
citokine i adhezijske molekule. Inhibicija NF-kB sustava može prevenirati upalni odgovor i 
promijeniti ekspresiju proinflamatornih citokina. Angiotenzin II može aktivirati NF-kB sustav, 
inducirajući fosforilaciju i degradaciju inhibitora kB faktora (IkB).  Ipak, mehanizam toga 
djelovanja nije do kraja razjašnjen. Poznato je, osim toga, da angiotenzin II može aktivirati 
obitelj mitogen-aktivirajućih protein kinaza (MAPK) koji su uključeni u NF-kB indukciju 
putem različitih citokina. Imajući u vidu sve navedeno, moguće je pretpostaviti da  bi 
angiotenzin II  mogao imati  regulatorni učinak na  koštani metabolizam.
U prethodnim istraživanjima dokazano je da angiotenzin II na staničnim linijama osteoblasta 
porijekla stapesa stimulira produkcija interleukina 6 te smanjuje aktivnost alkalne fosfataze. 
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Genetskim analizama ustanovljena je povezanost polimorfizma genotipa sustava renin-
angiotenzin–aldosteron kod osoba oboljelih od otoskleroze (M235T, ACE I/D). 
3. Oksidacijski stres 
Oksidacijski stres u osnovi je patološki proces. Reaktivni kisikovi spojevi koji nastaju 
njegovom aktivacijom izuzetno su štetni  i mogu dovesti do lipidne peroksidacije. Vrlo su 
kratkotrajnoga života ali sudjeluju u stvaranju takozvanih sekundarnih glasnika, kao što je 4-
hidroksinonenal (HNE) čiji je vijek života dulji, može se vezati za stanične proteine i tako 
djelovati na sustavnoj, a ne samo na lokalnoj razini. Mjerenjem ekspresije alkalne fosfataze 
uočeno je da medijatori oksidacijskog stresa, kao vodikovi radikali H2O2 iz ksantin/ksanin 
oskidaza sustava, mogu uzrokovati staničnu diferencijaciju u staničnim kulturama osteoblasta. 
HNE je aldehid koji se smatra jakim induktorom fibrinogeneze (mezenhemijalnih stanica) i 
glavnim markerom lipidne peroksidacije. Ovaj reaktivni aldehid je citotoksični i mutageni 
spoj, ali i signalna molekula s utjecajem na  staničnu proliferaciju, diferencijaciju i apoptozu. 
Upletenost HNE istraživana je u patofiziologiji različitih bolesti kao što su: kronična upala, 
neurodegenerativne bolesti, respiratorni distres sindrom odraslih, ateroskleroze i šećerne 
bolesti. U studijama staničnih kultura osteosarkoma zamijećeno je da ovaj aldehid uzrokuje 
inhibiciju stanične proliferacije u istim koncentracijama kojima uzrokuje apoptozu i inhibira 
staničnu diferencijaciju. Kao takav, moguće je da je upravo HNE jedna od važnih signalnih 
molekula koje reguliraju metabolizam humanih koštanih staničnih kultura
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4. Cilj istraživanja
Aktivnu fazu otoskleroze karakterizirju znakovi upale uz prisustvo brojnih multinuklearnih 
osteoklasta, osteocita i proliferativnih endotelijanih stanica u pseudovaskularnim prostorima i 
aktivnim otosklerotičnim žarištima. Prethodna istraživanja potvrdila su ulogu različitih 
proinflamatornih citokina u patofiziologiji otoskleroze. Unatoć dosadašnjim istraživanjima 
(virusi, bakterije, mehanička trauma) potencijalni tzv. trigerring faktor inflamacije u 
patofiziologiji otoskleroze još uvijek nije otkriven.  Angiotenzin II istraživan je kao mogući 
faktor koji pokreće inflamatorne putove u patofiziologiji otoskleroze. Aktivirajući inflamaciju 
Ang II može aktivirati i oksidacijski stres koji može biti odgovoran za  različite oblike 
kohlearnoga oštećenja (difuzija reaktivnih kisikovih spojeva u unutarnje uho). Osim 
transformirajućega faktora rasta B, faktora rasta fibroblasta, endotelina i inzulin faktora rasta, 
i produkti lipooksigenacije važni su medijatori djelovanja angiotenzina. Jedan od glavnih 
produkata procesa oksidacijskog stresa i lipidne peroksidacije s dokazanim učincima na 
stanične kulture osteoblasta  je 4-hidroksinonenal (HNE).  Povezujući učinke angiotenzina II i 
produkta oksidacijskog stresa (HNE) na stanične kulture osteoblasta, za pretpostaviti je da bi 
upravo angiotenzin II mogao biti novi lokalni regulator koštanoga metabolizma.
Cilj ovoga istaživanja bio je ustanoviti ulogu angiotenzina II i oksidacijskoga stresa na 
koštani metabolizam općenito odnosno u patofiziologiji otoskleroze, provedenim 
istraživanjem na dva eksperimentalna stanična modela: 
1  Istražiti utjecaj angiotenzina II na upalni odgovor primarnim staničnih kultura 
 stapesa (zahvaćenog otosklerozom i zdravoga stapesa)
2  Istražiti interakciju angiotenzina II i HNE-a (kao produkta oksidacijskoga stresa)  na 
 koštani metabolizam na stanicama humanoga osteosarkoma (HOS) 
28
II.  Utjecaj angiotenzina II na sekreciju proinflamatornih 
 citokina iz primarnih staničnih kultura otoskleroze
UVOD
Uloga angiotenzina II (Ang II) na koštani metabolizam prethodno je već istraživana. Ang II 
važan je regulator sustava tjelesne homeostaze, a upleten je i u različite stanične inflamatorne 
putove i kao takav važan je modulator staničnoga rasta. U ovom dijelu istraživanju ispitali 
smo utjecaj Ang  II na sekreciju proinflamatornih citokina iz primarnih humanih  staničnih 
kultura otoskleroze.
MATERIJALI I METODE 
Primarne stanične kulture stapesa 
Uzorci zdravoga stapesa i stapesa zahvaćenog otosklerozom iskorišteni su za dobivanje 
primarnih staničnih kultura. Ove stanične kulture karakterizirane su u prethodnim 
istraživanjima. Sastoje se od osteoblasta različitih fenotipova (s izraženim receptorima za 
PTH, sposobnošću sekrecije osteokalcina, produkcije alkalne fosfataze i stvaranju  mineralnih 
nodula). 
Sekrecija citokina iz staničnoga medija 
Stanični medij uzoraka otoskleroze (n=6) i kontrolne grupe (n=6), sakupljeni su nakon 24h 
tretmana (Ang II 10-7M, ili bazalni uvjeti) i analizirani na sekreciju proinflamatornih citokina. 
Uzorci su analizirani na 40 proinflamatornih citokina koristeći RayBio® Human 
Inflammation antibody array G3, RayBiotech, Norcross, GA. 
mRNA ekspresija proinflamatornih citokina 
Ukupna RNA izolirana je iz staničnih kultura otoskleroze i kontrolne grupe (RNA 2Plus, MP 
Biomedicals, France). Sinteza, purifikacija i hibridizacija biotin označenih komplementarnih 
(cRNA) uzoraka učinjena je korištenjem Oligo GEArray® Human inflammatory cytokines 
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and receptors MicroArray, EHS-011, SA Biosciences, Frederick, MD. Ukupno je testirano 
126 gena.
Kvantifikacija mRNA ekspresije pro-inflamatornih citokina putem RT-PCR 
Ukupna RNA izolirana je iz uzoraka otoskleroze i kontrolne grupe. Komplementana DNA 
sintetizirana je RT-PCR metodom uz prethodnu standardizaciju na uzorcima humanih stanica 
osteosarkoma (HOS i SaOS, American Type Culture Collection, Molsheim, Francuska). 
Amplifikacija putem PCR metode učinjena je za BCL-6 i CCL25.
Imunocitokemija 
U cilju diferenciranja staničnih kultura korištena su sljedeća monoklonalna antitijela: za 
humane osteoblaste  i osteoklaste (CDH11 klon 4D10  i CD61 klon Y2/51, Sigma-Aldrich, 
Francuska i za humane makrofage (CD68 klon KP1 DakoCytomation, Glostrup, Danska).  
REZULTATI
Sekrecija citokina iz staničnog medija 
U bazalnim uvjetima uočena je veća  koncentracija IP-10 i IL-1b u uzorcima otoskleroze nego 
u kontrolnoj grupi (88 ± 6.9 prema 36 ± 4.7 srednje vrijednosti za IP-10 et 51 ± 6.9 prema 26 
± 5.1 srednje vrijednosti za IL-1b, p<0,05, ANOVA, n=6). Ovaj rezultat u skladu je s 
prethodno poznatim o jačoj aktivnosti leukocita i osteoklasta (IL-1) i jačom angiogenetskom 
aktivnosti (IP-10) u kulturama otoskleroze. Također u bazalnim uvjetima u uzorcima 
otoskleroze  uoćena je i smanjena koncentracija inhibitora metaloproteinaze 2, TIMP-2 
(11296 ± 1705.7 prema 21410 ± 3278.2 srednje vrijednosti, p<0,05, ANOVA, n=6). 
Ekspresija ostalih citokina nije se bitno razlikovala u bazalnim uvjetima između otoskleroze i 
kontrolne grupe. 
U uvjetima stimulacije s Ang II uočena  je povećana koncentracija interferon gamma (IFN-γ) 
u obje grupe uzoraka (99 ± 27 prema 136 ± 9.1 srednje vrijednosti za otosklerozu i 90 ± 25.3 
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prema 141 ± 27 srednje vrijednosti za kontrolu, p<0,05, ANOVA, n=6).  Također u uvjetima 
stimulacije s Ang II uočena je povećana koncentracija interleukina 10 (IL-10) u uzorcima 
otoskleroze (70 ± 7.2 prema 116 ± 12.5 srednje vrijednosti, p<0,05, ANOVA, n=6). U 
kontrolnim uzorcima u uvjetima stimulacije s Ang  II uočena je manja koncentracija 
inflamatornoga proteina makrofaga, MIP-1a, (22 ± 6.7 prema 9 ± 3.8 srednje vrijednosti, 
p<0,05, ANOVA, n=6),  i interkleukina 11, IL-11 (124 ± 7.3 prema 98 ± 8 srednje vrijednosti, 
p<0,05, ANOVA, n=6). U uzorcima otoskleroze u uvjetima stimulacije s Ang II uočena je 
smanjena koncentracija sTNFRII citokina (18330 ± 2991.9 prema 11547 ± 2130.6 srednja 
vrijednost, p<0,05, ANOVA, n=6), ali bez utjecaja na sekreciju  TNF-α.
mRNA ekspresija proinflamatornih citokina  
Ukupno je testirano 126 proinflamatornih citokina. Detektirana je ekspresija 15 citokina i 
citokinima sličnih molekula. Uočene su siginifikantne međusobne razlike. U bazalnim 
uvjetima, ekspresija BCL-6 bila je veća u otosklerozi nego u kontrolnom uzorku (48 ± 21.7 
srednje vrijednosti kontrolnih uzoraka u odnosu na otosklerozu 328 ± 39.7 p<0.05, unpaired t-
test). Stimulacija s Ang  II smanjila je ekspresiju BCL-6 u uzorcima otoskleroze (424 ± 63.3 u 
bazalnim uvjetima prema  105 ± 64.7 nakon stimulacije p<0.05, paired t-test). Rezultati qRT-
PCR analize nakon normalizacije sa S14-genom potvrdili su više vrijednosti BCL-6 u 
uzorcima otoskleroze. Ipak, inhibicija BCL-6 nakon stimulacije angiotenzinom II nije 
potvrđena. Slični rezultati dobijeni su i nakon normalizacije s GAPDH genom.  
Imunocitokemija
U obje grupe uzoraka diferencirane su stanice prema korištenim antitijelima (osteoblasti, 
osteoklasti, makrofazi). Nije uočena razlika između ispitivanih uzoraka što ukazuje da 
prethodno uočena razlika u produkciji proinflamatornih citokina nije uvjetovana 
kvantitativnom razlikom staničnih populacija među ispitivanim uzorcima. 
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ZAKLJUČAK
Dobiveni rezultati podržavaju hipotezu o upletenosti angiotenzina II u patofiziologiji 
otoskleroze aktiviranjem različitih proinflamatornih citokina i faktora rasta. Ipak, neophodna 
su dodatna istraživanja u cilju daljnjeg razumijevanja uloge angiotenzina II u patofiziologiji 
ove bolesti, ali i  u metabolizmu stapesa općenito.
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III.  Interakcija angiotenzina II i 4-hidroksinonenala na koštani  
metabolizam i u patofiziologiji otoskleroze  
UVOD
Oksidacijski stres  i angiotenzin II (Ang II) imaju zajednički utjecaj na stanični rast i razvoj 
putem reaktivnih kisikovih tvari koji su upleteni u različite signalne puteve angiotenzina II. 4-
hidroksinonenal (HNE) kao produkt oksidacijskoga stresa je pronađen kao sastavni dio 
različitih stanica i tkiva, ali njegova fiziološka uloga još uvijek nije u potpunosti razjašnjena. 
Prethodna istraživanja o ulozi HNE-a na koštani metabolizam pokazala su njegov inhibitorni 
utjecaj na staničnu proliferaciju i diferencijaciju te stimulaciju apoptoze. Cilj ovoga dijela 
istraživanja bio je utvrditi mogući zajednički utjecaj Ang  II i HNE-a na koštani metabolizam 
općenito i u patofiziologiji otoskleroze. 
MATERIJALI I METODE
Imunohistokemija je provedena na histološkim uzorcima otoskleroze (n=15) i kontrole (n=6). 
Korištena su monoklonska antitijela na HNE. Humane stanice osteosarkoma (HOS) korištene 
su za analizu utjecaja angiotenzina II i HNE na proliferaciju (inkorporacija 3H-timidina), 
diferencijaciju (detekcija aktivnosti alkalne fosfataze putem NBT/BCIP eseja) i indukcija 
apoptoze putem protočne citometrije (Annexin-V-Fluos Staining Kit). Imunoblot  metodom 
procijenjena je moguća interakcija između angiotenzina II i HNE-a.   
REZULTATI
Imunohistokemijom utvrđena su protutijela na HNE u svim ispitivanim uzorcima. Uočena je 
jasna razlika u distribuciji navedenih protutijela u dvije grupe uzoraka. U kontrolnim 
uzorcima uočeno je jednoliko nakupljanje protutijela i to u području periosta, dok je u 
uzorcima otoskleroze uočeno povećano nakupljanje protutijela u područjima novog stvaranja 
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kosti i područjima pojačane koštane pregradnje. Rezultati proliferacije pokazali su da u 
određenim koncentracijama Ang II (0.1 nM) i HNE  (2.5 µM) stimuliraju proliferaciju HOS 
(p<0.0002). Smanjene aktivnosti alkalne fosfataze uočeno je  kod koncentracije Ang II od 0.1 
nM  i HNE-a od 1 µM i 2.5 µM (p<0.01). Suprotne tomu koncentracije HNE-a od 10 µM 
samostalno povećavaju aktivnost alkalne fosfataze (p<0.05) i u kombinaciji s Ang II u 
koncentracijama od 0.1 ili 0.5 nM (p<0.01). Inhibicija apoptoze zabilježena je kod stanica 
tretiranima samostalno s Ang II i to u koncentracijama od 0.1 i 0.5 nM   (p<0.05). Suprotno 
tomu stimulacija apoptoze (p<0.01) zabilježena je kod stanica tretiranima samostalno s HNE-
om od 10 µM  ili u kombinaciji s Ang II za sve koncentracije osim za 1 nM. Rezultati 
ispitavanja nekroze stanica pokazali su da tretiranje stanica s Ang II u koncentracijama od 0.5 
nM  i HNE-a od 1 µM  smanjuje postotak nekrotičnih stanica (p<0.05). Povećanje postotka 
nekrotičnih stanica zabilježeno je kod koncentracija HNE od 10 µM   samostalno (p<0.01) ili 
u kombinaciji s Ang II u koncentracijama od  0,1 nM (p<0.02)  i 0,5 nM i    1 nM (p<0.002) 
kao i u kombinaciji HNE od 5 µM   s 0,1 nM  i 0.5 nM  Ang II (p<0.05) i koncentraciji Ang  II 
od  1 nM  (p<0.003). Imunoblotom je dokazano postojanje interakcije između HNE-a i Ang 
II.
ZAKLJUČAK
Dobiveni rezultati potvrđuju hipotezu o upletenosti HNE (oksidacijskoga stresa) u 
patofiziologiji otoskleroze. Rezultati istraživanja interakcije Ang II i HNE-a pokazuju njihov 
značajan zajednički utjecaj na proliferaciji, diferencijaciju i apoptozu osteoblasta odnosno na 
koštani metabolizam općenito.
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IV. Konačan zaključak
Rezultati ova dva istraživanja pružaju novi uvid u ulogu angiotenzina II i oksidacijskoga 
stresa i njegovih sekundarnih glasnika (4-hidroksinonenala, HNE) u patofiziologiji 
otoskleroze i općenito metabolizmu stapesa. Angiotenzin II inducira sekreciju različitih 
proinflamatornih citokina u primarnim staničnim kulturama otoskleroze. Također uočena je 
interakcija angiotenzina II i oksidacijskoga stresa (HNE) na stimulaciju proliferacije HOS 
stanica. Heterogena distribucija HNE u uzorcima otoskleroze i kontrolnim uzorcima 
potvrđuje ulogu oksidacijskoga stresa u patofiziologiji bolesti. Konačno, rezultati upućuju na 
moguću modifikaciju uloge angiotenzina II  u patofiziologiji otoskleroze putem produkata 
oksidacijskoga stresa.  Imunoblot metoda ukazala je na  moguću direktnu interakciju HNE i 
Ang II. U prethodnoj studiji uočen različit odgovor staničnih kultura otoskleroze i kontrolnih 
uzoraka na stimulaciju angiotenzinom II mogao bi dijelom biti moduliran i pod utjecajem 
oksidacijskoga stresa.    
___________________________________________________________________________
DISCIPLINA : FIZIOLOGIJA I PATOFIZIOLOGIJA EPITELA
___________________________________________________________________________
KJUČNE RIJEČI : koštani metabolizam, gubitak sluha, angiotenzin II, oksidacijski stres, 
upala 
___________________________________________________________________________
ADRESA : INSERM U-867,  Faculté de Médecine Xavier Bichat
16 Rue Henri Huchard
75890 Paris, Cedex 18 
___________________________________________________________________________
35
PUBLICATIONS
1. Rudic M, Nguyen C, Nguyen Y, Milkovic L, Zarkovic N, Sterkers O, Ferrary E, 
Bozorg Grayeli A. Effect of Angiotensin II on Inflammation Pathways in Human 
Primary Bone Cell Cultures in Otosclerosis. (submitted for publication)
2. Rudic M, Milkovic L, Zarkovic K, Borovic-Sunjic S, Sterkers O, Ferrary E, Bozzorg 
Grayeli A, Zarkovic N. Angiotensin II and 4-hydroxynonenal (HNE) interaction in 
otosclerosis and in osteoblast-like cells. (submitted for publication)
3. Rudić M, Kranjcec Z, Lisica-Šikić N, Kovačić M. Giant basal cell carcinoma of the 
forhead- case report. Coll Antropol  (in print) 
4. Nguyen Y, Couloigner V, Rudić M, Grayeli AB, Ferrary  E, Sterkers O. An animal 
model of cochlear implantation with perylymphatic drug delivery. Acta Otolaryngol. 
2009;129(11):1153-1159
5. Gjurić M, Rudić M. What is the best tumor size to achieve optimal functional result of 
vestibular schwanoma surgery? Skull base 2008;18(5)317-25
6. Rudić M, Grayeli AB, Cazals-Hatem D, Cyna-Gorse F, Bouccara D, Sterkers O. 
Temporal bone central giant-cell granuloma presenting as a serous otitis media. Eur 
Arch Otorhinolaryngol. 2008;265(5);587-91 
7. Pham BN, Rudić M, Bouccara D, Sterkers O, Belmatoug N, Bébéar JP, Couloigner V, 
Fraysse B, Gentine A, Ionescu E, Robier A, Sauvage JP, Truy E, Van Den Abbeele T, 
Ferrary E. Antibodies to myelin protein zero (P0) protein as markers of auto-immune 
inner ear diseases. Autoimmunity. 2007;40(3):202-7 
8. Kovacic M, Rudić M, Nekic I, Lisica-Šikić N, Kranjčec Z, Šimurina T. Giant 
pilomatrixoma (benign calcifying epithelioma of Malherbe) of the neck and face. 
Dermatol Surg. 2007;33(3):340-3
9. Šimurina T, Mikulandra S, Mraović B, Sonicki Z, Kovačić M, Dželalija B, Rudić M. 
The effect of propofol and fentanyl as compared with sevoflurane on postoperative 
vomiting in children after adenotonsillectomy. Coll Antropol. 2006;30(2):343-7. 
10. Rudić M, Milicić J, Letinić D. Dermatoglyphs and larynx cancer. Coll Antropol. 
2005;29(1):179-83.
36
TABLE OF CONTENTS
I. Introduction! 38
1. The anatomy and physiology of the human ear 39
1.1. Anatomy 39
1.2. Physiology 41
1.3. The development of the human ear 42
2. Overview of the stapes (otosclerosis) pathophysiology 44
3. Epidemiology of otosclerosis 46
4. Etiology of otosclerosis 47
4.1. The genetics of otosclerosis 48
4.2. Measles virus infection 50
4.3. Hormonal influences 52
4.3.1. Parathyroid hormone and parathyroid hormone-related peptides receptor 
expression in otosclerosis 53
4.4. Inflammation factors 53
5. Medical treatment of otosclerosis 55
6. Otosclerosis-like lesions 57
7. Renin-Angiotensin-Aldosteron System 58
7.1. Overview 58
7.2. Angiotensin II 61
7.3. Angiotensin II signaling pathways 64
7.4. Angiotensin II and pathophysiology of otosclerosis 65
8. Oxidative stress 67
8.1. Overview 67
8.2. 4-hydroxynonenal (HNE) 68
9.  The goal of the study 73
II. Angiotensin II and cytokine production in Human Otosclerotic Primary Bone Cell 
Cultures! 75
1. Introduction 76
1.1. Angiotensin II effect on bone cells 76
2. Article: “Effect of Angiotensin II on Inflammation Pathways in Human Primary Bone 
Cell Cultures in Otosclerosis “ 80
III. Angiotensin II and oxidative stress in pathophysiology of otosclerosis! 106
1. Introduction 107
1.1. Angiotensin II and reactive oxygen species (ROS) 107
1.2. Reactive oxygen species in human ear diseases 109
2. Article: “Angiotensin II and 4-hydroxynonenal (HNE) interaction in otosclerosis and 
in osteoblast-like cells” 112
IV. General discussion! 140
Bone (stapes) metabolism 141
Angiotensin II and bone metabolism 144
Angiotensin II and stapes metabolism 147
37
Angiotensin II and activation of pro-inflammatory cytokines in primary otosclerotic 
bone cell cultures 149
Angiotensin II and oxidative stress in otosclerosis 153
V. Perspectives! 159
VI. References! 163
VII. Figures and Tables Index! 192
38
I. INTRODUCTION
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1. The anatomy and physiology of the human ear 
1.1. Anatomy
Based on anatomical and physiological considerations, the ear can be divided into 3 parts: 
outer (external), middle and inner ear (Figure 1). The external ear consists of the pinna 
(auricle) and the external auditory  canal. The middle ear consists of the tympanic membrane, 
ossicular chain with supporting ligaments and middle ear space. The sound is conducted from 
the tympanic membrane to the inner ear by three bones, the malleus (hammer), incus (anvil) 
and stapes (stirrup), Figure 2. The malleus is shaped like a club, its handle is embedded in 
tympanic membrane, running from its centre upwards. The head of the club lies in a cavity of 
the middle ear above the tympanic membrane (the attic) where is suspended by  a ligament. 
Here the head articulates with the cone shaped incus. The incus runs backwards from the 
malleus and has sticking down from it, a very little thin projection known as its long process, 
which hangs freely in the middle ear. It has right angle bend at its tip which is attached to the 
stapes (stirrup), the third bone, shaped with an arch and a foot plate. The stapes is the smallest 
bone in the body. It is about 3 millimeters long and weights about 3 milligrams. It consists of 
two legs, the anterior and posterior crura and a footplate. The two crura are joined superiorly 
at the head, which articulates with the lenticular process of the incus. Each leg resembles a 
trough, with the concave surfaces facing each other. Of the two legs, the anterior crus is very 
delicate and less curved. On the posterior crus is a roughened area in the region of the head 
for the attachment of the tendon of the stapedial muscle. Cartilage covers the articulating 
surface of the head. The stapes lies almost  horizontally, at  right angles to the process of the 
incus. Its base, or footplate, is surrounded by the elastic annular ligament that  attaches it to the 
margins of the vestibular (oval) window. However the stapes remains free to vibrate in 
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transmitting the sound to the labyrinth. The foot plate covers the oval window (an opening 
into the vestibule of the inner ear or cochlea), with which it articulates by the stapedio-
vestibular joint (Duckert et al., 1993). The inner ear is the inner most portion of the ear. It is 
filled with fluid (perylimph and endolymph) and comprises both hearing and balancing organs 
(cochlea and labyrinth).
Figure 1- Schematic view of the anatomy of the human ear 
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Figure 2- Auditory ossicles connections, Atlas of Human Anatomy (Sobotta 2001)
1.2. Physiology
Given the immobility of the human external ear, it is assumed that  it serves only  as a passive 
tunnel that collects and filters the sound. However, experimental studies have shown that 
there are two main functions of the human external ear. Firstly it  aids in sound localization 
and secondly  it increases the acoustic pressure at the tympanic membrane in the 1.5 to 5kHz 
range, which is the frequency range most important for speech perception. The middle ear 
ossicles form a transmission pathway that conducts sound energy from the tympanic 
membrane, at the interface of the external and middle ear, to the oval window of the cochlea. 
The tympanic membrane moves the manubrium or handle of the malleus. In turn, the long 
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process of the incus and manubrium move together because the malleoincudal joint is 
essentially  fixed. In contrast, the joint between the incus and the stapes is flexible. Therefore, 
because the stapes is fixed at its posteroinferior border, movement of the tympanic membrane 
causes it  to rock in and out of the oval window. The changes in acoustic pressure caused by 
the stapes moving in and out of the oval window are transmitted instantaneously  by the 
perilymph through the cochlear partition and then to the round window. This pressure 
transmission through the cochlear partition causes it to move either upward or downward, 
depending on the direction of the pressure change. Change initiates a mechanical traveling 
wave that reaches a maximum at  some point on the basilar membrane depending on the 
frequency of the stimulating sound. The mechanical traveling wave moves from the base to 
the apex of the cochlea largely owing to a reduced stiffness of the basilar membrane in the 
apical direction.  This traveling wave disturbance causes the hair cells in the organ of Corti to 
stimulate the dendritic endings of the cochlear nerve, thus signaling to the central auditory 
system that a sound stimulus has occurred (Lonsbury-Martin et al., 2003).
1.3. The development of the human ear
The development of the ear structures is a complex process. The critical period of ear 
development begins in the early embryologic period (three weeks of gestation), the inner ear 
appearing first. The inner, middle and outer portions of the ear have different embryological 
origins and development can be arrested at any stage. The result is a range of abnormalities 
from mild to severe and a disorder of one part does not necessarily signify  in disorder in 
another, but proximity in terms of time development, originating tissue, anatomic 
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characteristics, and function does mean that multiple malformations are possible (Wareing et 
al., 2006). 
The middle ear cavity  and lining of the middle ear and Eustachian tube develop  from the 
expanding terminal end of the first pharyngeal pouch with a small contribution from the 
second pharyngeal pouch. This is apparent in the fourth week of gestation. In the fifth and 
sixth week of gestation the mesenchyme between the branchial cleft  and the developing inner 
ear has condensations destined to become the ossicles. The head of the malleus, the body  and 
short process of the incus develop  from the neural crest mesenchyme of the first branchial 
arch (Meckel cartilage). The handle of the maleus, the long process of the incus, and tympanic 
surface of the stapes footplate develop from the second branchial arch (Reichert cartilage). 
The vestibular surface of the footplate and annular ligament arise from the mesoderm of the 
otic capsule. The stapes appears slightly before maleus and incus. It is initially ring shaped 
and penetrated by  the stapedial artery. By 10 weeks, the stapes has already  started to assume 
the familiar stirrup shape. By the time ossification begins from the solitary centre at 16 weeks, 
the structure is a model of the future stapes. It is reduced in bulk throughout fetal life to 
develop its slender architectural form. 
The maturation of the bony labyrinth plays a role in the pathogenesis of the otosclerosis. The 
otic capsule arises from mesenchyme surrounding the otic vesicle at 4 weeks of embryologic 
development. At 8 weeks, the cartilaginous framework is begun. At 16 weeks, endochondral 
bone replacement of this framework begins in 14 identifiable centers (Donaldson et al., 1992; 
Nager 1993). In some people complete bony replacement does not occur and leaves cartilage 
in certain locations. One of these regions, the fissula ante fenestram, is anterior to the oval 
window and is usually  the last area of endochondral bone formation in the labyrinth. 
According to the temporal bone studies this region is affected in 80-90% of patient with 
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otosclerosis (Bastian et al., 1996). The otic capsule reaches its adult size by week 22 of 
gestation (Wareing et al., 2006). 
2. Overview of the stapes (otosclerosis) pathophysiology 
Otosclerosis (localized bone dysplasia) is a primary  disease of the human otic (labyrinthine) 
capsule and stapes footplate, causing hearing and balance disorders, depending on the site, 
size, and histologic features of the pathologically involved area. When describing otosclerosis 
it is important to distinguish between the histological and clinical form of the disease (Declau 
et al., 2007). Histological otosclerosis refers to a disease process without clinical symptoms 
and is discovered only  on routine sectioning of the temporal bone. Clinical otosclerosis refers 
to the presence of otosclerosis foci at the site where it causes conductive hearing loss by 
interfering with the motion of the stapes or of the round window membrane (Guild 1944; 
Shambaugh 1949; Arnold et al., 1987). Otosclerotic plaques are mainly localized anterior to 
the oval window (fissula ante fenestram region) and on the stapes footplate (80%), round 
window (30%), pericochlear region (21%) and the anterior part of the internal auditory canal 
(19%). Other localizations although very rare have also been described: malleus, incus, facial 
canal, semi-circular canals and endolymphatic canal (Guild 1944). So far, otosclerotic foci 
have not been described in the external auditory canal (Hueb et al., 1991). 
There are three forms of histologic lesions of the otosclerosis: otospongiosis (early phase), 
transitional phase and otosclerosis (final phase). The early, active phase lesions consist of 
histiocytes, osteoblasts and the most active cell group  osteocytes (Fraysse et al., 1994). They 
absorb the bone around pre-existing blood vessels that causes higher and better 
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microcirculation. Otoscopic finding can reveal the reddish hue caused by this higher 
vascularization, known as Schwartze sign (Roland et al., 2006). 
As osteoblast becomes more involved, these areas grow rich in amorphous ground substance 
and deficient in mature collagen, resulting in formation of new spongy bone. At hematoxylin-
eosin staining, this new bone appears densely blue known as mantles of Manasse (1912). The 
late phase is characterized with the formation of sclerotic, dense bone in areas of previous 
bony resorption. The vascular spaces that were previously  dilated are narrowed due to bony 
deposits. Otosclerosis begins in endochondral bone, as the spongious and sclerosis continue 
the endosteal and periosteal layers also become involved (Roland et al., 2006). Its clinical 
presentation is mainly conductive hearing loss (CHL), although sensorineural hearing loss 
(SHL) and mixed hearing loss (MHL) may also occur. Symptom onset usually occurs by the 
early third decade of life, but onset is not unusual later in life. Bilateral form of disease is 
present in almost 80% of cases (Roland et al., 2006). 
Otosclerosis is also often associated with osteogenesis imperfecta (van der Hoeve syndrome) 
in a classic triad of hearing loss (conductive, mixed, or sensorineural), spontaneous bone 
fractures, and blue sclera (McKenna et al., 1998). 
Otoscopic examination findings are usually  normal, although 10% of patients demonstrate 
previously  mentioned Schwartze sign. Tuning-fork examination reveals signs of conductive 
hearing loss. Early in the disease course, pure-tone audiometry usually  demonstrates low-
frequency conductive hearing loss. High-frequency  losses begin to manifest  with gradual air-
bone gap widening. If cochlear involvement is not present, otosclerosis is limited to maximal 
conductive loss of 50-65 dB across all frequencies. If cochlear involvement is present, a 
mixed hearing loss appears, with high frequencies more affected. Stapes fixation produces an 
audiometric artifact known as the Carhart notch, which is characterized by elevation of bone 
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conduction thresholds of 5 dB at 500 Hz, 10 dB at  1000 Hz, 15 dB at 2000 Hz, and 5 dB at 
4000 Hz (Roland et al., 2006). Cochlear otosclerosis is characterized by the presence of 
mixed or primary  sensorineural hearing loss where air-bone gaps are minimal, and the speech 
discrimination scores are better than what would be anticipated with the degree of hearing 
loss (Donaldson et al., 1993). Tympanometry usually reveals a type As or A tympanogram. 
Acoustic reflexes are often abnormal and may provide the earliest evidence of otosclerosis. 
Advancing fixation affects both ipsilateral and contralateral acoustic reflexes, even in 
unilateral disease. The course of the otosclerosis is very  variable and so far there are no 
known factors that could suggest the progression of the disease (Glasscock et al., 1990). 
However, there are evidence showing that during puberty, pregnancy and the menopause 
hormonal factors could influence the disease progression (Glasscock et al., 1990; Donaldson 
et al., 1993).
Today surgical treatment (modern stapedotomy) remains the best possible treatment option for 
otosclerosis (Gjurić et al. 2007).
3. Epidemiology of otosclerosis
The otosclerosis is predominantly  a Caucasian disease correlating well with their geographic 
distribution throughout the world and with the mean prevalence estimated at 3/1000 or 0.3% 
(Karosi et al., 2009). Clinical otosclerosis is very rare among black, oriental and American 
Indian populations. The Japanese and South American populations have the 50% of the 
incidence of that of Caucasians (Altman et al., 1967; Tato et al., 1967; Thy et al., 2009). In 
distinguishing the clinical of histological form of otosclerosis several authors have studied the 
prevalence of the later. The mean prevalence was estimated to be 8.3% in Caucasian 
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population (Altman et al., 1967; Donaldson et al., 1993). Interestingly the study of Declau et 
al. (2007) reported the histologic prevalence of otosclerosis to be much lower, 3.4%. These 
results are in agreement with the histologic prevalence among Japanese people that is reported 
to be 2.56% (Ohtani et al., 2003) suggesting a possible common biochemical disease 
pathway. The average age at presentation is 33 years. Recent reports show shift  to the age 
between 40 and 50. The incidence ration between female and male is 2:1 and it  has been 
reported that otosclerosis advances more rapidly in females than males. About 60% of the 
patients with clinical otosclerosis report a family history  of the disease. The remaining 40% of 
cases are either autosomal dominant inherited cases with failure of penetrance in other family 
members, phenocopies, new mutations or rare cases transmitted with alternate model of 
inheritance (Gordon 1989; Sabitha et al., 1997; Thys et al., 2009).
4. Etiology of otosclerosis 
The etiology  of otosclerosis despite the variety  of theories proposed in the past is still not 
clear. In 1977 Wright suggested a vascular thrombosis and Glasscock in 1990 a repetitive 
micro fractures in the fissula ante fenestram region as a possible causal factors. These theories 
could not be confirmed by histological findings done by  Guild in1994. Donaldson in 1993 
based on a similar histological finding between the osteogenesis imperfecta and otosclerosis 
proposed a possible causal-link. In half of the otosclerosis cases there is a hereditary trait and 
multiple genetic and environmental factors contribute to its development. 
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4.1. The genetics of otosclerosis 
In 1861 the first report on a familiar pattern of hearing loss due to otosclerosis was presented 
by Toynbee. Later, another family  case of hearing loss was documented by Magnus (1876). In 
1922, Albrecht was first to conclude that otosclerosis could be inherited as an autosomal 
dominant disease in certain families. In 1960 Larson supported this hypothesis and found that 
in most autosomal dominant families, the penetrance is incomplete and lies between 25-40%. 
Fowler in 1966 conducted a twin study and found concordance for clinical otosclerosis in 
nearly all 40 pairs of monozygotic twins, which supported the initial theory that otosclerosis 
has a genetic basis. But this author concluded that due to the lack of evidence on the genetic 
transmission of histologic otosclerosis, it is not known whether the genetic basis of 
inheritance is related to the formation of the otosclerotic focus within the temporal bone or the 
tendency for a lesion to progress once it has already started, or both. Further studies showed 
that the genetic background facilitates the progression of the disease, but a triggering factor is 
probably  needed. Morrison and Bundy (1970) in a detailed genetic study  in larger otosclerotic 
families concluded that otosclerosis is autosomal dominant disease with 40% of penetrance. 
The results of that study were confirmed in 1975 (Gapany-Gapanavicus et al.) and 1984 
(Causse et al.). Although a strong familial background exists, 40-50% of all clinical cases 
have been reported to be sporadic, by reduced penetrance and characterized by other model of 
inheritance besides autosomal dominant. Today several known loci for otosclerosis have been 
localized (OTSC1, OTSC2, OTSC3, OTSC4, OTSC5, OTSC6, OTSC7, OTSC8 and 
OTSC10) on chromosomes 15q, 7q, 6p, 16q, 3q, 6q, 9p and 1q (Tomek et al., 1998; Van Den 
Bogaert et al., 2001, 2002, 2004; Chen et al., 2002; Brownstein et al., 2006; Thys et al., 2007; 
Bel Hadj et al., 2008; Schrauwen et al., 2011). However, to date none of the otosclerosis-
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causing genes have been identified despite the known chromosomal localization. Recently a 
new location on chromosome 7q22.1, located in the gene RELN (reelin protein that has a 
crucial role in the regulation of neuronal migration and positioning in the brain development) 
has been associated with otosclerosis. What is known today of RELN function has not an 
evident link with otosclerosis pathogenesis, but this finding could offer a new insight in the 
molecular mechanism related to the development of the disease (Schrauwen et al., 2009, 
2010). Still, many otosclerosis patients do not  have a family history of otosclerosis or do not 
follow a clear Mendelian segregation of disease and they represent the so called complex 
form of otosclerosis, caused by environmental and genetic factors. 
Autoimmune reaction against the otic capsule has been suggested as a possible etiologic 
factor in otosclerosis, and autoantibodies against type II collagen have been detected in the 
sera of patients with otosclerosis. The first genetic case-control association study of collagen 
types I and II genes with otosclerosis was done by McKenna in 1998. The COL2A1 gene was 
first analyzed due to its connection with the globuli interossei and the hypothesis that an auto-
immune reaction to type II collagen could be involved in otosclerosis (Yoo 1984; Sorensen et 
al., 1988). Studies on association of COL1A1 and otosclerosis have demonstrated an even 
more significant association between clinical otosclerosis, both familial and sporadic, and a 
Sp1 binding site polymorphism in the first intron of the COLIA1 gene (McKenna et al., 
2004). In 2007 Chen et al. further confirmed the correlation between the COL1A1 expression 
and otosclerosis.
Like in many  other diseases, the associations with the human leukocyte antigen (HLA) have 
been investigated for otosclerosis. HLA is an important factor associated with many  diseases, 
especially those with an immunological component. The HLA system represents the major 
histocompatibility complex in humans and is encoded by a complex DNA segment on 
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chromosome 6. Several studies showed an association between HLA system and otosclerosis 
(Miyazawa et  al., 1996) while in others no association could be determined (Nibu et al., 
1990). 
The transforming growth factor-β1 (TGF- β1) is a member of the TGF-β superfamily and 
plays an important role in the embryonic development and maintenance of both cartilage and 
bone. It is also important for the development of the otic capsule. In human otosclerotic bone 
cell cultures TGF- β1 can modify the phenotypic expression of glycosamynoglycans (GAG), 
fibronectin and collagen of the extracellular matrix (Bodo et al., 1995). In 2 large independent 
population studies (Janssens et al., 2005; Thys et al., 2009) TGF-β1 has been associated with 
otosclerosis. Based on the association with the TGF-β1 family the 13 new candidate genes 
were selected and further analyzed related to the metabolism of the otic capsule, involvement 
in the syndromic or non-syndromic forms of stapes fixation and other hypothesis related to 
the development of the otosclerosis. Two genes, bone morphogenetic proteins 2 and 4 (BMP2 
and BMP4) showed a significant association. Results showed that the individuals who possess 
the T allele of a single nucleotide polymorphism (SNP) in the 3’ untranslated region of BMP2 
have a higher risk of developing otosclerosis. The other single nucleotide polymorphism 
(SNP) association was an amino acid-changing SNP lying on exon 4 of BMP4 (Conne et al., 
2000; Schrauwen et al., 2008).
4.2. Measles virus infection 
Over the past 20 years many authors have studied the potential role of measles virus infection 
in the pathophysiology of otosclerosis. The hypothesis was assumed on a similarity between 
otosclerosis and Paget’s disease where evidence suggested a possible viral etiology (Singer, 
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1999). In 1986 McKenna et al. for the first time reported the presence of paramyxoviral 
neucleocapsids resembling structures in the osteoblast–like cells of the otosclerosis origin. 
Later, several studies supported this hypothesis based on electron microscopy observations, 
immunohistologic studies, and RNA detection in the otosclerotic tissue (Arnold et al., 1987; 
McKenna et al., 1990; Niedermayer et al., 1994; Arnold et al., 1996; McKenna et al., 1996). 
On the contrary, a study reported by Bozorg Grayeli et al. in 2000 could not confirm these 
results. The study was carried out on a large number of otosclerotic samples (35 patients) and 
measles virus could not be detected in none of the analyzed samples by  multiple highly 
sensitive detection methods. They concluded that high incidence of acute infections by 
viruses such as herpes simplex virus and measles virus in the general population, and the 
presence of these viruses in different  organs including the inner ear in normal individuals 
challenges the possible causal relationship  between the measles virus and the chronic disease. 
In 2007 Arnold et al. suggested the decrease in otosclerosis incidence due to a measles 
vaccination in the early 1970s. But since the otosclerosis develops mostly  between the 3rd and 
5th decade of life it is too early  to draw a definitive conclusion. The measles virus shows 
certain organotropism to the otic capsule and only human and primates are host of the measles 
virus due to their complementary  cell surface structures CD46 and CD150 (Dorig et al., 1993; 
Tatsuo et al., 2000). Latest study done by Karosi et al. in 2008 showed the existence of 4 new 
novel splice variants of the measles virus receptor CD46 only present in the otosclerotic 
stapes footplate. Histologic study of Sizklai et al. in 2009 confirmed the presence of measles 
virus in the stapes footplate of patients with histologically  diagnosed otosclerosis. Measles 
virus may be a triggering factor in the inflammatory  events which occur during the active 
phase of otosclerosis in a subpopulation of patients. However, the exact role of measles virus 
in the pathogenesis of otosclerosis remains to be further analyzed. 
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4.3. Hormonal influences
Estrogen deficiency is considered to be a cause of osteoporosis in women, and estrogen 
substitute therapy has shown beneficial effect in those cases. Although it is well established 
that estrogen inhibits bone resorption (Pacifici et al., 1996), its effect on osteoblasts is still 
unclear. In otosclerosis, hearing deterioration has been associated with pregnancy, and thus 
sex hormones were believed to be involved in the progression of the disease (Menger et al., 
2003). A more recent study  compared female patients with and without children in a relatively 
large population (n=154, Lippy  et al., 2005). This retrospective comparison did not show a 
difference of hearing loss between the 2 groups. However, considering the methodological 
limitations of such a study, definitive conclusions cannot be drawn. Estrogen has an inhibitory 
effect on bone resorption by  directly  inhibiting osteoclast activity  as well as decreasing auto- 
and paracrine production of cytokines such as IL-1 and IL-6 and tumor necrosis factor (TNF, 
Pacifici et al. 1996). Contradictory observations have been published concerning the 
estrogenic effect in osteoblasts, depending on the model and experimental protocol. Both 
decrease and increase of alkaline phosphatase activity  and osteoblastic proliferation have been 
reported. This variability  might be explained by the predominant type of estrogen receptor 
present in the target tissue (Bord et al., 2000). Imauchi et al., (2004) investigated the effect of 
17β-Estradiol on bone remodeling via diastrophic dysplasia sulphate transporter (DTDST) in 
otosclerosis and in a human osteoblast-like cell line (SaOS-2). 17β-Estradiol inhibited 
DTDST in SaOS-2 which expressed type alpha and beta receptors mRNAs. In otosclerotic 
cell cultures which expressed only type alpha receptors,  no effect could be observed. Authors 
concluded that the response to estrogens in terms of DTDST activity might be related to the 
expressed receptor type.  It is possible that exacerbating effects of estrogens in patients with 
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otosclerosis may be mediated by peculiar profiles of estrogen receptor in otosclerotic cells 
and therefore regulatory  mechanisms related to the estrogen receptor profile in the 
otosclerotic cells need to be further analyzed.
4.3.1. Parathyroid hormone and parathyroid hormone-related peptides receptor 
expression in otosclerosis
Considering the major role of parathyroid hormone in the physiology of bone metabolism 
mediated via osteoblasts (Aurbach et al., 1992) and the histological aspect of otosclerosis, the 
role of this hormone in the etiology of the disease has been investigated. Fano et al., (1993) 
showed that higher PTH concentration was required to stimulate the adenylate cyclase activity 
(AC) in stapes cells. The study conducted by Bozorg Grayeli et al., (1999) showed a lower 
PTH-PTHrP receptor mRNA expression in the otosclerotic samples associated with a lower 
cAMP response. This difference supports the hypothesis that abnormal cellular response to 
PTH may contribute to the abnormal turnover in otosclerosis. 
4.4. Inflammation factors
Previous studies have demonstrated the possible role of inflammatory and regulatory 
cytokines in the etiopathogenesis of otosclerosis (Karosi et al., 2005). Tumor necrosis factor-
alpha (TNF-α) is an inflammatory cytokine produced by monocyte-macrophage system which 
regulates the differentiation and activation of bone-derived mesenchymal cells. Its increased 
expression in otosclerotic bone could result  in an extensive osteoclast activation cascade and 
pathologic bone-turnover (Karosi et al., 2005, 2006; Stankovic et al., 2006). Cytokines such 
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as osteoprotegerin (OPG), receptor activator of nuclear factor-kappa B (RANK) and RANK 
ligand (RANK-L) play  a major role in the system that directly  controls bone turnover 
(Zehnder et al., 2005). RANK-L is expressed by many  cells including osteoblasts which are 
directly  involved in bone turnover. It  also regulates the differentiation, activation, and survival 
of osteoclasts by its specific RANK receptor. Osteoprotegerin or tumor necrosis factor–alpha 
super family  member 11b (TNFalphaSF11b) is the main inhibitor of the tumor necrosis factor 
alpha and an antagonist  of the RANK-L. It blocks the osteolysis and osteoclast formation and 
induces the osteoclast  apoptosis. Its main function is to maintain and secure the normal bone 
turnover (Boyce et al., 2007). 
Cytotoxic enzymes (elastase, collagenase, cathepsin-D/B), inflammatory cytokine mediators 
such as TNF-alpha, interleukin-1 (IL-1), interleukin-6 (IL-6) and complement fragments 
(C3a, C3b, C5a) are released from otosclerotic foci in the early  stages of the disease. It is 
possible that these molecules flow into the perilymph and interfere with the electromotility of 
outer hair cells, causing the sensorineural hearing loss (Karosi et al., 2005, 2006). In a recent 
study, Sziklai et al. (2009) showed that short-term effects of the TNF-α will not cause hearing 
loss, but its long-term effects might lead to sensorineural hearing loss associated with changes 
in the gene expression of the sensory  epithelium. The increased TNF-α production could 
trigger the focal bone resorption, thus the administration of monoclonal anti TNF-α antibody 
could be considered as a potential medical treatment option in types of cochlear otosclerosis 
with sensorineural hearing loss (Fricker et al., 2007). 
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5. Medical treatment of otosclerosis
So far there have been several medical treatment options suggested for otosclerosis (NaF, 
biphosphonates and bioflavonoids). 
The hypothesis of a potential preventive role of sodium fluoride (NaF) in otosclerosis was 
supported by epidemiological studies showing that disease was associated with areas of low-
fluoride content in the drinking water (Daniel, 1969). In 1980s Causse et al. thought that 
moderate doses of NaF could inhibit proteolytic enzymes and therefore decrease disease 
progression. In 1989 Bretlau et al. evaluated the effect of sodium fluoride treatment in 
patients with otosclerosis in a prospective clinical double-blind, placebo-controlled study of 
95 patients. Their results showed a statistically  significant greater deterioration of hearing loss 
in the placebo group than in the group actively treated with 40 mg of sodium fluoride daily. 
These results supported the view that sodium fluoride can change otosclerotic active lesions 
to more dense, inactive otosclerotic lesions. More recently Bozorg Grayeli et al. in 2003 
studied the possible molecular effect of sodium fluoride (NaF) in otosclerosis. They  showed 
that sodium fluoride affects the otosclerotic cells by inhibiting the diastrophic dysplasia 
sulphate transporter (DTDST) activity  via intracellular calcium and cAMP. This transporter is 
implicated in the sulfation of bone matrix glycosaminoglycans (GAG). Previous studies 
(Bodo et  al., 1997) had demonstrated that otosclerotic cell cultures produce bone matrix GAG 
with a higher level of sulfation. The inhibitory effect of the sodium fluoride on DTDST 
activity may reduce GAG sulfation, participate in the reduction of bone remodeling and 
eventually lead to the preservation of the sensorineural hearing function in otosclerotic 
patients (Bozorg Grayeli et al., 2003). In 2006, Imauchi et al. further showed that the 
observed increased activity of DTDST in otosclerotic cells can be inhibited by 
Dexamethasone. The effect could be mediated via inhibition of autocrine/paracrine 
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interleukin 6 (IL-6) secretion that has stimulatory effect on DTDST. This observation opened 
new pharmacological insights in the treatment of hearing loss in otosclerotic patients. 
The use of biphosphonates have also been studied as a potential therapy option in 
otosclerosis. In 1993 Keneddy et al. performed a study to evaluate the role of etidronate 
disodium for the treatment of progressive hearing loss in patients with otosclerosis. The 
results showed a trend (not statistically significant) toward stabilization or improvement in air 
conduction thresholds in some frequencies (1000 and 4000 Hz) and in bone conduction 
thresholds at other frequencies (500, 1000, and 2000 Hz). Other studies on the use of 
biphosphonates in otosclerosis showed no biphosphonates effect on hearing preservation and 
severe side effects were observed (Yesil et al., 1998). In 2008 Kanzaki et al. performed a 
study on an animal model (osteoprotegerin knock out mice) and showed that the use of 
nitrogen-containing biphosphonates, risedronate, could prevent both degenerative changes of 
auditory ossicles and progressive hearing loss. 
Flavonoids or biflavonoids (flavonols and flavanols) have also been studied as potential 
therapeutical agents in otosclerosis. They are  most commonly known for the antioxidant 
activity. Additionally, at high experimental concentrations that would not exist in vivo, the 
antioxidant abilities of flavonoids in vitro are stronger than those of vitamin C and E. Sziklai 
et al. (1995) investigated the possible beneficial role of bioflavonoids in an otosclerosis-like 
lesions.  On an animal model it was observed that flavonoids interference in bone remodeling 
process is induced by  prostaglandin E2 (PGE2). The fact that PGE2 effects are mediated 
through cyclic AMP in bone turnover and flavonoids act synergistically with PGE2 in 
collagen synthesis confirm a cyclic AMP phosphodiesterase inhibitory  role of flavonoids. 
Previously the beneficial role of Ipriflavone (7-isopropoxy-isoflavone) was observed  while in 
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the 1995 the same effect was observed but for another flavonoid (Quercetine or 7-
pentahydroxyflavone), Sziklai et al. 
6. Otosclerosis-like lesions 
So far there are several otosclerosis-like lesions of the stapes footplate and otic capsule 
observed: Osteogenesis imperfecta, Paget’s disease, osteopetrosis, osteoporosis, rare bone 
diseases. 
Osteogenesis imperfecta is characterized by multiple bone fractures, often as a consequence 
of only minimal trauma. In about 50% of cases, hearing loss of conductive or mixed type is 
present. There is a small similarity of the histological findings between osteogenesis 
imperfecta and otosclerosis. However there are some obvious differences. Most important, in 
otosclerosis the disease affects manly endochondral layer of the otic capsule as opposed to the 
osteogenesis imperfecta where all three layers of the otic capsule are always involved 
(Alkadhi et al., 2004). 
Paget’s disease is a metabolic bone disease characterized by excessive bone resorption and 
formation due to activated osteoclasts. An overall prevalence is about 3% (Klein et al., 1995). 
Like otosclerosis it has a later onset in life and a possible viral pathogenesis has been 
reported. Histological images are far different from those seen in otosclerosis and hearing loss 
in affected patient is usually not due to ossicular lesion (Thys et al., 2009). 
Osteopetrosis is another bone disease characterized by lack of resorption of cartilage in 
primitive bone, resulting in an increased bone density of different bones in the body, including 
the temporal bone. Hearing loss is most likely due to a compression of acoustic nerves 
(Balemans et al., 2005).
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Osteoporosis is a disease characterized by a reduced bone mineral density and changes in 
bone structure. Studies of the disease have shown a higher prevalence of the disease in 
otosclerosis patients suggesting a possible common genetic pathogenesis (Clayton et al., 
2004).
Otosclerosis and otosclerosis-like lesions have also been reported in different rare bone 
diseases like: Camurati-Engelmann disease (Huygen et al., 1996). A very rare sclerosing bone 
dysplasia characterized by  a constant  bone turn-over. Sensorineural hearing loss observed in 
the course of the disease is most likely caused by narrowing of the internal auditory canals. In 
families with certain genetic diseases the congenital stapes fixation has been noted: X-linked 
stapes fixation with perylimphatic gusher (de Kok et al., 1995), stapes ankylosis, broad 
thumbs and toes syndrome (Teunissen et al., 1990), proximal syphalangism (Gong et al., 
1999), and facio-audio-symphalangism (van den Ende et al., 2005). The last three syndromes 
are associated with the Noggin gene mutation. The Noggin protein binds and inactivates 
BMPs (bone morphogenetic proteins) and has a role in the bone metabolism (Zimmerman et 
al., 1996; Liu et al., 2003).
7. Renin-Angiotensin-Aldosteron System 
7.1. Overview
The renin-angiotensin-aldosterone system (RAAS) is a major physiological regulator of 
arterial pressure and hydro-electrolyte balance (Haber et al., 1983; Santos et al., 2000). This 
system is also considered not only as an endocrine system but also as an autocrine/paracrine 
modulator of tissue functions of different organs like heart, blood vessels, kidney, brain and 
59
endocrine glands (Gasparo et al., 2000). There are three important components of this system: 
1) renin, 2) angiotensin, and 3) aldosterone. Renin, a proteolytic enzyme that is primarily 
released in the circulation by the kidneys, stimulates the formation of angiotensin in blood 
and tissues, which in turn stimulates the release of aldosterone from the adrenal cortex. When 
renin is released into the blood, it  acts upon a circulating substrate, angiotensinogen, that 
undergoes proteolytic cleavage to form the decapeptide angiotensin I. Vascular endothelium, 
particular in the lungs, has an enzyme, angiotensin converting enzyme (ACE), that cleaves off 
two amino acids to form the octapeptide, angiotensin II (Ang II) although many  other tissues 
in the body (heart, brain, vascular) can also form angiotensin II. Once formed angiotensin I 
can be processed by several proteases originating, in addition to angiotensin II, in to several 
biologically active angiotensin peptides (Figure 2). Thus angiotensin (Ang 2-10), and 
angiotensin (Ang 3-10) are formed via amino peptidases (Page et al., 1974). These amino-
derivates of angiotensin I can then be further processed into the biologically  active peptides 
Ang-2-8 (Ang III), Ang-3-8 (Ang IV) via angiotensin-converting enzyme and to Ang-3-7 via 
post-proline cleaving enzymes (Green et al., 1982; Neves et al., 1995). Nevertheless, 
angiotensin II remains to be the central product of the renin-angiotensin system. 
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Figure 3- Simplified illustration of the protheolytic pathway for the formation of biologically 
active angiotensin peptides. ACE: Angiotensin converting enzyme; Amp A: Aminopeptidase A; 
Amp: Aminopeptidases; Cbp: Carboxypeptidases; D-Amp: Dipeptidyl-aminopeptidase I-III; 
NEP: Neural-endopeptidase 24.11; PCP: Prolyl-carboxypeptidase; PEP: Prolyl-
endopeptidases (Santos RAS et al., 2000) 
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7.2. Angiotensin II 
The first insight into the regulation of blood pressure came from the discovery of a 
vasopressor agent by  Tigersted and Bergman in 1898. They called this factor “renin” because 
it was extracted from the kidney. This pioneering work led to the description of reno-vascular 
hypertension in animals and humans (Goldblatt  et al. 1934). In 1940, Braun Menendez et al. 
isolated a vasoconstrictor substance from the renal venous blood. A similar finding was made 
simultaneously  by Page and Helmer (1940) after the injection of renin to an animal. The 
group also isolated a so-called “renin activator” later know as angiotensinogen. The pressor 
substance was named hypertensin and angiotonin and later it was isolated and shown to be an 
octapeptide (Skeggs et al., 1956; Bumpus et al., 1957; Elliot and Peart, 1957). In 1958, 
Braun-Memendez and Page agreed on the term angiotensin for this highly potent pressor 
octapeptide. 
Afterwards various components of the cascade leading to the formation of Ang II were 
characterized, including angiotensinogen, angiotensin converting enzyme (ACE), and Ang I, 
and Ang III. The synthesis of the peptide Ang II by Bumpus et al. (1957) and by Rittel et al. 
(1957) was followed by a continuing series of investigations on the structure-activity 
relationship  of angiotensin analogs, mainly in the hope of finding a peptide antagonist. The 
sequence of angiotensin II was described as Asp-Arg-Val-Tyr-Ile-His-Pro-Phe in the human 
and various animals.
In 1987, a committee of the International Society for Hypertension, The American Heart 
Association, and the World Health Organization proposed abbreviating angiotensin to Ang 
using decapeptide angiotensin I as the reference for numbering the amino acids of all 
angiotensin peptides (Dzau et al., 1987).
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Ang II, a bioactive octapeptide, plays a key role in the regulation of cardiovascular 
homeostasis (Gasparo et al., 2000). The wide spectrum of Ang II target tissues includes the 
adrenals and kidney (aldosterone release, which in turn acts on kidneys to increase sodium 
and fluid retention), brain (stimulates thirst centers within the brain), pituitary gland 
(stimulates the release of vasopressin, antidiuretic hormone), vascular smooth cells (constricts 
resistance vessels, thereby increasing systemic vascular resistance and arterial pressure), and 
the sympathetic nervous system (stimulates norepinephrine release from sympathetic nerve 
endings and inhibits norepinephrine re-uptake). Ang II may also function as a paracrine and 
autocrine hormone inducing cellular growth and proliferation and controlling extracellular 
matrix formation (Dzau et al. 1987; Griffin et al., 1991; Weber et al., 1995). Other 
angiotensin-derived metabolites such as angiotensin 2-8 (Ang III), angiotensin 1-7, or 
angiotensin 3-8 (Ang IV) have all been shown to have biological activities (Table 1), (Peach, 
1977; Schiavonne et al., 1990; Ferrario et al., 1991; Ferrario et  Iyer, 1998; Wright et al., 
1995).
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Table 1. Amino acid sequences of Angiotensin II precursors and metabolites (De Gasparo et 
al., 2000)
Designation Peptide Sequence
Angiotensinogen Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His Leu-LeuVal-Tyr-Ser
Ang I Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu
Ang II Asp-Arg-Val-Tyr-Ile-His-Pro-Phe
Ang III        Arg-Val-Tyr-Ile-His-Pro-Phe
Ang IV                 Val-Tyr-Ile-His-Pro-Phe
Angiotensin 1-7 Asp-Arg-Val-Tyr-Ile-His-Pro
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Pharmacological studies have shown several types of Ang II receptors (Hagiwara et al., 
1998). Ang II receptor type 1 (AT1) regulates two distinct signaling pathways that involve G 
proteins. One pathway  involves activation of phospholipase C, with subsequent stimulation of 
the production of inositol 1,4,5-triphosphate, and the other involves the regulation of the level 
of cAMP via the activation or inhibition of adenylate cyclase. The signaling pathway of Ang 
II receptor type II (AT2) remains to be explained. More recently the Ang II receptor type 4 
(AT4) has been described and it appears to be involved in memory  acquisition and recall 
(Gasparo et al., 2000). 
Most of the known effects of Ang II are mediated through the AT1 receptor. In vitro as well as 
in vivo studies suggest that the AT2 receptor has antagonistic effect on AT1 (Gasparo et al., 
2000). There is an inactivation of MAPK, anti-proliferative effect, promotion of apoptosis, 
differentiation and regeneration, opening of delayed K+ channels and closing of T-type Ca2+ 
channels. The re-expression of AT2 receptor in various diseases suggests a role of this 
receptor in its pathophysiology. Like the AT2 receptor, the AT4 receptor also opposes the 
effect of AT1 receptor (Gasparo et al., 2000). 
Specific non-peptide antagonist, such as losartan and other sartans block AT1 receptors, while 
non-peptide compounds, such as PD123317 and PD123319, antagonize AT2 receptors.
7.3. Angiotensin II signaling pathways 
Ang II activates several nuclear transcription factors, including signal transducer and activator 
of transcription factors (STAT), activator protein 1 (AP-1), NF-κB and cyclic adenosine 
monophosphate (cAMP) response element-binding (CREB) protein (Zahradka et al., 2002; 
He et al., 2006). Among these, the NF-κB is particularly  interesting because it plays a pivotal 
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role in control of multiple immune response genes, including cytokines and adhesion 
molecules. Its inhibition is shown to prevent inflammatory  responses and attenuate the 
expression of pro inflammatory cytokines. NF-κB is retained in the cytoplasm by an 
inhibiting subunit, inhibitor of κB (IκB). In response to pro inflammatory cytokines the IκB is 
phosphorylated leading to the NF-κB activation. A previous study  has clearly shown that Ang 
II activates NF-κB by  inducing the phosphorylation and degradation of IκB (Kawano et al., 
2006). 
Ang II is also known to activate the family of mitogen-activated protein kinases (MAPK), 
including extracellular signal-regulated kinases (ERK 1 /2), c-jun N-terminal kinase (JNKs, 
also known as SAPKs), p38MAPKs. The MAPKs are regulatory proteins that control cellular 
response to growth, apoptosis and stress signals (Martin et al., 2005). Ang II activates all 
these MAPKs except big MAPK-1 (Daniels et al., 2005; Znao et al., 2005; Wang et al., 
2006). The activation of the other three MAPK signaling pathways can result in the NF-κB 
activation by phosphorylating and degrading the IκB. A study in human endothelial cells by 
Guo et al., (2006) demonstrated that stimulation of NF-κB DNA binding by Ang II is 
dependent in MAPK activation. Results showed that p38MAPK, but not  JNK or ERK, is 
involved in Ang II-induced NF-κB activation. 
7.4. Angiotensin II and pathophysiology of otosclerosis 
The progression of hearing loss in otosclerosis occurs in 25 to 76% of females during 
pregnancy and may explain the female predominance reported in this disease 
(Schuknecht et al., 1974). No consistent biological explanation has been advanced for this 
phenomenon (Donaldson et al., 1993). During pregnancy, the plasma angiotensinogen 
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concentration is increased and the RAAS is stimulated resulting in elevated plasmatic Ang II 
concentrations (Schrier et al., 1997). The tissue Ang II production may also increase during 
pregnancy as suggested by observations in the smooth muscles of decidual spiral arteries 
(Moran et al., 1997). Considering the progression of otosclerosis during pregnancy and the 
increase of angiotensinogen production during this period, the implication of Ang II in 
otosclerosis seemed to be possible. In a study by Imauchi et al. in 2008, this hypothesis was 
investigated through two types of experiments. Authors tested whether functional 
polymorphisms of RAAS could be associated with otosclerosis in a large case-control study. 
The results of the study demonstrated that  T235 variant allele related to higher 
angiotensinogen plasmatic concentrations was associated with otosclerosis. Furthermore, 
ACE I/D polymorphism seemed also to be associated with the occurrence of the disease. The 
proportion of DD genotype associated to an increased ACE activity was also higher in 
patients with otosclerosis than in control subjects. Patients with both TT and DD genotypes 
had an increased risk of otosclerosis compared with patients with DD or TT genotypes only. 
The results of the same study also demonstrated the presence of angiotensinogen and Ang II 
receptor types 1 and 2 in otosclerotic cultures. This study also showed in increased IL-6 
release in the culture media and a reduced activity  of alkaline phosphatase under the effect  of 
Ang II (10-7 M, 24h) only in cultures derived from otosclerosis and not in control stapes. 
These results suggested that RAAS is implicated in the progression of otosclerosis, and that 
Ang II does not have the same effects in otosclerosis as in normal stapes. It has been 
previously  described that Ang II increases the autocrine-paracrine production of IL-6 in 
vascular smooth muscle cells, and this interleukin is a well-known mediator of bone 
resorption and a pro inflammatory cytokine. The difference between otosclerotic and normal 
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stapes could be related to a different Ang II receptor profile or differences in the intracellular 
signaling pathways. This issue is crucial and has to be investigated further.
8. Oxidative stress 
8.1. Overview 
Oxidative stress takes place in tissues under the effect of toxic agents, inflammation, 
ischemia, or physical trauma. These situations may  lead to an excessive formation of reactive 
oxygen species (ROS), and disequilibrium in the steady–state between formation and 
elimination of ROS (Halliwell et al., 1989). This stress can cause various acute, as well as 
chronic diseases, such as cardiovascular (Ignaro et al., 2007), neurodegenerative diseases 
(Emerit et al., 2004) and malignant tumors (Dreher et al., 1996). Nowadays, there is growing 
evidence about the physiological generation of ROS that can occur as a byproduct of other 
biological reactions. NADPH oxidase is known to be the major source of ROS, but ROS 
generation also occurs with mitochondria, peroxisomes, cytochrome P-450, and other cellular 
elements (Bedard et al., 2007). Several growth factors and cytokines (e.g. TGF-β and PDGF) 
through binding to different types of cell membrane receptors can elicit a rise in intracellular 
ROS. Furthermore, it has been reported that ROS activate MAPK pathways in several 
systems, including extracellular signal regulated kinase (ERK) 1/2, Jun-NH2-terminal kinase 
and P38 MAPK cascades (Henrotin et al., 2003). With an excessive amount of ROS in the 
cellular membrane environment, lipid peroxidation occurs and lipid cell constituents are 
damaged. Lipids are essential in cell membranes and among the first molecules susceptible to 
the damage caused by reactive oxygen species. Free radical reactions in tissues are 
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accompanied by oxidative degradation of polyunsaturated fatty acids of membrane lipids 
(Esterbauer et al., 1990). This process results in the production of highly reactive aldehydes 
which are named “second messengers” as opposed to the primary free radicals that initiate 
lipid peroxidation (Esterbauer et al., 1967, Schauenstein et al, 1977). Unlike reactive oxygen 
species (ROS), reactive aldehydes are relatively long-lived. Therefore, they might diffuse 
from the site of their production and attack distant intracellular or extracellular targets. 
Among many different aldehydes, most thoroughly  studied are malondialdehyde, acrolein and 
the 4-hydroxyalkenal family, in particular 4-hydroxynonenal (HNE). 
8.2. 4-hydroxynonenal (HNE)
4-hydroxyalkenals are endogenous end-products of polyunsaturated membrane fatty acid, 
lipoprotein, and phospholipid peroxidation. HNE is the major lipid peroxidation product of 
ω-6 polyunsaturated fatty acids (linoleic and arachidonic acid) (Esterbauer et al., 1991; 
Zarkovic 2003; Schaur 2003) Figure 4. 
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Figure 4- Pathway of lipid peroxidation (Spicket et al., 2010)
HNE is a second messenger of free radicals and a major bioactive marker of lipid 
peroxidation (Zarkovic, 2007). This reactive aldehyde has been generally considered to be 
merely a toxic end-product of lipid peroxidation contributing to the deleterious effects of 
oxidative stress. Thus, the importance of HNE has been considered in the pathophysiology of 
several diseases such as those involving chronic inflammation, neurodegenerative diseases, 
ischemia/ reperfusion, adult respiratory distress syndrome, atherogenesis and diabetes 
(Borovic et al., 2007). On the other hand, HNE has attracted a great deal of interest in recent 
years because of its role as a signaling molecule. Numerous studies in the last  decade have 
clearly  demonstrated that HNE can cause apoptosis, differentiation, modulate cell growth, and 
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affect various kinases involved in signal transduction (Esterbauer et al., 1991; Zarkovic et al., 
2002; Dianzani et al., 2003). The role of HNE in signaling processes is intriguing because its 
pleomorphic effects are concentration dependent; at low levels, HNE promotes cell 
proliferation, whereas at higher concentrations, it  induces cell cycle arrest, differentiation, and 
finally apoptosis (Awasthi et al., 2005). For this reason, the regulation of intracellular 
concentrations of HNE might be crucial for the nature of cell cycle signaling. It was found 
that HNE can induce cell growth, accompanied by the activation of MAPKs (ERK, JNK and 
p38) and induction of c-fos, c-jun gene expression, and AP-1 DNA binding activity (Kakishita 
et al., 2001). Studies have also shown that HNE induces various enzymes including 
phospholipase C, adenylate cyclase, caspase 3, protein kinase C and other kinases involved in 
signal transduction cascades, strongly comprising a role of HNE in signaling cascades. It is 
also able to influence cellular functions by regulating the genes encoding for other molecules 
such as heat-shock protein genes (Allevi et al., 1995), c-myc (Barrera et al., 2005), c-fos , c-
jun (Ruef et al., 1998), c-myb (Barrera 1996), cyclins (Barrera et al., 2005), p53 gene family 
(Laurora et al., 2005), procollagen type I, and TGF-β1 (Poli et al., 1995). 
Moreover, HNE is found to be a physiological constituent of many human and animal tissues 
(Esterbauer et al., 1967, 1990; Poli et al., 2000; Zarkovic et al., 2009) however its 
physiological role has yet to be clarified, but  it is likely  that HNE could have an important 
role in the regulation of cellular growth (Zarkovic et al., 1993; Barrera et al., 1991; Kreuzer et 
al., 1998). 
Relatively high steady state concentrations of HNE in cell membranes indicated the primary 
site of its origin, from where it  can diffuse acting as a second messenger of free radicals. 
Unlike free radicals or the other ROS, HNE has the unique feature to remain stable for some 
time and binds to macromolecules with high reactivity, especially to proteins, causing 
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alteration of their tertiary structure and their function. These alterations are mainly  conducted 
through formation of covalent bond with cysteine, lysine and histidine amino acid residues 
(Zarkovic et al., 2003; Uchida et al., 2003). HNE mostly reacts with SH groups of proteins 
and peptides generating HNE-protein conjugates that can be determined by the use of 
monoclonal antibodies. On the other hand, such reaction with glutathione (GSH) represents its 
most important detoxification mechanism (Borovic et al., 2007).
In addition, detoxification mechanisms of HNE are important to define the amount of cellular 
protein modified by HNE. GSH is the most important intracellular antioxidant that protects 
cells from HNE. Consequently, after administration of HNE, the amount of HNE-modified 
proteins can be deduced by intracellular level of GSH. This level is crucial for cellular 
sensitivity to HNE toxicity (Borovic et al., 2007). Although GSH could act alone, 
detoxification reaction is accelerated by GSH metabolizing enzymes such as glutathione S-
transferases (GSTs). Noteworthy, Ramana et al., (2006) reported that conjugates of GSH with 
HNE activate PKC and stimulate NF-κB and AP-1-dependent gene transcription leading to an 
increase in cell growth.
In conclusion, the unique pathways and the primary molecular targets of intracellular signal 
transduction mediated by HNE are still unknown. However, it seems that a unique receptor is 
not necessary  for HNE to achieve growth regulating effect. On the other hand complexity  of 
possible interactions with signal-transduction pathways increased enormously. Possible 
signaling pathways of HNE involved in oxidative stress influenced bone cell growth are 
summarized in Figure 5
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Figure 5- 4-hydroxynonenal (HNE) potential signaling pathways in pathophysiology of bone 
cell growth as defined using bioactive glass in vitro (Mrakovcic et al., 2010)
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9.  The goal of the study
Active phase of otosclerosis is accompanied by signs of inflammation. There are numerous 
multi nucleated osteoclasts, osteocyte-like cells and proliferating endothelial cells in the 
pseudo-vascular spaces of the active otosclerotic foci. Mostly, CD8 positive, cytotoxic T 
lymphocytes and activated osteoclasts with possible cytokine secretion are found in the 
peripheral zone of active foci. Previous studies have suggested different types of pro-
inflammatory and regulatory cytokines playing a role in the etiopathogenesis of otosclerosis 
(Sziklai et al., 2009, Karosi et al., 2006). The origin or the triggering factor of this 
inflammation is not elucidated. Participation of microorganisms such as bacteria, virus, fungi 
or even mastication trauma has been advocated (Schrauwen et al., 2010; Niedermayer et al., 
1996). Another issue in the pathophysiology of otosclerosis is the persistent inflammation 
during several years. In a pathophysiological model proposed for diabetes mellitus type 1, a 
coxsackie virus is the triggering factor in the destruction of the islets of Langerhans. The 
inflammation is maintained by an auto-immune reaction which appears secondarily  and 
completes the endocrine tissue destruction (Tirabassi et al., 2010). This model is a possible 
explanation for the chronic inflammation in otosclerosis considering several reports on auto-
immune activity  in patients with otosclerosis (Schrauwen et al., 2010). However, auto-
immunity is not constantly observed in otosclerosis (Karosi et al., 2010).
In order to elucidate other factors which may participate in the maintenance of the 
inflammation, Ang II was investigated (Imauchi et al. 2008). By inducing or promoting 
inflammation, Ang II can potentially induce oxidative stress in otosclerosis. Potentially, this 
stress has dramatic effects on bone remodeling. Reactive oxygen species (ROS) diffusion into 
the inner ear might also explain inner ear lesions during otosclerosis. 
74
The goal of this research was to study the role of Ang II and oxidative stress in bone and 
especially in otosclerosis through 2 experimental models:
 1)  Investigation on the effect  of Ang II on inflammation pathways in human 
  primary bone cell cultures in otosclerosis and normal human stapes 
 2)   Study of Ang II and HNE interaction in a human osteoblast-like cell line 
  (HOS)
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II. ANGIOTENSIN II AND CYTOKINE PRODUCTION 
IN HUMAN OTOSCLEROTIC PRIMARY BONE CELL 
CULTURES 
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1. Introduction 
Ang II effects on tissue remodeling and repair have been previously studied in humans and 
animals. Ang II is implicated in the key events of inflammation and alters the composition of 
the extracellular matrix through various growth factors and cytokines. In the present study, we 
aimed at further investigation of Ang II effect on cytokine production in human primary 
otosclerotic bone cell cultures. 
1.1. Angiotensin II effect on bone cells
Ang II tissular effects
In addition to its well-known effect on cardiovascular system and body fluid homeostasis, 
Ang II can act as a local growth factor with effect  on both proliferation and cellular 
hypertrophy  (Lamparter et al., 1998). Ang II can stimulate the proliferation of heart myocytes, 
fibroblasts, fetal mesangial cells, and adrenal cells. It also plays an important role in various 
models of tissue repair in various models of tissue injury  (Lamparter et al., 1998). Bone is one 
of the most prominent tissue in which constant  remodeling requires a continuous regulation of 
growth activities. A variety  of systemic and local growth factors have been implicated in this 
process (Mundy  et al., 1993). Vasculature plays an important role in bone remodeling under 
normal and pathological conditions. Ang II binding sites have been located in almost every 
organ system and it has been shown that Ang II is generated locally by  endothelial cells 
(Millan et al., 1989). Endothelial and bone cells are likely to interact through paracrine 
mediators because of their close anatomical relationship. One of these mediators could be Ang 
II. 
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Ang II significantly contributes to bone demineralization in hypertensive patients (Shimizu et 
al., 2008). Previously, it was observed that the use of ACE inhibitors reduced the risk of 
fractures in a large retrospective case-control study on osteoporosis (Rejnmark et al., 2006). 
Ang II cellular effects
Ang II has potent effects on the proliferation and function of osteoblasts (Lamparter et al. 
1998). In vitro Ang II not only stimulates bone cell proliferation but has also proved to be a 
stimulator of collagen synthesis, suggesting that it might play an anabolic role in the 
remodeling process in rodents and in human. Moreover, Ang II appears to be a potent 
suppressor of osteoblastic differentiation in the new-born rat calvaria model (Hagiwara et al., 
1998). Ang II was found to decrease the mRNA expression of osteocalcin, a well-known 
marker of osteoblastic differentiation. Similarly, the alkaline phosphatase activity and the 
formation of mineralization nodules were also inhibited. 
These effects seem to be mediated not only by Ang II receptors (AT1 and 2) but also by 
paracrine mediators (Shimiza et al., 2008, Inagami et al., 1999). Indeed, incubation of bone 
cells responsive to Ang II with the hormone followed by co-cultures of responsive cells with 
those lacking Ang II binding sites also elicited effects on co-cultured cells. Several mediators 
of Ang II have been previously described such as transforming growth factor-beta (TGF-β, 
Gibbons et al., 1992), basic fibroblast growth factor (bFGF, Stirling et al., 1990), platelet 
derived growth factor (PDGF, Naftilan et al., 1989), insulin-like growth factor I, (IGF-I, 
Delafontaine et al., 1993) parathyroid hormone-related protein (PTHrP, Pirola et al., 1992), 
and prostaglandins (Trachte et al., 1990), which could be responsible for these paracrine 
effects of Ang II on bone cells. These mediators are produced by different bone cell 
populations and act on osteoclasts (Hatton et al., 1997). 
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In osteoporosis, Ang II treatment in osteoblasts up-regulate RANKL expression through ERK 
pathway, leading to osteoclast  activation and differentiation (Kim et al., 2003). RANKL up-
regulation appears to be a key step  in osteoclast differentiation, activation and bone resorption 
by Ang II. Indeed, osteoblast / stromal cells express RANKL in response to several bone-
resorbing factors including vitamin D3 to support osteoclast  differentiation from their 
precursors. Osteoclast  precursors, which express RANK, recognize RANKL through cell-to-
cell interactions with osteoblasts / stromal cells and differentiate into mature osteoclasts in the 
presence of M-CSF. Targeted disruption of either RANKL or RANK in mice causes a lack of 
osteoclasts and an osteopetrotic phenotype. Moreover, Ang II activates NF-κB in osteoclasts 
leading to an anti apoptotic effect and the immune response activation in these cells (Kong et 
al., 1999). As osteoclast differentiation is also regulated by a variety of hormones, local 
factors, and inflammatory cytokines such as IL-1 and tumor necrosis factor alpha (TNF-α), 
RAAS seems to be a significant modulator of the osteoclast differentiation via several 
pathways. 
The important role of Ang II in bone metabolism is integrated in a larger regulation system 
where this hormone and others implicated in bone metabolism (e.g. estrogens) interact. In an 
animal osteoporosis model, the continuous administration of Ang II accelerates osteoclast 
activation induced by  estrogen deficiency. Indeed, estrogen antagonizes the bioactive effect of 
Ang II through signaling cross-talk in vascular smooth muscle cells (Takeda Masubara et al., 
2002, Liu et al., 2002). This interaction opens therapeutic insights for Ang II receptor 
blockers. These agents could be used to treat hypertensive elderly  patients, especially the 
female population to prevent or reduce osteoporosis. Further clinical trials with Ang II 
receptor blockers are necessary to confirm this hypothesis. 
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The goal of this part of the project was to further investigate the role that Ang II might have 
on the osteoblast-like cells (primary otosclerotic stapes cell cultures) and to assess the pro-
inflammatory cytokine secretion in response to the Ang II stimulation.
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ABSTRACT
Introduction: The aim of this study was  to assess the expression and production of 
inflammation mediators in basal condition and after AngII in otosclerosis. Materials 
and methods: Human stapedial cell cultures (6 otosclerosis and 6 controls) were 
incubated with AngII (10-7 M, 24 H) or vehicle. Cytokines and their mRNA expression 
were assessed by antibody and cDNA arrays. Results: In basal conditions, 
otosclerosis cultures produced higher amounts IL1b and IP-10, and smaller amounts 
TIMP-2. AngII promoted inflammation by increasing IFN-gamma, and IL-10, and by 
decreasing MIP-1 alpha and sTNF-RII. Conclusions: Otosclerotic cultures  produced 
higher pro inflammatory cytokines in basal condition. AngII appeared to promote 
inflammation via these mediators in otosclerosis.
Key words: Bone dystrophy, angiotensin II, hearing loss, inflammation, bone 
remodeling
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INTRODUCTION
Otosclerosis is a bone remodeling disorder of the human otic capsule and one of the 
most frequent causes of acquired hearing loss in adult Caucasians  [Roland & Samy, 
2006]. Its prevalence is estimated as 0.3% of population in Western countries 
[Roland & Samy, 2006]. This disease affects both ears in 80% of the cases [Roland & 
Samy, 2006]. The disease is usually discovered between the third and fifth decades 
of life with a significant female predominance (2:1 sex ratio) [Roland & Samy, 2006]. 
Pregnancy has been reported to accelerate the progression of hearing loss due to 
otosclerosis [Roland & Samy, 2006]. This relation suggests  the implication of 
hormonal changes during the pregnancy in the disease progression.
Initially, the bone remodeling occurs  on the anterior part of the oval window and 
stapes (i.e. fissula ante fenestram), reducing the stapedial mobility, and leading to a 
conductive hearing loss. As  the disease progresses, the bone surrounding the 
cochlea is involved causing a sensorineural hearing loss  [Menger & Tange, 2003]. 
Cytotoxic enzymes (elastase, collagenase, cathepsin-D/B), inflammatory cytokine 
mediators  (TNF-alpha, interleukins, IL-1 and 6) and complement fragments (C3a, 
C3b, C5a) released from otosclerotic foci can diffuse into the perylimph, interfere with 
the electromotility of the cochlear sensory cells, lead to tissue damage and cause 
sensorineural hearing loss [Sziklai et al., 2009].
The etiology of otosclerosis  remains still unclear. Even if several monogenic forms of 
this  disease have been reported, otosclerosis  frequently appears  as a complex 
disease in which multiple environmental and genetic factors are involved [Stankovic 
et al., 2010].
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The hypothesis of angiotensin II (AngII) implication in the progression of otosclerosis 
is  based on the observation that otosclerosis progresses during pregnancy, and that 
plasmatic AngII concentrations increase during this period [Schrier & Durr, 1987] .
AngII effects on tissue remodeling and repair have been largely studied in human 
and animals  [Guo et al., 2006]. This hormone is implicated in the key events of 
inflammation, and alters the composition of the extracellular matrix through multiple 
growth factors and cytokines (e.g. prostaglandins, transforming growth factor-beta, 
basic fibroblast growth factor, platelet derived growth factor, insulin-like growth factor, 
parathyroid hormone related peptide, and IL-6) [Lamperter et al., 1998]. AngII 
stimulates bone cells directly (stimulation of DNA and collagen synthesis, cell 
proliferation), and modulates their activity indirectly via other bone cell populations 
such as osteoclasts [Lamperter et al., 1998; Asaba et al., 2009]. In a previous study, 
we reported a genetic association between otosclerosis  and 2 genetic 
polymorphisms increasing the plasmatic AngII concentration (AGT M235T and ACE I/
D) [Imauchi et al., 2008]. AngII receptors and angiotensinogen mRNA could be 
detected in primary bone cell cultures derived from human stapedial samples. 
Furthermore, AngII stimulated the production of IL-6, and reduced the alkaline 
phosphatase activity in otosclerotic cell cultures but not in control cultures [Imauchi et 
al., 2008]. This observation suggested that the AngII affects otosclerotic bone 
differently from normal stapes, and may elicit local inflammation during pregnancy.
The objective of this study was to further investigate the expression and production 
on inflammation mediators in human otosclerotic primary bone cell cultures and the 
effect of AngII on this activity.
85
MATERIALS AND METHODS
Human primary bone cell cultures
Stapedial bone fragments were harvested from patients undergoing surgery for 
otosclerosis and a group of control patients undergoing transpetrous surgery for a 
cerebellopontine angle tumor. All patients  were adults (mean age: 52 years, range: 
31-62). In the otosclerosis  group (2 males  and 4 females), the diagnosis was based 
on clinical data, audiometry, and CT-scan. In the control group (3 males  and 3 
females), the diagnosis was based on preoperative imaging, the intraoperative 
observations and the pathology. In this group, no past history of middle ear disease, 
no conductive hearing loss, and no otosclerosis  foci on CT-scan was noted. Ethics 
committee approval and patients’ consent were previously obtained for the 
samplings. The diagnosis of otosclerosis  was based on clinical, audiometric, and 
computed tomography scan findings and confirmed by the preoperative aspect of the 
stapes.
The primary culture of bone cells from human stapes has been previously described 
and characterized [Bozorg Grayeli et al., 1999]. Briefly, stapedial explants were 
placed in a culture medium composed of DMEM (Dulbecco Modified Eagle Medium) 
with 4.5% glucose (Gibco BRL Life Technologies, Cergy-Pontoise, France), 12.5 mg/
L vancomycin (Lilly, Saint Cloude, France), and 30% fetal calf serum (FCS, Gibco 
BRL Life technologies, Cergy-Pontoise, France) in 10 cm2 culture dishes, in a 
humidified atmosphere with 5% carbon dioxide at 37°C. All experiments  were 
performed on confluent cells between first and third passages. After 3 washes with a 
serum-free media, cells were incubated culture media without FCS containing AngII 
(Sigma-Aldrich, St; Louis, MO, final concentration, 10-7 M) or vehicle (basal condition) 
during 24 hours.
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Cytokine protein expression in the culture medium
Cell-free culture supernatants in otosclerosis (n=6) and control groups (n=6), were 
collected after 24h of treatment (AngII 10-7M, or vehicle) for protein microarray assay. 
Supernatants were assayed for the following 40 cytokines  and chemokines by a 
human cytokine antibody array (RayBio® Human Inflammation antibody array G3, 
RayBiotech, Norcross, GA), according to the manufacturer’s instructions: Eotaxin, 
Eotaxin-2, granulocyte, granulocyte macrophage, and macrophage colony 
stimulating factors (G-CSF, GM-CSF, and M-CSF respectively), intercellular adhesion 
molecule 1 (ICAM-1), interferon gamma (IFN-g), I-309, Interleukins  (IL) 1a,1b, 2-4, 6, 
6sR, 7, 8, 10, 11, 12 p40, 12p70, 13, 15-17, interferon gamma induced protein 10 
(IP-10), monocyte chemotactic proteins (MCP-1 and 2), monokine induced by IFN-g 
(MIG), macrophage inflammatory proteins (MIP-1a, b, and d), RANTES (regulated 
upon activation, normal T cell expressed and secreted), transforming growth factor 
(TGF)-b1, tumor necrosis factors (TNF-a and b), soluble TNF receptors (s TNF RI 
and II), platelet derived growth factor (PDGF BB), and metallopeptidase inhibitor-2 
(TIMP-2). In addition, the array contained positive (biotinylated protein), negative 
(bovine serum albumin), and internal control (spiking-in protein with no cross 
reactivity with proteins in the array). The following molecules were also assessed for 
control and normalization: glyceraldehyde 3-phosphodehydrogenase (GAPDH), 
beta-2 miocroglobulin (B2M), heat shock protein 1 beta (HSPCB), and actin beta 
(ACTB). In our experiments, values obtained for the internal control were highly 
reproducible between different slides (data not shown). Hence, the internal control 
signal was not used for normalization between slides.
Briefly, after hybridization at room temperature, slides were incubated with 
biotynilated antibodies and labeled with conjugated streptavidin. The images were 
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captured by a laser scanner. Signal for each protein was normalized according to the 
positive control intensity (ACTB in this study) after subtraction background. The 
positive control of the first sample was considered as 1 and the signal intensities of 
all other samples were calculated according to the formula: Normalized signal 
intensity of particular spot = signal intensity of particular spot * (positive signal 
intensity sample 1 /positive signal intensity sample in particular spot).
Pro-inflammatory cytokines mRNA expression
Total RNA was extracted from 3 primary cell cultures among the 6 in each group 
(otosclerosis, control) using RNA 2Plus extraction solution (MP Biomedicals, France), 
and by a previously described method [Chomczynski & Sacchi, 1987]. Synthesis, 
purification and hybridization of biotin-labeled cRNA to custom array membranes 
were performed according to the manufacturer’s recommendations (Oligo GEArray® 
Human inflammatory cytokines and receptors MicroArray, EHS-011, SA Biosciences, 
Frederick, MD). Briefly, cRNA was  labelled by TruLabeling AMP 2.0 (0.1-3 µg of total 
RNA was used). Target cRNA was added to the labeled cRNA on GEArray slides for 
hybridization and washing. After local background subtraction, average signal 
intensity from duplicate spots was normalized by the expression of several 
housekeeping genes (ribosomal protein S27, glyceraldehyde 3 phosphate 
dehydrogenase, beta-2 microglobulin, heat shock protein 90 alpha B1, and ACTB) 
using Alpha Imager HP automatic image capture software (AlphaInnoTec, France). 
Similarly to antibody arrays, the presented results  are relative concentrations 
normalized by ACTB. Normalization by other house-keeping proteins yielded similar 
results (data not shown). 
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The mRNA expression of the following cytokines and cytokine-related molecules was 
assessed in all samples : ATP-binding cassette, sub-family F, member 1 (ABCF1), B-
cell CLL/lymphoma 6 (BCL6), Burkitt lymphoma receptor 1 (BLR1), Complement 
components 3, 4A, 5, Chemokine (C-C motif) ligands (CCL) 1-5, 7, 8, 11, 13, 15-21, 
23-26, Chemokine (C-C motif) receptor (CCR) 1-9, CCAAT/enhancer binding protein, 
beta (CEBPB), C-reactive protein, pentraxin-related (CRP), Chemokine (C-X3-C 
motif) ligand 1 (CX3CL1), Chemokine (C-X3-C motif) receptor 1 (CX3CR1), 
Chemokine (C-X-C motif) ligands (CXCL)1-3,5, 6, 9-14, CXCR4     Chemokine (C-X-
C motif) receptor 4, Endothelial differentiation, sphingolipid G-protein-coupled 
receptor 3 (EDG3), ICEBERG caspase-1 inhibitor, interferon alpha 2 (IFNA2) and 
gamma (IFNG), Interleukin 10 (IL10), and its  receptors, alpha and beta (IL10RA, 
IL10RB), IL11 and its receptor alpha (IL11RA),IL12A and B, and their receptors beta 
1 and 2 (IL12RB1, IL12RB2), IL13, IL13RA1, IL15, IL15RA, IL16, IL17A, IL17C, 
IL17RA, IL18, IL18R1, IL1A, IL1B, IL1R1, IL1R2, Interleukin 1 receptor antagonist 
(IL1RN), IL2, IL20, IL21, IL22, IL2RA, IL2RB, IL2RG, IL3, IL4, IL5, IL5RA, IL6, IL6R, 
Interleukin 6 signal transducer (IL6ST), IL8, IL8RA and B, IL9, IL9R, Lymphotoxin 
alpha and beta (TNF superfamily, members 1 and 3, LTA and LTB) Leukotriene B4 
receptor (LTB4R), Macrophage migration inhibitory factor (MIF) Platelet factor 4 (PF4 
or CXCL4), Small inducible cytokine subfamily E, member 1 (endothelial monocyte-
activating, SCYE1), Secreted phosphoprotein 1 (SPP1, osteopontin, bone 
sialoprotein I, early T-lymphocyte activation 1), Tumor necrosis factor (TNF, TNF 
superfamily, member 2), Tumor necrosis factor receptor superfamily members 1A, 
and B (TNFRSF1A, TNFRSF1B), CD40 ligand (CD40LG), Toll interacting protein 
(TOLLIP), Chemokine (C motif) ligand, and receptor 1 (XCL1, XCR1).
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Quantification of cytokine mRNA expression by qRT-PCR
Total RNA from 4 primary cell cultures among the 6 in each group (otosclerosis, 
control) were used in these experiments. All the samples in the gene array assays 
were included in qPCR evaluation. The RNA pellet was suspended in 20 µL of water 
and stored at –20°C. Complementary DNA was synthesized by a reverse 
transcription (RT-PCR).  The reaction mix (final volume 20 µL) contained 1 µg of the 
total RNA, SuperScript II RT (Invitrogen, France), 5X first-strand buffer (250 mM Tris-
HCl pH 8.3, 375 mM KCl, 15 mM MgCl2) and 0.1 M DTT. The mix underwent: 95°C 
for 30 sec, 70°C for 7 min, 42°C for 65 min, 95°C for 6 min and 30°C for 1 min. qRT-
PCR parameters were determined in preliminary experiments on human 
osteosarcoma cell lines (HOS, and SaOS, American Type Culture Collection, 
Molsheim, France). BCL-6, CCL25 cDNA were amplified by PCR using 5 µL of 
reverse transcription product and the following primers: BCL-6 sense 5’-
A C C T G G T G G A G A A C A A C C T G - 3 ’ a n d a n t i s e n s e 5 ’ -
TTCTGGGATTGTTTCCTTGG-3’; CCL25 sense 5’-GATAAAACCGTCGCCCTACA-3’ 
and antisense 5’-ATCAGGCCAACTCCCTCTTT-3’. The amount of targeted mRNA 
was corrected by those of S14 and GAPDH mRNA using the following primers: S14 
s e n s e 5 ’ - T C A C T C A G G A A G A ATA C C AT T T T G - 3 ’ a n d a n t i s e n s e 5 ’ -
C C G A T T T C T G A T T C T A A C A G G A C - 3 ’ ; G A P D H s e n s e 5 ’ -
A A G G C T G G G G C T C A T T T G - 3 ’ a n d a n t i s e n s e 5 ’ -
GTGTGGTGGGGGACTGAG-3’ (Gibco BRL Life technologies, Cergy-Pontoise, 
France). Quantitative PCR was performed in total volume of 20 µL with the use of 
SYBER Green JumpStart Taq ReadyMix (Sigma-Aldrich, France) containing Tris-HCl 
20 mM pH 8.3, KCl 100 mM, MgCl2 7 mM, 0.4 mM each dNTP (dATP, dCTP, dGTP, 
dTTP) stabilizers, Taq DNA Polymerase 0.05 unit/µL, JumpStart Taq antibody and 
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SYBER Green I. DNA was amplified for 40 cycles (Chromo 4, Biorad, Marnes-la-
Coquette, France). Reactions were prepared in duplicate and heated to 94°C for 2 
min, 58°C for 30 sec, 72°C for 30 sec, melting curve 55°C to 95°C every 0.5°C. To 
detect the amplification log phase, the fluorescence quantification of product was 
determined at each cycle. The cycle at which the fluorescence reached the threshold 
(CT) was recorded, averaged between duplicates and normalized to the averaged 
CT value. The ratio between samples with and without treatment was calculated by 
relative quantification. Melting curves were also measured to ensure that only a 
single product was amplified. A 10 µL sample of the PCR product was run on a 2% 
agarose gel with Sybersafe (Invitrogen, France) and 100-bp molecular weight ladder. 
Control and otosclerosis samples were paired during experiments  to allow 
comparison of otosclerosis versus control as well as basal versus AngII conditions.
Immunocytochemistry
Cell cultures from patients with otosclerosis (n=4) and control patients (n=4) were 
grown on permanox slides (Lab-Tek Chamber Slide, Nalge Nunc International, 
Rochester, NY). At confluence, cells were fixed in 4% paraformaldehyde for 20 
minutes. Upon fixation they were rinsed in phosphate buffered saline (PBS, Gibco, 
Invitrogen, France) and incubated with NH4Cl for 5 minutes. Cells were 
permeabilized by triton-100-X 0.1% (Sigma-Aldrich, France). They were further 
saturated in blocking solution composed of PBS, 1% albumin bovine powder   (Sigma 
Aldrich, France), 0.5% of TWEEN 20 (Sigma-Aldrich, France) and 5% of goat serum 
(Invitrogen, France) for 10 minutes. Cells were further incubated with primary 
antibody diluted 1/100 for 1 hour at room temperature. They were subsequently 
rinsed in PBS and incubated with the secondary antibody diluted at 1/20 for 30 
minutes at room temperature. Again cells were rinsed with PBS and incubated with 
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ExrAvidine Peroxydase (Sigma-Aldrich, France) diluted 1/20 for 30 min at room 
temperature. They were finally stained with the AEC (3-Amino-9-ethylcarbazole) 
Staining Kit (Sigma-Aldrich, France) for 10 minutes at room temperature.
The following primary antibodies have been used: for osteoblasts, monoclonal mouse 
anti-human CDH11, clone 4D10 (Sigma-Aldrich, France); for osteoclasts, monoclonal 
mouse anti-human CD61, clone Y2/51 and for macrophages, monoclonal mouse 
anti-human CD68, KP1 clone (DakoCytomation, Glostrup, Denmark).
Statistical Analysis
For antibody and gene array analysis a repeated measures 2-way ANOVA was 
performed followed by a Bonferroni post-test when ANOVA showed a significant 
effect (p<0.05). For gene array analysis, basal versus AngII conditions in the same 
samples were compared by a paired t-test. Controls were compared to otosclerotic 
samples by an unpaired t-test. For qPCR analysis, the difference fold was tested by a 
one-sample t-test for a difference from a hypothetical value of 1. Data were 
expressed as mean ± standard error of the mean. Difference or effect was 
considered significant at p<0.05.
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RESULTS
Release of cytokines and cytokine-related proteins in culture medium
In basal condition, IP-10 and IL-1b concentrations were higher in otosclerosis than in 
control stapes (Table 1). This observation was in accordance with a higher leukocyte 
or osteoclast activity (IL), and an increased angiogenetic activity (IP-10) in cultures 
derived from otosclerotic stapes. Furthermore, a lower activity of metalloprotease 
inhibitor 2 (TIMP-2) was detected in basal conditions in otosclerotic cell cultures. This 
observation was also compatible with a higher bone turn-over in this  disease (Table 
1). The expression of other proteins did not differ between otosclerosis and control 
samples in basal condition.
AngII stimulated the IFN-γ release in culture media in both otosclerosis and control 
cell cultures. Ang II also increased the IL-10 concentration in otosclerosis culture 
media. It inhibited macrophage inflammatory protein (MIP-1a) and Interleukin 11 
(IL-11) release only in control stapes and not in otosclerosis. AngII appeared also to 
reduce the soluble tumour necrosis factor receptor II (sTNFRII) concentration in 
otosclerosis culture media without altering the tumour necrosis factor-alpha (TNF-α) 
levels.
mRNA expression of cytokines and cytokin-related proteins 
In total, 126 key genes involved in the inflammatory response were analyzed by gene 
array. mRNA expression of 15 cytokines or cytokine-related molecules could be 
detected by this  technique (Fig 1). A significant inter individual variation was 
observed. In basal condition, BCL-6 mRNA expression was higher in otosclerosis 
than in control (48 ± 21.7 arbitrary units in control versus 328 ± 39.7 in otosclerosis 
for BCL-6, n=3, p<0.05, unpaired t-test). Angiotensin II reduced BCL-6 mRNA 
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expression only in otosclerosis  (424 ± 63.3 in basal condition versus 105 ± 64.7 after 
AngII, p<0.05, paired t-test). Real-time quantitative RT-PCR (qPCR) after 
normalization by S14 mRNA expression confirmed higher levels of BCL-6  mRNA in 
otosclerosis in comparison to control stapes in basal condition (Table 2).  However, 
the reduction of BCL-6 mRNA expression after Ang II in otosclerosis  observed by 
gene array could not be confirmed by qPCR. Similar qPCR results  were obtained 
after normalization by GAPDH (data not shown).
Immunocytochemistry
Both control and otosclerotic cells showed positive labeling with osteoblast, 
osteoclast and macrophage specific antibodies. There was no difference of labeling 
between otosclerosis  and control samples (Fig 2). This observation suggested that 
difference in pro-inflammatory cytokine production was not related to quantitative 
differences of cell types between otosclerosis and control cultures.
DISCUSSION
AngII is implicated in the key events of inflammation and bone turnover via various 
growth factors and cytokines [Lamperter et al., 1998; Asaba et al., 2009]. In previous 
studies, we showed that two genetic polymorphisms related to higher plasmatic AngII 
concentrations (AGT M235T and ACE I/D) were associated to a higher relative risk of 
otosclerosis occurrence in a French Caucasian population. We also observed that 
AngII receptors, and angiotensinogen mRNA were expressed in bone cell cultures 
obtained from otosclerotic and control stapes. Moreover, in vitro AngII stimulated the 
production of a pro inflammatory cytokine (interleukin-6, IL-6) as measured by ELISA, 
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and reduced the alkaline phosphatase activity in otosclerotic osteoblast-like cell 
cultures. These effects appeared to be specific to otosclerosis since they were not 
observed in control cell cultures [Imauchi et al., 2008]. In order to elucidate the 
mechanism of the increased bone turnover and to identify targets for therapeutic 
action, this study focused on the effect of AngII on inflammation mediators  in 
otosclerosis. 
In basal condition, 2 pro inflammatory cytokines (IL-1b, IP-10) were released by 
otosclerotic cells in larger quantities than in control stapes. Interleukin 1-beta is 
produced by activated macrophages as a proprotein, which is  proteolytically 
processed to its active form by caspase 1 (CASP1/ICE). This  cytokine is an important 
mediator of the inflammatory response, and is  involved in a variety of cellular 
activities including cell proliferation, differentiation and apoptosis [Kapoor M, et al. 
2011]. Its higher production in otosclerosis  is in accordance with the abnormally high 
tissue turnover in the disease foci. Interferon (IFN) inducible protein (IP-10) is 
expressed in various cells including lymphocytes, monocytes, and fibroblasts. Its 
production is mainly induced by IFN-gamma and tumor necrosis factor (TNF)-alpha 
among others. IP-10 is mainly known for its  hemotactic activity but it is also produced 
in response to acute or chronic inflammation by attracting CD8 and NKT lymphocytes 
to tissues involved in the pathogenesis  of many disorders  such as skin inflammation, 
multiple sclerosis, pulmonary/liver fibrosis, type 1 diabetes, autoimmune myasthenia 
gravis, acute cardiac allograft rejection and Celiac disease [Dufour et al., 2002]. In 
this  study we did not observe the increased IL-6 production after AngII which we 
reported previously [Imauchi et al., 2008]. This could be explained by the difference 
of assessment technique (antibody array versus ELISA), or the lower number of 
samples in the present study. 
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In basal condition, tissue inhibitor of metalloproteinases TIMP-2 had a lower 
concentration in otosclerosis than in control cultures. This cytokine has a unique role 
among TIMP family members to directly suppress the proliferation of endothelial 
cells. Its role is critical in the maintenance of tissue homeostasis by suppressing the 
tissue proliferation in response to angiogenic factors, and in inhibiting the protease 
activity in tissues undergoing extracellular matrix remodeling (e.g. otosclerotic foci). 
Hence, lower concentrations of TIMP-2 might be related to higher bone turnover. 
Abnormalities of TIMP expression in the connective tissue could be related to the 
incidence of otosclerosis [McPhee JR et al., 1991].
In our study, AngII stimulation led to an increased release of IFN-gamma which is a 
pro-inflammatory cytokine. IFN-gamma is  secreted by Th1, Tc, dendritic, and NK 
cells. It is known for its antiviral, immunoregulatory and anti-tumor properties 
[Shroder K et al., 2004]. In bone, IFN-gamma suppresses osteoclast formation and 
promotes apoptosis by rapidly degrading the RANK (receptor activator of nuclear 
factor-kappa B) adaptor protein TRAF6 in the RANK-RANKL (ligand) signaling 
system. RANK stimulates the production of NF-kappa B which induces the 
transcription of anti apoptotic genes and plays a major role in remodeling. IFN-
gamma is currently employed in the treatment of chronic granulomatous diseases 
and osteopetrosis [Shroder K et al., 2004]. 
AngII also stimulated IL-10 or human cytokine synthesis inhibitor factor (CSIF). IL-10 
is  primarily produced by monocytes and to a lesser extent by lymphocytes. It has 
pleiotropic effects, inhibiting synthesis of pro inflammatory cytokines such as IFN-γ, 
IL-2, IL-3, TNFα and GM-CSF produced by macrophages and regulatory T-cells. 
IL-10 also displays potent abilities to suppress the antigen presentation capacity of 
antigen presenting cells. However, it is also stimulatory towards certain T cells, mast 
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cells and stimulates  B cell maturation and antibody production. Similarly to IFN-
gamma, it can block NF-kappa B activity [Moore et al., 2001].
AngII inhibited the production of macrophage inflammatory protein (MIP)-1a, and 
IL-11 only in control cells.  MIP-1a is a chemokine, produced by macrophages and 
activates human granulocyte leading to an acute neutrophilic inflammation. It is also 
capable of inducing the synthesis  of other pro inflammatory cytokines such as TNF-
alpha, IL-1 and 6 from fibroblasts and macrophages [Sherry et al., 1988]. IL-11 
participates in the regulation of bone cell proliferation and differentiation and could be 
used as a therapeutic agent for osteoporosis. It increases the cortical thickness and 
strength of long bones in mice [Yang & Yin, 1993]. 
Finally, tumor necrosis factors are involved in systemic inflammation at its  acute 
phase. Inhibition of sTNF RII by AngII in otosclerosis cultures  would promote 
inflammation by increasing the amount of free TNF [Locksley et al., 2001].
Gene array and qPCR results indicated a higher BCL-6 mRNA expression in 
otosclerosis and in basal conditions in comparison to control stapes. BCL-6 gene 
encodes for the B-cell lymphoma-6 protein which acts as a sequence-specific 
repressor of transcription, and has been shown to modulate the transcription of 
STAT-dependent IL-4 B-cell response. BCL-6 has also been shown to regulate the 
expression of several chemokine genes, to negatively regulate the proliferation of the 
monocytic / macrophage lineage via IL-6/STAT signaling, and to modulate chemokine 
gene expression [Woo et al., 2002]. Chemokine expression is  repressed by BCL-6 
both in B-cell lines and macrophages. MIP-1alpha and IP-10 appear to be repressed 
by BCL-6 in B-cells. This effect probably passes through a functional binding site in 
the MIP-1alpha promoter but not in the IP-10 gene [Schaffer et al., 2000]. In our 
study, BCL-6 mRNA expression was  higher in otosclerosis  than in controls, in basal 
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condition supporting its role in the cellular proliferation. Its  inhibition by AngII may 
explain the activation of different pro-inflammatory cytokines.
In conclusion, these data support the hypothesis that AngII is implicated in 
inflammation and bone turnover regulation in otosclerosis, via different growth factors 
and cytokines. They indicate several potential targets for their anti-inflammatory or 
anti-catabolic actions such as IL-11 and TIMP-2. Nevertheless further investigations 
are necessary to clarify the role of AngII in the pathophysiology of otosclerosis  and 
stapes metabolism.
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Figure 1- Cytokine and cytokine-related mRNA expression levels in control and 
otosclerotic human primary bone-cell cultures and the effect of Angiotensin II. 
Relative levels of mRNA expression were assessed by gene array in primary bone 
cell cultures (n=3) after total RNA extraction. Circles indicate individual values, 
horizontal bars  the mean value and vertical bars the SEM. Significant value 
dispersion was noted. Only the 15 cytokines or cytokine-related proteins out of 126 
had a detectable mRNA expression by this method. *: p<0.05, paired t-test for basal 
versus angiotensin II, and unpaired t-test for control versus otosclerosis. Cont: 
control, Otos: Otosclerosis, -: Basal condition, +: Incubation with angiotensin II at 10-7 
M, 24H.
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Figure 2- Immunocytochemistry in primary bone cell cultures of control and 
otosclerotic stapes: Both control (A, C, E) and otosclerotic (B, D, F) stapedial bone-
cell cultures showed positive reactivity for macrophage (CD68, A and B), osteoclast 
(CD61, C and D) and osteoblast (cadherin 11, E, and F). There was no difference of 
reactivity between otosclerosis and control by microscopic examination.
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Table 1- Comparison of cytokine relative concentrations between control and 
otosclerotic human primary bone-cell cultures
Control
basal
Control
+Ang2
Otosclerosis
basal
Otosclerosis
+Ang2
EOTAXIN 87 ± 8.9 88 ± 8.6 108 ± 10.3 102 ± 12.9
EOTAXIN-2 77 ± 12.7 70 ± 14.8 109 ± 15.8 108 ± 29.1
GCSF 191 ± 20.5 217 ± 19.2 203 ± 22.9 212 ± 7.2
GM-CSF 83 ±14.2 79 ± 4.64 89 ± 6.8 85 ± 4.5
ICAM-1 81 ± 56.3 106 ± 86.6 21 ± 3.4 23 ± 4.1
IFN-g 90 ± 25.3 141 ± 27.0§ 99 ± 27.0 136 ± 9.1§
I-309 4 ± 1.39 10 ± 4.8 16 ± 5.0 11 ± 2.6
IL-1a 172 ± 20.5 197 ± 13.0 189 ± 25.4 208 ± 16.4
IL-1b 26 ± 5.1 33 ± 11.3 51 ± 6.9£ 65 ± 7.4£
IL-2 184 ± 14.9 207 ± 12.5 182 ± 6.1 199 ± 8.9
IL-3 1406 ± 105.6 1631 ± 145.7 1384 ± 111.5 1421 ± 143.4
IL-4 49 ± 12.0 48 ± 5.5 61± 5.3 67 ± 7.6
IL-6 432 ± 93.3 448 ± 67.3 566 ± 219.4 519 ± 192.5
IL-6sR 42 ± 4.2 38 ± 6.5 45 ± 2.8 42 ± 5.1
IL-7 210 ± 32.6 270 ± 20.5 211 ± 30.7 252 ± 23.2
IL-8 999 ± 216.0 1212 ± 431.0 818 ± 263.7 554 ± 125.0
IL-10 82 ± 9.1 111 ± 13.5 70 ± 7.2 116 ± 12.5*
IL-11 124 ± 7.3 98 ± 8.0* 117 ± 14.8 104 ± 6.8
IL-12 p40 29 ± 4.4 23 ± 3.1 39 ± 7.6 34 ± 10.4
IL-12 p70 191 ± 10.7 225 ± 28.7 262 ± 24.2 212 ± 15.1
IL-13 122 ± 15.6 141 ± 7.7 125 ± 19.2 155 ± 12.9
IL-15 166 ± 8.7 180 ± 9.7 162 ± 7.8 175 ± 6.2
IL-16 58 ± 14.9 77 ± 24.4 91 ± 13.4 114 ± 7.5
IL-17 113 ± 9.7 126 ± 10.1 119 ± 9.5 116 ± 8.7
IP-10 36 ± 4.7 55 ± 12.1 88 ± 6.9£ 70 ± 13.1£
MCP-1 589 ± 153.1 630 ± 192.6 379 ±75.9 359 ± 46.7
MCP-2 29 ± 6.0 25 ± 5.5 45 ± 6.6 46 ± 10.4
M-CSF 54 ± 7.6 41 ± 7.9 47 ± 5.9 46 ± 5.2
MIG 229 ± 26.6 242 ± 13.5 228 ± 25.7 218 ± 15.6
MIP-1a 22 ± 6.7 9 ± 3.8* 22 ± 4.3 17 ± 1.6
MIP-1b 240 ± 16.7 225 ±10.8 287 ± 27.5 309 ± 23.5
MIP-1d 24 ± 5.8 30 ± 2.6 34 ± 6.6 33 ± 3.6
RANTES 23 ± 3.8 29 ± 6.2 40 ± 10.7 35 ± 7.9
TGF-b1 276 ±15.8 281 ± 22.6 275 ± 9.3 274 ± 4.0
TNF-a 184 ±10.9 212 ± 11.4 185 ± 12.3 197 ± 9.24
TNF-b 222 ±16.1 224 ± 7.0 189 ± 11.7 200 ± 5.2
s TNF RI 592 ± 297.1 764 ± 472.0 194 ± 33.3 192 ± 35.6
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s TNF RII 113 ± 6.0 121 ± 6.7 129 ± 5.6 106 ± 7.4*
PDGF-BB 9 ± 1.9 11 ± 4.5 19 ± 3.1 14 ± 2.9
TIMP-2 21410 ± 3278.2 18330 ± 2991.9 11296 ± 1705.7£ 11547 ± 2130.6£
Relative concentrations (in arbitrary units) were assessed by antibody array in 
primary cell culture media (n=6) for 40 cytokines  and normalized by the expression of 
beta actin in the same culture in basal condition and after stimulation by angiotensine 
2 (AngII, 10-7 M, 24h). Results are expressed as  means ± SEM in arbitrary unites. A 
2-way repeated-measures ANOVA compared otosclerosis  to control stapes, and 
basal to AngII conditions. It was followed by a Bonferroni post-test only when 
ANOVA showed a significant effect.  
*: p<0.05 Bonferroni post-test, versus basal condition. 
£: p<0.05 ANOVA for otosclerosis effect, Bonferroni post- test: not significant 
§: p<0.05 ANOVA for AngII effect, Bonferroni post- test: not significant 
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Table 2- mRNA expression levels of BCL-6 in primary human osteoblast-like cell 
cultures of control and otosclerotic stapes evaluated by real-time qRT-PCR
BCL-6 ΔCT Basal ΔCT Ang2 ΔΔCT
(Basal-Ang2)
Stimulated-Basal
Difference fold
(2 –ΔΔCT)
Control (n=4) -3.5±0.27 -3.2±0.75 0.3±0.97 1.8±0.59 (ns)
Otosclerosis (n=4) -2.7±0.34 -2.8±0.76 -1.3±0.72 1.4±0.62 (ns)
ΔΔCT (Otosc-Cont) 0.3±0.49 0.4±0.82
Otosc-Cont difference 
fold (2 –ΔΔCT) 1.7 ±0.20* 1.2±0.74 (ns)
Cell cultures were obtained from 4 patients with otosclerosis  and 4 control patients. 
Total RNA was extracted from cultures in basal condition and after angiotensin II 
(AngII, 10-7 M, 24H). Real-time qRT-PCR was performed in duplicates. Ribosomal 
S14 was used as the reference gene. Control and otosclerosis samples were paired 
during experiments  to allow comparison of otosclerosis  versus control as well as 
basal versus AngII conditions. Values are expressed as mean ± SEM. Difference fold 
refers  to basal versus angiotensin II condition in rows and to control versus 
otosclerosis in columns.
ΔCT = Avg.Bcl-6 or CCL25 CT- Avg. S14 CT, ΔΔCT = Avg. ΔCT, AngII - Avg. ΔCT, basal for 
the rows and ΔΔCT = Avg. ΔCT,Otosclerosis - Avg. ΔCT, control for the columns.
 * P<0.05, one sample t test for a difference from a hypothetical value of 1. ns: not 
significant
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III. ANGIOTENSIN II AND OXIDATIVE STRESS IN 
PATHOPHYSIOLOGY OF OTOSCLEROSIS 
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1. Introduction
 
Oxidative stress and Ang II interact for tissue remodeling via reactive oxygen species (ROS) 
which intervene in numerous signaling pathways of Angiotensin II (Ang II). HNE or 4-
hydroxynonenal as a second messenger of ROS is found in many  different human tissues and 
its physiological roles are still not entirely understood. Recent  studies of the HNE influence 
on bone cells have demonstrated its inhibitory effect on the bone cell proliferation and 
differentiation and its stimulatory effect on apoptosis. 
The goal of the present study was to further investigate and understand the interaction 
between Ang II and HNE in the pathophysiology  of otosclerosis by studying the in vitro 
model of osteoblast-like cells. 
1.1. Angiotensin II and reactive oxygen species (ROS)
ROS are involved in transducing many of the Ang  II effects and are produced in response to 
agonist-receptor binding. ROS are molecules ultimately derived from oxygen but  have 
undergone univalent reduction, so that they readily react with other biological products 
(Griendling et al., 2000). ROS include superoxide anion (O2°-), hydrogen peroxide (H2O2), 
hydroxyl radical (OH°), nitric oxide (NO°) and peroxynitrite (OON°), (Griendling et al., 
1994; 2000, Zafari et al., 1998). Among these, the superoxide anion and the hydrogen 
peroxide have been shown to be produced under Ang II effect and to alter the activity of 
specific signaling proteins and enzymes (Griendling et al., 2000). The signaling mechanism 
by which Ang II activates the oxidase is not entirely understood. Zafari et al. (1998) provided 
evidence that arachidonic acid metabolites are involved in the oxidase activation. Arachidonic 
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acid is produced by Ang II in several different pathways. This molecule can be directly 
generated by phospholipase A2 action on membrane phospholipids or indirectly via 
phospholipase D-mediated degradation of phohphatidylcholin to phosphatidic acid and its 
subsequent dephosphorylation to diacylglicerol and monoacylglycerol (Lassegue et al. 1993). 
Touyz et al. (1999) showed that inhibition of phospholipase D attenuated the oxidase 
activation under Ang II effect. 
In vascular smooth muscle cells superoxide anion production induced by  Ang II is mediated 
by NAD(P)H oxidase (Ushio-Fukai et al., 1996). The superoxide anion produced upon Ang II 
stimulation is converted to hydrogen peroxide. In endothelial cells, Ang II also increases the 
production of superoxide anion via activation of membrane-associated NAD(P)H oxidase 
(Munzel et al., 1999, Zhang et al., 1999, Lang et al., 2000).  In addition, it activates nitric 
oxide synthase to release nitric oxide (Saito et al., 1996, Schena et al., 1999). Arachidonic 
acid metabolites are not the only  lipid activators of NAD(P)H oxidase, and phospholipase A 
inhibition has very little effect on NAD(P)H oxidase activity (Griendling et al., 2000).
ROS are involved in multiple physiologic responses to Ang II, including vascular smooth cell 
growth, induction of vascular inflammatory  response, impairment of endothelium-dependant 
relaxation and cardiac hypertrophy (Griendling et al., 2000). Ang II also induces the 
inflammatory response in the vessel walls. Such response is observed in otospongiotic foci 
during the active phase of otosclerosis (Schrader et al. 1990). It  is present in monocytes and 
macrophages and induces such pro-inflammatory molecules such as VCAM-1, MCP-1 and 
the thrombin receptor. These molecules are redox sensitive, and especially in the case of 
MCP-1 and the thrombin receptor, interact with ROS in Ang II mediated gene expression has 
been demonstrated (Griendling et al., 2000). 
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Determination of which Ang II signaling pathways are redox sensitive has been subject of 
several recent  studies. Study of the early  signaling events found that neither phospholipase C 
nor Ca2+ influx are mediated by ROS after Ang II stimulation (Griendling et al., 2000). On the 
contrary, phosphorylation of the epidermal growth factor receptor (EGF-R) appears to be an 
important step  in the activation of downstream kinases by  Ang II and is mediated through 
NAD(P)H oxidase derived ROS (Murasawa et al., 1998, Eguchi et al., 1998). Moreover, Ang 
II induces the tyrosine phosphorylation of the platelet derived growth factor (PDGF) receptor. 
This phenomenon leads to the conclusion that  ROS participate in the formation of the most 
proximal tyrosine kinase-related signaling complexes in response to Ang II (Linseman et al., 
1995). It has been already mentioned that Ang II can activate the MAPKs signaling pathway 
including ERKs, JNK and p38MAPKs (Abe et al., 1996, Ushio-Fukai et al., 1998). Research 
on which of these MAPKs is redox sensitive has shown that Ang II activation of p38MAPK 
and JNK are indeed redox sensitive (NAD(P)H oxidase) while some studies showed that 
activation of ERKs is insensitive to redox (Griendling et al., 2000). As for other enzymes 
activated via Ang II (i.e. phospholipase D, phospholipase A2, FAK, Fyn, janus kinase 2 
(JAK2), STAT1 and ras), it still remains unclear whether they are redox sensitive or not 
(Griendling et al., 1997, Berk et al., 1999). 
1.2. Reactive oxygen species in human ear diseases
It is known that inner ear hair cell damage and death may occur as a result of local ROS 
production. The main sources of these molecules within the cochlea appear to be the hair 
cellsʼ mitochondria, or enzymes such as xanthine oxidase and NADPH oxidase. The electron 
transport chain in the mitochondria is thought to be a major production means of intracellular 
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superoxide, since hair cells are known to be highly energy-demanding and oxygen-consuming 
cells (Henderson et al., 1999; Ciorba et al., 2010). 
Once generated, ROS are responsible for direct cellular damage to lipids, proteins, and DNA, 
triggering apoptosis or necrosis and may also diffuse among the inner ear scalae (Henderson 
et al., 2006; Clerici et al., 1996). In hair cells, death may occur either through necrosis or 
apoptosis (Henderson et al., 1999). In animal models, several conditions of increased ROS 
production related to cochlear damage have been described, including exposure to noise and 
to drugs (i.e. aminoglycosides and cisplatin, Ciorba et al., 2010). In humans, ROS appeare to 
be involved in hair cell damage in some cases of genetic hearing loss (i.e. Pendred syndrome), 
presbycusis, and Menière’s syndrome (Ciorba et al., 2010). Several animal or in vitro models 
have been proposed for treatment against  ROS-mediated damage (Henderson et al, 2006; 
Goldvin et al., 1998; Wang et al., 2002). In rats the increase of antioxidant supplies in the 
cochlea may effectively prevent hair cell damage and hearing loss (Lorito et al., 2006). 
Pharmacological interventions have been directed at: interrupting the lipid peroxidation 
process, thus preserving the integrity  of cell membranes (i.e. by lazaroids), preventing noise-
mediated inner ear damage by cochlear ischemia/reperfusion (i.e. by pentoxifylline and 
sarthran) and preventing cell apoptosis, by inhibitors of cell death pathways such as JNK 
inhibitors, D-JNK-1, riluzole or minocyclin (Henderson et al., 2006; Goldvin et al., 1998; 
Corbacella et al., 2004).
Recently  Ciorba et al., (2010) provided the first evidence of the presence and production of  a 
biologically relevant ROS, superoxide in the perilymph of patients affected by  profound 
hearing loss and treated with cochlear implantation. This molecule is produced by  xanthine 
dehydrogenase/xanthine oxidase (XA/XO) enzyme system. High levels of ROS and related 
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enzymes in human inner ear perilymph (above 25 mmoles per mg of protein) may  be an 
expression of previous damage to the organ of Corti and to the inner ear.
In otosclerosis, ROS may be produced in otosclerosis foci. Their first target is bone cell 
populations. In bone, ROS might participate in the acceleration of bone turnover (Borovic et 
al., 2007). After diffusion into the inner compartment through the cochlear endosteum, they 
can participate in the cochlear damages and the sensorineural hearing loss (Henderson et al., 
2006). 
The aim of this part of the project was to investigate the presence of HNE in otosclerotic and 
normal human stapes, and to evaluate the interaction between Ang II and HNE in human 
osteoblast-like cells in terms of cellular proliferation, differentiation, and apoptosis. 
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ABSTRACT
Introduction: Otosclerosis  is  a complex disease characterized by an abnormal bone 
turnover of the human otic capsule resulting in conductive hearing loss. Angiotensin 
(Ang) II, a major effector peptide of the renin-angiotensin system is an important 
regulator of the cardiovascular system and body fluid homeostasis, and an important 
local cellular growth factor. Oxidative stress and reactive oxygen species (ROS) have 
a major role in different signaling pathways of Ang II. The aim of the present study 
was to investigate the role of Ang II and 4-hydroxynonenal (HNE) a second 
messenger of ROS, interaction in otosclerosis, on in vitro model of osteoblast-like 
cells in order to further understand the pathophysiology of the disease. 
Materials and Methods: Immunohistochemistry was performed on tissue samples 
taken from 15 otosclerotic patients  and 6 controls. Antibodies against HNE have 
been used. Human Osteosarcoma cell lines (HOS) were used to analyze the Ang II 
and HNE effect on proliferation (3H-thymidine incorporation assay), differentiation 
(detection of alkaline phosphatase activity by NBT/BCIP assay, Roche) and induction 
of apoptosis  by flow citometry  (presence of apoptotic cells was determined by 
Annexin-V-Fluos Staining Kit, Roche, Germany). Immunoblot analysis was performed 
to determine whether there is an existing binding between the Ang II and HNE. 
Results: Immunohistochemical detection of HNE-protein adducts showed positivity 
on both control and otosclerotic samples but with different distribution areas. 
Association of Ang II in concentration of 0,1 nM and HNE of 2,5 µM stimulated the 
proliferation of the HOS cells  (p<0.0002). Decrease in alkaline phosphatase activity 
(ALP) was observed in cell cultures treated with 0,1 nM Ang II and HNE 
concentrations of 1 µM or 2,5 µM (p<0,01). On the contrary, 10 µM HNE alone 
(p<0,05) or in combination with 0,1 or 0,5 nM Ang II (p<0,01) increased ALP activity 
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with the exception of 1 nM Ang II. Decrease in apoptosis (p<0,05) was observed in 
cells treated just with Ang II (0,1 and 0,5 nM). On the contrary increase in apoptosis 
(p<0,01) was detected in almost all cell cultures treated with 10 µM HNE, alone or in 
combination with Ang II, with the exception of 1 nM Ang II. Results of necrosis have 
shown that treatment with 0,5 nM Ang II and 1 µM HNE reduced the level of necrotic 
cells (p<0,05). Increase in necrosis was observed in all treatments with 10 µM HNE, 
alone (p<0,01) and in combination with 0,1 nM Ang II (p<0,02) and 0,5 nM Ang II and 
1 nM Ang II (p<0,002) as well as in all treatments with combination of 5 µM HNE with 
0,1 nM and 0,5 nM Ang II (p<0,05) and 1 nM Ang II (p<0,003). Immunoblot analysis 
showed clear binding between the Ang II and HNE. 
Conclusion: Our results support the hypothesis of the involvement of the HNE and 
thus ROS in the pathophysiology of otosclerosis. Furthermore the results of the Ang 
II and HNE effect on the osteoblasts proliferation, differentiation and apoptosis, 
support their observed role as an important signaling molecules in bone remodeling.   
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INTRODUCTION
Otosclerosis is a complex disease characterized by an abnormal bone turnover 
localized to the human otic capsule resulting in conductive hearing loss1. Its 
incidence in Western populations is 0.3%. In 80% of cases the disease has a 
bilateral form.  It is  more frequent in women than in men2,3. Several hypotheses  have 
been proposed concerning the etiology of otosclerosis including viral infection, and 
auto immunity, but the etiology appears to be complex multifactorial and still unclear. 
Potential implication of various environmental and genetic factors have been reported 
(measles virus, auto immunity, HLA system) 4-8.
Angiotensin (Ang) II, a major effector peptide of the renin-angiotensin system is an 
important regulator of the cardiovascular system and body fluid homeostasis, and an 
important local cellular growth factor9-11. Research of the Ang II effects on bone cells 
have demonstrated its  stimulatory effects on osteoblasts  (stimulation of DNA 
synthesis, cell number and collagen synthesis in osteoblastic precursor cells)12-17. 
Previously we have shown an existing association between otosclerosis  and two 
genetic polymorphisms related to plasmatic Ang II concentrations (AGT M235T and 
ACE I/D)18.  We also demonstrated the in vitro effects of Ang II in otosclerotic stapes 
(pro-inflammatory cytokine secretion, reduction in alkaline phosphatase activity)18.
Oxidative stress and reactive oxygen species (ROS) have a major role in different 
signaling pathways of Ang II19-22. Ang II stimulates the ROS formation via activation of 
NADPH oxidase9,23. Furthermore, several important physiological functions of Ang II 
(e.g. cell growth, hypertrophy, proliferation, apoptosis  and cell migration) are directly 
mediated by ROS22. As highly reactive and unstable free radical molecules, ROS, 
can react and damage cell macromolecules such as proteins, DNA and lipids. 
Primary targets  of ROS are polyunsaturated fatty acids in membrane phospholipids 
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and in other lipid containing structures thus producing more stabile reactive radicals 
in a process called lipid peroxidation. Recent studies have shown that lipid 
peroxidation products can cause lipid hydroperoxide-derived modifications of Ang II 
which can modulate its biological activity19. A major bioactive marker of lipid 
peroxidation, derived from ω-6 polyunsaturated fatty acids like arachidonic acid and 
linoleic acid, is 4-hydroxynonenal (HNE), an reactive aldehyde, that acts as a second 
messenger of free radicals and a signaling molecule24,25. It is found in different 
human tissues and its physiological roles are not entirely understood26-30. Our 
previous research has revealed the HNE role in differentiation, apoptosis and cell 
proliferation in human osteoblast-like cells  26,29,30 and a positive impact on cell growth 
when it is present in physiological concentration31. We have also found that HNE  is 
generated by osteoblasts while grown in vitro on the surfaces of bioactive glasses 
(e.g. material used in medicine for enhancement of osteogenesis) 32. 
The aim of the present study was to understand the role of Ang II and HNE, in 
otosclerosis, on in vitro model of osteoblast-like cells in order to further understand 
the pathophysiology of the disease. 
MATERIALS AND METHODS
Tissue samples
In this series, the stapedial bones were harvested from patients  undergoing surgery 
for otosclerosis (n=15) and control group of patients undergoing translabyrinthine 
surgery for a vestibular schwanoma (n=6). Ethics committee approval and patients’ 
consent were previously obtained for the bone samplings. The diagnosis of 
otosclerosis was based on clinical, audiometric, and computed tomography scan 
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findings and confirmed by the preoperative aspect of the stapes. All samples were 
fixed in 10% buffered formalin and decalcified in 0.5 mol/L Na-EDTA for 72 hours. 
Samples were then dehydrated in a series of alcohol solution (70%, 96%, absolute) 
and xylene and then embedded in paraffin blocks.
Immunohistochemistry
Immunohistochemistry for HNE-modified proteins was carried out on formalin-fixed 
paraffin embedded stapes samples using monoclonal antibodies obtained from 
culture medium of the clone ‘HNE 1g4’, produced by a fusion of Sp2-Ag8 myeloma 
cells with B-cells  of a BALB-c mouse immunized with HNE-modified keyhole limpet 
hemocyanine. The antibody is specific for the HNE-histidine epitope in HNE-protein 
(peptide) conjugates and gives only 5% cross-reactivity with HNE-lysine and 4% with 
HNE-cysteine.
Immunohistochemistry was performed in a two-step procedure using an EnVision kit 
(DAKO, Denmark), where the first step was incubation with anti-HNE monoclonal 
antibodies (dilution 1:10) during 2 h in humid chambers at room temperature. The 
second step was incubation with peroxidase labelled polymer conjugated to goat 
anti-mouse immunoglobulins during 30 min. Finally, the reaction was visualized by a 
DAB (3,3-diaminobenzidine tetrahydrochloride in organic solvent) giving a brown 
colour and using haematoxylin contrast staining (blue). Negative control was done on 
one histological slice of the same tissue, without application of HNE-histidine-specific 
monoclonal antibodies. All immunohistochemical analyses were done by a 
pathologist experienced in the HNE-immunohistochemistry without prior knowledge 
of the study group design.
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Preparation of fresh HNE
(E)-4-hydroxynonenal-dimethylacetal (HNE-DA, Alexis Biochemicals) was obtained 
as 1mg/ml liquid, preserved in chloroform and kept at –20°C. Before use, it is 
activated according to the manufacturer’s  protocol. Briefly, HNE-DA is evaporated by 
nitrogen blow and 1mM HCl is added to hydrolyze HNE for 1h. HNE concentration is 
determined by spectrophotometer measuring the spectra from 200 to 350nm and 
calculated value upon the absorption maximum at 223nm. HNE concentration is 
calculated upon the formulae c(mol/l)= Axd/13750, where is  c-concentration of HNE 
in mol/l; A-measured absorbance; d-sample dilution; 13750-molar extinction 
coefficient of HNE in water.
Human osteosarcoma (HOS) cell culture
The human osteosarcoma cell line (HOS) was obtained from the American Type 
Culture Collection (ATCC). Cells were maintained in DMEM (Dulbeco’s Modified 
Eagle’s Medium, Sigma USA) with 10% fetal calf serum (FCS, Sigma, USA) in an 
incubator (Heraeus, Germany) at 37°C, with a humid air atmosphere containing 5% 
CO2. The cells were detached from confluent cultures with a 0.25% trypsine solution 
for 5 minutes. Viable cells upon (trypan blue exclusion assay) were counted on a 
Burker-Turk hemocytometer and used for experiments.
Cell Proliferation 
Cells  have been seeded at 1x104 per well in 96-well microwell plate in 100 µl of 
DMEM medium with 0.25% of FCS and left for 48 hours. Upon 48 hours medium was 
removed and replaced with a fresh medium free of FCS. Cells were further treated 
with different concentrations of HNE (1µM, 2.5µM, 5µM and 10µM) and Ang II 
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(Sigma-Aldrich, France, 0.1nM, 0.5nM, 1nM) in two different sets of experiments. In 
the first type of experiment the HNE was added first followed by Ang II after one hour, 
while in the second experiment first the Ang II was added followed by HNE after one 
hour. Previously we used higher concentrations of Ang II (10 nM and 100 nM). The 
obtained results have shown that these concentrations  have deleterious effect on 
HOS cell proliferation both alone and even more if cells  were treated with HNE in 
concentration-dependent manner. For this reason, and since normal human plasma 
Ang II levels are from 12-35 pg/ml when measured at rest and increasing on 
standing, exercise, dehydration, or sodium depletion,  we have focused on lower Ang 
II concentrations.
The rate of radioactive 3H-thymidine incorporation into DNA is used to estimate the 
replicate activity of HOS cells. After 12 hours of incubation with compounds, 
radioactive 3H-thymidine ([6-3H] thymidine, 1mCi/ml, Amersham Biosciences, USA) 
was added 0.1 µCi to each well and incubation is continued for the following 6 hours. 
The cells  were then harvested on glass filter in a cell harvester (Skatron, Norway) 
and 3H-thymidine incorporation was measured using a liquid scintillation β-counter 
(Beckman 7400, USA). Results are expressed as percentage of positive control. 
Cell Differentiation
Cells  were seeded 2x104 per well in 96-well plate in DMEM with 1% of FCS and left 
for 24 hours. Afterwards the medium was replaced by fresh medium containing 
different concentrations of HNE (1µM, 2.5µM, 5µM and 10µM) and Ang II (0.1nM, 
0.5nM and 1nM). Given that the proliferation results where more interesting where 
HNE was added first and upon 1 hour Ang II, we decided to carry out all our 
treatments in this way. The treatment was repeated every second day. Control cells 
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were stimulated to differentiate with 10-7 M dexamethasone (Sigma, USA), 5x10-6 M 
L-ascorbic acid (Sigma, USA) and 10-3 M β-glycerophosphate (Sigma, USA). After 10 
days of treatment, cells were stained for alkaline phosphatase (ALP) by NBT/BCIP 
assay (Roche, Switzerland). This assay is  based on a chromogenic reaction initiated 
by the cleavage of the phosphate group of BCIP by alkaline phosphatase present in 
the cells. Cell cultures were washed three times with tris-buffered saline (TBS), pH 
7.0 and fixed with 4% buffered paraformaldehyde for 30 minutes at 4°C. Staining was 
performed by adding 200 µl/well of stain and incubated at 37°C for 60 minutes. 
Insoluble purple precipitates were solubilised with 200 µl of SDS 10% HCl and 
incubated for 18 h. The optical density measurement was done at 595 nm.
Induction of Apoptosis
Flow Cytometry
Cells  were seeded in 6-well plates (Sarstedt, Germany) at the density of 250 000 
cells/well in DMEM with 0.25% FCS for 48 hours. After 2 day cultivation, medium was 
replaced and cells were treated with HNE and Ang II according to previously 
described treatment and left for 24 hours. The presence of apoptotic cells was 
determined by Annexin-V-Fluos Staining Kit (Roche, Germany) according to 
manufacturer protocol. Briefly, cells were collected and washed in phosphate buffer 
saline (PBS), centrifuged and resuspended in Anexin-V-Fluos labeling solution 
(Anexin-V-Fluoresce/Propidium iodide (PI) negative). After 15 minutes incubation at 
room temperature cells  were analyzed on FACSCalibur flow cytometer (Becton 
Dickinson, USA). The percentage of cells  nonapoptotic live cells (Annexin V-FITC 
negative/PI negative), apoptotic cells (Annexin V-FITC positive/PI negative) and 
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necrotic cells (Annexin V-FITC positive/PI positive), was calculated by application of 
FlowJo software (Tree Star Inc., USA).
Immunoblot Analysis
Ang II and bovine serum albumin (BSA, fatty acid free, Sigma, USA) were prepared 
in a concentration of 0.1 mg/ml, mixed with 5x10-5 and 5x10-4 M HNE (final 
concentrations) and left for one hour at room temperature. Prepared samples (100 µl) 
were spotted onto nitrocellulose membrane (Amersham). The membrane was 
incubated in blocking solution (2 % nonfat milk powder in PBS) at room temperature 
for 60 min and subsequently incubated overnight with mouse monoclonal antibody 
directed against HNE-histidine epitope. The blot was incubated with 3 % H2O2 to 
block endogenous peroxidases  and then washed and incubated with EnVision (Dako, 
Denmark) for 30 min. Immune complexes were visualized using the 3,3'-
diaminobenzidine tetrahydrochloride (Dako, Denmark) staining and scanned for 
quantification of signals. Negative controls were included in all experiments in which 
the antibody was omitted and replaced by control diluent (1% BSA in PBS).
Statistical Analysis
All assays were performed in triplicates. Values were expressed as means ± SD. 
Comparisons were assessed a by two-tailed Student’s test considering values of 
p<0.05 as significant.
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RESULTS
Immunohistochemistry
Both control and otosclerotic samples  showed positivity for HNE antibodies. Control 
samples showed clearly marked HNE positivity in periosteal bone regions while 
otosclerotic samples showed localized regions of HNE positivity with no regular 
distribution (Figure 1).
Proliferation of HOS cells 
The influence of Ang II and HNE on the cellular growth was analyzed on human 
osteosarcoma cell line (HOS). The effect of Ang II and HNE on the cell proliferation 
depended on the concentration used. Results showed that association of Ang II in 
concentration of 0.1nM and HNE of 2.5 µM stimulated the proliferation of the HOS 
cells (p<0.0002, Figure 2). On the other hand association of 10 µM HNE with all Ang 
II concentration or alone showed significant decrease in cell proliferation (alone 
p<0.00005; 0.1 and 0.5 nM Ang II p<0.001; 1 nM Ang II p<0.0004). All values were 
calculated as percentage of the respective control.
Differentiation of HOS cells by Ang II and HNE 
Alkaline phosphatase (ALP) activity
Results are expressed as a percentage of the positive control (treatment with 
dexamethasone, L-ascorbic acid and β-glycerophosphate as inducers of osteoblastic 
differentiation). We observed decrease in ALP activity in cell cultures treated with 0.1 
nM Ang II and HNE concentrations of 1 µM or 2.5 µM (p < 0.01). On the contrary, 10 
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µM HNE alone (p < 0.05) or in combination with 0.1 or 0.5 nM Ang II (p < 0.01) 
increased ALP activity with the exception of 1 nM Ang II (Figure 3). 
Apoptosis induction
The used Annexin-V-Fluos Staining Kit can distinguish apoptotic cells, FITC+PI-, from 
necrotic cells, FITC+PI+, so we presented both results. Results  are expressed as a 
percentage of the control value (FITC+PI- cells without any treatment for apoptotic 
cells and FITC+PI+ cells without any treatment for necrotic cells).
We have observed decrease in apoptosis (p<0.05) in cells treated just with Ang II 
(0.1 and 0.5 nM). On the contrary increase in apoptosis  (p<0.01) was detected in 
almost all cell cultures treated with 10 µM HNE, alone or in combination with Ang II, 
with the exception of 1 nM Ang II (Figure 4). 
Results of necrosis  have shown that treatment with 0.5 nM Ang II, 1 µM HNE or 
combination of 1 µM HNE with 0.5 nM Ang II reduce the level of cells in necrosis 
(p<0.05). Increase in necrosis was observed in all treatments with 10 µM HNE, alone 
(p<0.01) and in combination with 0.1 nM Ang II (p <0.02); 0.5 nM Ang II and 1 nM 
Ang II (p<0.002) as well as in all treatments with 5 µM HNE with Ang II of 0.1 and 0.5 
nM (p<0.05) and 1 nM Ang II (p<0.003, Figure 5).
Immunoblot analysis 
Using the HNE antibodies immunoblot analysis showed clear binding between the 
Ang II and HNE (Figure 6). 
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DISCUSSION 
In the present study we wanted to determine the interaction of Ang II and HNE in the 
otosclerosis by studying the in vitro model of osteoblast-like cells. In order to 
investigate whether HNE can be found in the otosclerotic bone we have performed 
immunohistochemical analysis  of formalin fixed paraffin embedded control and 
otosclerotic stapes samples, with the monoclonal HNE antibody that detects HNE-
protein conjugates, specifically the HNE-histidine epitope. Results showed that HNE-
protein conjugates are present in both samples, control and otosclerotic ones. 
However, difference between these samples was observed in a way that the HNE 
positivity in control samples was present only in periosteal region while otosclerotic 
samples showed no regular HNE positivity but rather multifocal areas mainly in the 
new bone or pathologic bone formation regions. The HNE presence in periosteal 
region of control samples suggests its  physiological role associated to cell 
proliferation and differentiation. On the other hand, otosclerotic samples, where 
abnormal and undesirable bone turnover is present, express HNE positivity mostly in 
multifocal areas  and it diminishes in periosteal regions. This clear difference in 
distribution patterns  of control and otosclerotic samples indicates HNE bifunctional 
role. Therefore, in normal conditions  HNE regulates the cell growth and 
differentiation, however in pathological conditions, like otosclerosis, seems that it 
loses its role in cell growth regulation but rather has a part in the pathology of the 
otosclerosis. Although, this immunohistochemical analyses is mostly qualitative and 
not quantitative, yet when comparing the brown color intensity we can observe that it 
does not differ greatly. This implies that HNE is associated with the cell growth but 
the difference of its  role (physiological-pathological) is  mainly associated with the 
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origin of the cells. If the cell originates in periosteal region HNE is  involved in normal 
physiological process of cell growth but if cell are forming new bone in multifocal 
regions of otosclerotic bone, HNE is involved in pathophysiology of this disorder. 
As a second messenger of ROS, HNE has high reactivity to bind to macromolecules, 
especially proteins, and can also be carried to the distant places and released from 
protein in certain conditions such as pH change affecting biomolecules distant from 
the place of its  origin31. This  could be one of the ROS diffusion mechanisms into the 
inner ear. Previously ROS have been determined in the human inner ear and 
perylimph by the activity of other ROS such as xantine dehydrogenase/xantine 
oxidase (XA/XO) enzyme system33. In animal models, several conditions of 
increased ROS production related to cochlear damage have been described, 
including exposure to noise and to drugs (i.e. aminoglycosides and cisplatin). In 
humans, ROS appeared to be involved in hair cell damage in some cases of genetic 
hearing loss (i.e. Pendred syndrome), presbycusis, and Menière’s syndrome33.Once 
generated, ROS are responsible for direct cellular damage to lipids, proteins, and 
DNA, triggering apoptosis or necrosis and may also diffuse among the inner ear 
scalae33. 
Our previous results have shown that HNE acts as a signaling molecule affecting cell 
proliferation, differentiation and apoptosis in dose-dependent manner26,32.  This is  in 
compliance with our current results clearly distinguishing physiological and supra-
physiological role of HNE. Consequently, we have also observed interesting dose-
dependent manner of combined Ang II effect. Our results with supra-physiological 
concentrations of HNE (5 and 10 µM) have shown that higher Ang II concentrations 
(0.5 and 1 nM) multiply the negative effect of HNE on cell proliferation, differentiation 
and stimulates cell apoptosis and necrosis. Moreover, 10 µM HNE have shown to 
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decrease cell proliferation and induce differentiation, apoptosis and necrosis while 
addition of 1 nM Ang II completely directs towards necrosis. Combined effects of 5 
µM HNE with 1 nM Ang II and 10 µM HNE with 0.5 nM Ang II show attenuated effects 
compared to the highest concentration treatment. Thus 5 µM HNE reduces negative 
effect of HNE on cell proliferation, but on the other hand, with pronounced necrosis. 
Furthermore, lower Ang II concentration (0.5 nM) increases differentiation. The 
physiological concentrations of HNE (1 µM and 2.5 µM) are more likely interacting 
with lower concentration of Ang II (0.1 nM) indicating completely opposite effect 
mostly directed to cell proliferation, and reduction of cell differentiation, apoptosis and 
necrosis.
These results suggest that Ang II interacts with already observed bifunctional growth-
regulating HNE effect in a dose-dependent manner. However, previous studies 
confirmed the involvement of ROS in signaling pathways of Ang II. NADPH oxidase is 
known to be the major source of vascular ROS. Moreover, Ang II stimulates ROS 
generation via activation of NADPH oxidase, mainly through its G protein-coupled 
Ang II type 1 (AT1) receptor19. Although our protocol minimized the possible 
interactions between Ang II and HNE and since is  known that various cells 
metabolize 90-95% of 100 µM HNE within first 3 minutes34, because Ang II consist of 
one histidine we also investigated whether there is  an existing binding between Ang II 
and HNE. For that reason we performed the immunoblot analysis that showed clear 
positivity. The difference in color intensity of Ang II and bovine serum albumin (BSA) 
dots, for the same treatment, could be explained with the difference in their structure. 
BSA is  known to have 16 histidines comparing to 1 histidine of Ang II. Since the used 
monoclonal antibody specifically recognizes HNE-histidine epitope in HNE-protein 
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conjugates this is most likely the explanation for intensity difference. Consequently, 
we can assume that HNE could modulate the effect of Ang II per se.
In conclusion our results support the hypothesis of the involvement of the ROS in the 
pathophysiology of otosclerosis. Furthermore the results  of the Ang II and HNE effect 
on the osteoblast proliferation, differentiation and apoptosis, support their observed 
role as an important signaling molecules in bone remodeling.   
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Figure 1- Immunohistochemistry for HNE of the otosclerotic and control 
samples: Both control (A,B) and otosclerotic (C,D) samples  showed positivity for 
HNE antibodies. Control samples showed clearly marked HNE positivity in periosteal 
bone regions while otosclerotic samples showed localized regions of HNE positivity 
with no regular distribution
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Figure 2-Proliferation of HOS cells: 
a) The effect of Ang II and HNE on the cell proliferation depends on the concentration 
used. Higher concentrations of Ang II (10 nM and 100 nM) have deleterious effect on 
HOS cell proliferation both alone and even more if cells  were treated with HNE in 
concentration-dependent manner.
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b) Results showed that association of Ang II in concentration of 0,1nM and HNE of 
2.5 µM stimulated the proliferation of the HOS cells (p<0.0002). Association of 10 µM 
HNE with all Ang II concentration or alone showed significant decrease in cell 
proliferation (alone p<0.00005; 0,1 and 0.5 nM Ang II p<0.001; 1 nM Ang II 
p<0.0004).
Results are expressed as percentage of respective control. Ang II: Angiotensin II, 
HNE: 4-hydroxynonenal.
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Figure 3- Differentiation of HOS cells by Ang II and HNE: Results are expressed 
as a percentage of the positive control. Alkaline phosphatase activity (ALP) 
decreased in cell cultures treated with the combination of Ang II (0.1 nM) and HNE at 
or 2.5 µM (p<0.01, paired t-test). In contrast, 10 µM HNE alone (p<0.05) or in 
combination with 0.1 or 0.5 nM Ang II (p<0.01) increased ALP activity. ALP: Alkaline 
phosphatase, Ang II: Angiotensin II, HNE: 4-hydroxynonenal.
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Figure 4 - Induction of Apoptosis (FITC+PI-): Decreased apoptosis in cells 
treated with Ang II (0.1 and 0.5 nM) alone (p<0.05, paired t-test). In contrast, increase 
in apoptosis (p<0.01) was detected in almost all cell cultures treated with 10 µM 
HNE, alone or in combination with Ang II, with the exception of 1 nM Ang II. Ang II: 
Angiotensin II, HNE: 4-hydroxynonenal.
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Figure 5- Induction of Apoptosis (FITC+PI+):Results of necrosis  have shown that 
treatment with 0.5 nM Ang II, 1 µM HNE or combination of 1 µM HNE with 0.5 nM 
Ang II reduced the level of cells in necrosis (p < 0.05). Increase in necrosis was 
observed in all treatments  with 10 µM HNE, alone (p < 0,01) and in combination with 
0.1 nM Ang II (p < 0.02); 0,5 nM Ang II and 1 nM Ang II (p < 0.002) as well as in all 
treatments with 5 µM HNE with Ang II of 0.1 and 0.5 nM (p < 0.05) and 1 nM Ang II 
(p < 0.003). Ang II-Angiotensin II, HNE: 4-hydroxynonenal.
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Figure 6- Immunoblot analysis with HNE antibodies showed clear binding between 
the Ang II and HNE. Ang II: Angiotensin II, HNE: 4-hydroxynonenal, BSA: bovine 
serum albumin.
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IV. GENERAL DISCUSSION
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The results of these 2 studies provide a new insight on the role of Ang II and oxidative stress 
(ROS and its second messengers) in the pathophysiology of stapes metabolism namely 
otosclerosis. Ang II induces the secretion of different pro-inflammatory  cytokines in the 
primary otoslerotic cell cultures. Studies on Ang II effects and secondary  messenger of the 
ROS, (HNE) show interaction of these two factors and show positive influence on 
proliferation of human osteosarcoma cell-lines. The heterogeneous and diffuse distribution of 
HNE in otosclerotic bone supports the possible role of oxidative stress in the pathophysiology 
of the disease. Finally, oxidative stress products interact  with Ang II to alter bone cell 
response to this hormone. As indicated by immunoblot, at least a part of this interaction takes 
place at a level before Ang II receptors. In previous studies, we observed a difference of 
response to Ang II stimulation between otosclerotic and normal stapes. HNE is at least one of 
the explanations to this difference.
1. Bone (stapes) metabolism 
Bones are constantly remodeled through the synthesis of bone matrix by osteoblasts and the 
resorption of bone by osteoclasts. Perturbations in inflammatory  cytokines, growth factors 
and hormones cause an imbalance between osteoclasts and osteoblast activities and can result 
in different bone diseases such as osteoporosis, osteopetrosis and otosclerosis (Boyle et al., 
2003; Theill et al., 2002; Wada et al., 2006). The discovery of the receptor activator of nuclear 
factor-kB ligand (RANKL)/RANK/osteoprotegerin (OPG) signaling system provided a major 
breakthrough in understanding of the bone metabolism (Martin et al., 2005; Boyce et al., 
2007). Under physiological condition the RANKL produced by osteoblasts binds to the 
RANK on the surface of the osteoclast precursors, leading to the NF-kB activation (via 
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adaptor protein TRAF6) and translocation to the nucleus causing transcription of the 
osteoclastogenic genes. Osteoprotegerin acts as a soluble, neutralizing antagonist which 
competes with RANK on pre osteoclasts and osteoclasts for RANKL produced by  osteoblasts. 
Osteoprotegerin inhibits the differentiation, survival and fusion of osteoclastic precursor cells, 
supresses activation and promotes osteoclast apoptosis (Simonet et al., 1997; Udagawa et al., 
2000; Hofbauer et al., 2001; Zehnder et al., 2008). Osteoprotegerin is expressed in high levels 
within the inner ear, and is secreted into the perilymph and the surrounding bone through a 
lacunocanalicular system. It inhibits the active bone remodeling within the otic capsule 
(Zehnder et al., 2005, 2008). Inhibition of otic capsule remodeling is most present close to the 
cochlea and decreases with the distance from cochlear endosteum (Frisch et al., 2000; 
Zehnder et al., 2008). The active remodeling process seen in the osteoprotegerin knockout 
mice shows many similarities to otosclerosis seen in human temporal bones (Zehnder et al., 
2008). 
Otosclerosis is a primary disorder of the bone metabolism unique to the human temporal bone 
and is characterized by a disturbed resorption and deposition in bone (Niedermeyer et al., 
2002; Schrauwen et al., 2008). It is characterized by  spongiosis (active phase) and sclerosis 
(inactive phase) of the bony labyrinth which normally undergoes very little bone remodeling 
after birth (Frisch et al., 2000; Ealy  et al., 2008). The otic capsule is unique in its composition 
and pattern of bone remodeling. It remodels at a very low level compared with other bones in 
the body. Within the otic capsule, bone turnover varies from particularly  full inhibition 
(0,13%) in the innermost perilymphatic zone to gradually  increasing, yet  still reduced, level at 
the periphery (Frisch et al., 2000; Zehnder et al., 2006). The reason for this low level of bone 
turnover remains unclear. It has been suggested that this pattern of bone remodeling is a 
fundamental prerequisite for the normal function of the inner ear and has led to the 
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speculation that bone turnover in the otic capsule is controlled by intrinsic factors produced 
by the inner ear (Frisch et al., 2000, Adams et al., 2002; Zehnder et al., 2008). 
The causes of otosclerosis still remain unknown. Today otosclerosis is considered a complex 
disease caused by environmental and genetic factors. In addition to linkage analysis, 
association of several genes with otosclerosis has been reported. Previously, a TGF-ß1 gene 
was identified to be associated with the complex form of otosclerosis (Thys et al., 2007; Ealy 
et al., 2008). TGF-ß1 is an important factor in bone remodeling and in the induction of 
embryogenesis in the otic capsule. It can either stimulate chondrogenesis to promote otic 
capsule growth or selectively inhibit this process to permit perilymphatic space formation and 
capsular modeling (Bonewald et al., 1990; Frenz et al., 1991). The presence of TGF-ß1 at low 
levels stimulates osteoclast precursors to osteoclast  differentiation, and at higher levels 
inhibits osteoclastogenesis (Karst et al., 2004). Recent  studies showed that polymorphisms in 
BMP2 and BMP4, two members of the TGF-ß superfamily, play an important role in otic 
capsule chondrogenesis, and could contribute to the otosclerosis susceptibility (Lehnerdt et 
al., 2007, Schrauwen et al., 2007). Another gene TNF-α has been noted to be expressed in 
otosclerotic stapes. Its expression was associated with the detection of measles virus RNA 
(Karosi et al., 2005). Osteoprotegerin expression appears to be decreased in otosclerotic 
stapes footplates which are positive for measles viruses and TNF-α expression (Karosi et al., 
2006). 
In our study  of stapes metabolism and oxidative stress we used two different models: HOS 
(human osteosarcoma cell lines) which serves as a standard model for studying the bone 
metabolism, and primary otosclerotic cell cultures. The human otosclerotic stapes primary 
cell cultures were first described in 1968 (Petrovic and Shambough). The cultures were 
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described as highly  heterogenic with the presence of osteoblast-like cells, fibroblasts and 
intermediary cells. Later Bozorg Gayeli et al. (1999) studied the primary otosclerotic cells and 
for the first  time compared them to the normal stapedial cell cultures (2000). These cell 
cultures show several indicators of osteoblastic differentiation: alkaline phosphatase activity, 
mineralization nodules, presence of PTH receptors, osteocalcin production, and change of 
shape after PTH stimulation. Since the etiology of this disease is unknown, there is no valid 
animal model for the study of otosclerosis pathophysiology. 
2. Angiotensin II and bone metabolism
In the local milieu of bone, two major types of cells, osteoblasts and osteoclasts, are located in 
close proximity, exchange their signals, and coordinately resorb and form bone matrix (Zhao 
et al., 2006; Izu et al., 2008). Such events are controlled by molecules present in the local 
micro environment. These include cytokines, their modulators, and matrix proteins secreted 
by osteoblasts and osteoclasts (Myazono et al., 2004; Usui et al., 2004; Morinobu et al., 2005; 
Izu et al., 2008). The bone environment is quite heterogeneous, and there are also cells other 
than osteoclasts and osteoblasts. Bone microvasculatures serve as root to supply osteoclast 
progenitors, which are derived from hematopoietic lineage cells. These bone vasculatures are 
also considered to give rise to progenitors for osteoblastic cells from their perivascular 
regions (Izu et al., 2008). In addition to the anatomical relationship between the vascular cells 
and bone cells, these cells may be functionally  involved to coordinate regulation of bone mass 
(Izu et al., 2008). 
High blood pressure has been associated with bone loss in various clinical studies in humans 
(Lynn et al., 2006; Rejnmark et al., 2006). The epithelia of distal renal tubule, amiloride-
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sensitive epithelial sodium channels (ENaCs), which are controlled by the RAAS, represent 
the rate limiting step for sodium reabsorption. Recent clinical studies indicate that beta 
blockers and anti-hypertension drugs would reduce risk of bone fractures in the elderly 
populations (Sanada et al., 2004; Lynn et al., 2006). This suggests a possible link between 
vascular and skeletal systems. RAAS appears to act not only systematically but also locally  in 
several tissues, and bone micro-environments have been studied in this regard (Lavoie et al., 
1997; Sakai et al., 2007). Ang II expression has been reported in cartilage and bone (Kizer et 
al, 1997; Trujillo et al., 1999). Osteoblasts and osteoclasts both express AT1 receptor in cell 
cultures, suggesting the existence of local RAAS in bone (Hatton et al., 2997; Hiruma et al., 
1997; Shimizu et al., 2008). However, whether bone expresses RAAS components in vivo is 
not known. 
Ang II Receptors in bone
Ang II acts via AT1 and AT2 receptors, which are members of the 7-trans membrane-spanning 
G protein-coupled receptors. Many of Ang II actions are mediated through AT1 receptors 
(Senbonmatsu et al., 2003). In bony tissue, Ang II was reported to promote bone resorption 
via the AT1 receptor in cell culture system (Shimizu et al., 2008). Expression of AT1 receptor 
was observed in cultured osteoblasts and Ang II inhibits differentiation and bone formation 
via the AT1 receptor in rat calvarial osteoblastic cells (Bandow et al., 2007). Ang II 
significantly induces the expression of RANKL (receptor activator of NF-kB ligand) via AT1 
in osteoblast, leading to the activation of osteoclasts. 
Since osteoclast differentiation is regulated by a variety of hormones, local factors and 
inflammatory cytokines, such as IL-1 and TNF-α, RAAS might  also be involved in this auto/
paracrine system. Previously published work provides several potential mechanistic 
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connections for the control of bone resorption by  the AT1 receptor. For example, AT1 receptor 
signaling has been shown to inhibit  the development of osteoclast and to block macrophage 
infiltration in inflammatory  situations (Shimizu et al., 2008; Nagai et al., 2006). AT1 receptor 
antagonists also interfere with lipopolysaccharide activation of RAW264.7 osteoclast-like 
cells (Nagai et al., 2006). Ultrasound (mechanical strain) has been shown to increase 
RANKL, MP-1, and MIP in osteoblasts by signaling via AT1 receptor (Bandow et al., 2007). 
In contrast to AT1 receptor, AT2 receptor blockade did not yield a significant  effect in rat 
calvarial cells or in  human osteoblast  and osteoclast precursor cell co-cultures (Hagiwara et 
al., 1998; Shimizu et al., 2008). 
However, a recent study  showed that AT2 receptor blockade increased bone mass in adult 
mice (Izu et al., 2008). Indeed, AT2 receptor appears to inhibit osteoblastic basal activity in 
vivo as shown by the blockade-induced increase in bone formation rate. At the same time, 
AT2 receptor blockade suppresses in vitro bone resorption based on the analysis of osteoclast 
number and osteoclast surface and in organ culture. Thus, the dual role of AT2 receptor leads 
to a significant catabolic effect in bone. Latest studies demonstrating the presence of AT2 
receptor, ACE, and renin in bone microenvironment suggest that bone is also regulated by 
local RAAS and Ang II functions at least in part via AT2 receptor (Izu et al., 2008). 
Several publications raise the possibility that AT1 and AT2 receptors carry out negative cross-
talk within fibroblasts and vascular endothelial cells with respect to each other’s signaling 
pathways and responses. Similar antagonism may also exist in bone (Izu et al., 2008). 
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3. Angiotensin II and stapes metabolism
The role of Ang II was recently suggested in the human bone and other connective tissue 
remodeling. Considering the progression of otosclerosis during pregnancy  and the increase of 
angiotensinogen (AGT) production during this period, the implication of Ang II in 
otosclerosis seemed an interesting hypothesis (Imauchi et al., 2008). 
The angiotensinogen plasma concentration is associated with an ATG gene polymorphism 
represented by the substitution of a methionine by threonine at codon 235 (M235T) and 
yielding M235 and T235 alleles (Inoue et al., 1997). Individuals with T235 allele have a 
higher plasma AGT concentration and may have higher tissular Ang II concentrations 
(Jeunemaitre et al., 1992; Ward et al., 1993; Inoue et al., 1997). Two other polymorphisms are 
related to Ang II activity. The I/D polymorphism of the ACE, characterized by  the insertion (I) 
or deletion (D) of a 287-base pair (bp) sequence in the intron 16 of this gene, strongly 
influences serum ACE levels and may be associated with an increased cardiovascular risk 
(Niu et al., 2002). Whether this polymorphism may  influence the local tissular generation of 
Ang II is difficult to determine (Niu et al., 2002). Another polymorphism located in the 3’ part 
of the Ang II receptor Type 1 gene (A1166C) may also modulate the tissular response to Ang 
II and has been associated with primary hypertension (Baudin et al., 2005).
Imauchi et al. (2008) investigated the hypothesis of a possible implication of Ang II in 
otosclerosis through two types of experiments. They tested whether the functional 
polymorphism of the RAAS could be associated with otosclerosis in a large case-control 
study. Furthermore, they tested whether the Ang II receptors (AT1R and AT2R) and AGT 
were expressed in these cells and whether Ang II could influence the production of 
interleukin-6 (IL-6) in bone derived cells. Previously, Ang II has been shown to increase the 
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autocrine-paracrine production of IL-6 in vascular smooth cells and IL-6 was shown to be a 
mediator of bone resorption and a pro inflammatory cytokine. 
Results of Imauchi et al. genetic study (2008) in a large series of patients and controls showed 
that the T235 variant allele of the AGT gene, that  has shown to be related to high plasma 
AGT concentrations, was associated with otosclerosis. The ACE I/D polymorphism seemed to 
be also associated with the occurrence of otosclerosis. The proportion of DD genotype that is 
related to an increased enzymatic activity was higher in patients with otosclerosis than in 
control subjects. Patients both with TT and DD genotypes had an increased risk of 
otosclerosis with those with DD and TT genotypes only. The relation between AGT plasma 
concentrations and the M235T polymorphism of the AGT gene has been demonstrated by 
several studies. AGT plasma concentrations are 14-20% higher in TT than in MM  genotype. 
Several observations are in favor of increased tissue expression of AGT and Ang II in 
individuals with TT and MT genotypes in comparison with MM. The T235 allele is associated 
with hypertension, preeclampsia and diabetic nephropathy. The present study revealed higher 
blood pressure in the otosclerosis group, and this may be partly  explained by  the fact that 
inclusions in the otosclerosis group were only based on the middle ear disease and not the 
blood pressure. 
The T235 variant of the AGT gene allele prevails in black and Asian populations, in which the 
prevalence of symptomatic otosclerosis has been reported to be lower than that in Caucasians 
(Chole et al., 2001; Menger et al., 2003). Furthermore, a case-control study in a Belgian-
Dutch population did not find this association (Schrauwen et al., 2009). This observation may 
be due to the fact  that otosclerosis has probably several and variable predisposing factors, 
depending on the studied population, and that RAAS polymorphisms strongly interact with 
the environment and other genes to induce their effects.
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Imauchi et al. (2008) also showed the presence of AGT, AT1, and AT2 in otosclerotic cultures 
and increased Ang II induced secretion of IL-6 that inhibited the alkaline phosphatase activity 
specifically in the otosclerotic tissue. This observation is consistent with the implication of 
this hormone in the stapedial bone metabolism and supports the involvement of Ang II in 
otosclerosis. The observed difference between otosclerotic and control cultures in terms of 
response to Ang II may be attributed to the participation of inflammation in the otosclerotic 
process and thus a higher predisposition of otosclerotic cells to produce pro-inflammatory 
agents in response to hormonal stimulations. 
4. Angiotensin II and activation of pro-inflammatory cytokines in primary 
otosclerotic bone cell cultures
In the present study we focused on the Ang II effect on the secretion of a large panel of pro-
inflammatory cytokines in primary otosclerotic cell cultures. We showed differences in  the 
secretion of inflammation mediators between the otosclerotic and control stapes both in basal 
and Ang II-stimulated conditions. 
In otosclerotic stapes, in basal conditions two pro-inflammatory cytokines (IL-1b,  IP-10) 
were released in higher amounts in comparison to the control stapes. Interleukin 1-beta is an 
important mediator of the inflammatory response, and is involved in a variety of cellular 
activities; including cell proliferation, differentiation and apoptosis. Its higher production in 
the otosclerotic stapes is in accordance with a higher bone turnover in the disease foci.  The 
expression of interferon inducible protein IP-10 has been noted in various cells including 
lymphocytes, monocytes, and fibroblasts. Although IP-10 is mainly known for its hemotactic 
activity, it has a significant role in inflammation. 
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Control stapes showed higher production of TIMP2, a tissue inhibitor of metalloproteinases, 
in basal conditions and in comparison to otosclerosis. This cytokine plays an important part in 
tissue homeostasis by directly suppressing the endothelial cell proliferation, inhibiting the 
proliferation of various tissues in response to angiogenic factors, and reducing the protease 
activity in tissues undergoing extracellular matrix remodeling such as active otosclerotic foci 
(Stetler-Stevenson et al., 2005). 
Upon stimulation with the Ang II, otosclerotic cultures showed higher expression of several 
pro-inflammatory cytokines (IFN-gamma, IL-10). IFN-gamma is known as an antiviral, 
immunoregulatory and anti-tumor factor (Shroder et al., 2004). Today, IFN-gamma is used to 
treat chronic granulomatous diseases and osteopetrosis, an otosclerosis like lesion 
characterized by  an increased density  of various bones, including the temporal bone (Todd et 
al., 1992; Key et al., 1992). Interleukin-10 or human cytokine synthesis inhibitor factor 
(CSIF) is an anti-inflammatory cytokine. It  is primarily produced by monocytes and to a 
lesser extent by lymphocytes. This cytokine has pleiotropic effects on immunoregulation and 
inflammation. It can block NF-kappa B activity, and is involved in the AK-STAT signaling 
pathway (Moore et al., 2001). 
When stimulated by  Ang II, control cells showed inhibition of several other cytokines 
(MIP-1a, and IL-11). Macrophage inflammatory  protein (MIP) belongs to the family of 
chemotactic cytokines, known as chemokines. It is a highly potent pro-inflammatory cytokine 
capable of inducing the synthesis of other pro-inflammatory  cytokines like IL-1, IL-6 and 
TNF-α from fibroblasts and macrophages (Sherry et al., 1988). Interleukin 11 is a 
multifunctional cytokine and a key  regulator of multiple events in hematopoiesis (Yang et al., 
1993). It has been demonstrated that this interleukin participates in the regulation of bone-cell 
proliferation and differentiation and could be used as a therapeutic agent for osteoporosis. 
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Higher prevalence of osteoporosis has been observed in otosclerosis patients, suggesting a 
common genetic pathogenesis (Clayton et al., 2004). This common pathogenesis could be 
RAAS. In mice, IL-11 stimulates and increases the cortical thickness and strength of long 
bones (Locksley et al., 2001). 
Tumor necrosis factor alpha (TNF-α) is a cytokine involved in systemic inflammation and is a 
member of a group  of cytokines involved in the acute phase reaction (Locksley et al., 2001). 
Dysregulation, and in particular the overproduction of TNF have been implicated in a variety 
of human diseases. Among other it  is produced by monocytes-macrophage system that 
regulates the differentiation and activation courses of bone-derived mesenchymal cells. Its 
increased expression in otosclerotic bone could result in an extensive osteoclast activation 
cascade and pathologic bone turnover. So far it has been observed that TNF-alpha along with 
other cytokines is released from the otosclerotic foci in the early stage of the disease. Thus 
these molecules could flow into the perilymph and could interfere with the electromotility  of 
the outer hairy  cells, causing the sensorineural hearing loss (Karosi et al., 2009; Sziklai et al., 
2009). The increased TNF-alpha production could trigger the focal bone resorption, thus 
administration of monoclonal anti TNF-alpha antibody  could be considered as a potential 
medical treatment option in types of cochlear otosclerosis with sensorineural hearing loss 
(Sziklai et al., 2009).
In our study, Ang II-stimulated otosclerotic cultures showed inhibition of soluble TNF RII. 
This agent acts as a buffer for TNF. Its reduction can promote inflammation by  increasing the 
amount of free TNF. 
We also tested the mRNA expression of 126 genes involved in the inflammatory response. 
Although several genes were differently expressed only one, BCL-6, showed statistically 
significant difference in otosclerotic versus control cultures. BCL-6 gene encodes the BCL-
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lymphoma 6 protein that acts as a sequence-specific repressor of transcription, and has been 
shown to modulate the transcription of STAT-dependent Interleukin 4 responses of B cell. 
BCL-6 has also been shown to regulate the expression of several chemokine genes, while its 
function in other aspects of macrophage biology has not been studied. Also the precise role of 
BCL-6 in cell proliferation is poorly  understood. Recent results show that BCL-6 negatively 
regulates proliferation of the monocytic/macrophage lineage by suppressing an autocrine IL6/
STAT3-mediated gene expression program (Woo et al., 2002). Namely, BCL-6 negatively 
regulates the IL-6 transcription and inactivation caused by BCL-6 leads to spontaneous IL-6 
secretion and STAT3 activation, which in turn results in cellular hyper-proliferation 
phenotype characterized by an accelerated G1/S phase transition. Besides the IL-6/STAT 
signaling it is very  likely  that BCL-6 controls other aspects of cell cycle as well (Yick-Loi et 
al., 2005). An important class of genes regulated by BCL-6 is chemokines. Chemokines were 
repressed by  BCL-6 both in the micro-array study in B cell lines, but also in specific study of 
chemokine expression by macrophages (Schaffer et al., 2000; Dent et al., 2002). It  was 
already observed that  chemokines MIP-1alpha (inhibited secretion in otosclerotic stapes when 
stimulated with angiotensin II) and IP-10 (higher expression in otosclerotic stapes in basal 
condition) were repressed by  BCL-6 in B cells. It has been demonstrated as a functional 
binding site in the MIP-1alpha promoter but not the IP-10 gene (Schaffer et al., 2000). In our 
study the gene array analysis showed a significant over expression of BCL-6 gene in the 
otosclerotic stapes when compare to the control ones, in basal condition. The results were 
confirmed by the qPCR that showed significant higher BCL-6 expression in otosclerotic foci. 
When stimulated with Ang II the otosclerotic foci gene array analysis showed a significant 
inhibition of BCL-6 in otosclerotic foci. The results were not confirmed by the real time 
qPCR analysis. Nevertheless higher expression of BCL-6 in otosclerotic foci supports its role 
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in the cellular proliferation. And its inhibition caused by Ang II in otosclerotic foci suggests 
BCL-6 regulation of inflammation and activation of different pro-inflammatory cytokines.
From the obtained data, we concluded that Ang II could have an important role in the key 
events of inflammation and in the bone turnover regulation and metabolism of the human 
primary otosclerotic cell cultures, through different pro-inflammatory pathways. These data 
support are previous hypothesis of Ang II role in the pathophysiology of otosclerosis. 
However further investigations are necessary  to additionally clarify the role of the Ang II 
effect in the pathophysiology of otosclerosis and stapes metabolism. 
5. Angiotensin II and oxidative stress in otosclerosis
In the present study we focused on the possible Ang II and HNE (oxidative stress) interaction 
in pathophysiology of otosclerosis. By analyzing the histologic samples of normal and 
otosclerotic stapes we found that both samples expressed different positivity for HNE 
antibodies. While control samples showed clearly marked positivity in periosteal region, 
otosclerotic samples showed multifocal areas of HNE positivity mainly in the new bone or 
abnormal bone formation regions. These observations suggest that HNE (secondary 
messenger of ROS) is indeed involved in the pathophysiological processes of the otosclerosis. 
Moreover we could conclude that if the cells originate in periosteal region HNE is involved in 
normal physiological process of cell growth but if the cells are forming new bone like in 
multifocal regions of otosclerotic bone, HNE is involved in pathophysiology of this disorder. 
So far it has been observed that several important  physiological functions of Ang II are 
mediated through ROS (i.e. cellular growth, and inflammatory responses, Griendling et al., 
2000). Activating the NADPH oxidase enzyme system  Ang II stimulates ROS generation 
154
mainly through its G protein-coupled Ang II type 1 (AT1) receptor (Lee et al., 2008). In order 
to test the possible direct binding between the Ang II and HNE we have performed the 
Immunoblot analysis. The results showed that there could exist a possible interaction between 
the HNE and Ang II (histidine, serine, lysine and cysteine amino-acids could be possible 
binding sites). In the performed experiment due to higher number of histidine residues present 
in BSA higher binding was observed for BSA and HNE then for HNE and Ang II. However 
due to the experiment protocol (addition of HNE prior to Ang II) we cannot confirm direct 
binding between them. But we could conclude that  interaction is likely to exist  in a tissue and 
intracellular level but mainly  on the transmembrane proteins and receptors. HNE is mostly 
formed close to the cellular membrane and Ang II acts as a cytokine-like hormone and could 
react with the HNE.
Indeed one of the signaling pathways of Ang II includes activation of mitogen-activated 
protein kinases (MAPK), including extracellular signal-regulated kinases (ERK 1 /2), c-jun 
N-terminal kinase (JNKs, also known as SAPKs), p38MAPKs and big MAPK-1. Previously  it 
was observed that cells in respond to oxidative stress or HNE can also activate different 
mitogen activated proteins kinases (namely JNKs and  ERK family MAP kinases, Uschida et 
al. 1999). 
In studying the effect of Ang II and HNE on the cellular proliferation (HOS) we observed 
stimulation of cellular growth (DNA synthesis) in dose dependent concentrations. This might 
be due to the fact that HNE modulates the effect of Ang II or that  Ang II adds to the already 
noted bifunctional-growth regulating effect of HNE on osteoblast-like cells. 
To investigate the influence of Ang II and HNE on the cellular differentiation we analyzed the 
alkaline phosphatase activity  (ALP). In certain concentrations HNE (10µM) and Ang II (0.1 
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and 0.5nM) increased the activity of ALP  while in concentrations of HNE (1µM  or 2.5µM) 
and Ang II (0.1nM) no such effect was noted.  
The results of apoptosis induction showed that both HNE and AngII expressed the 
concentration dependent results. While in certain concentrations the decrease of apoptosis 
cells was noted in others no such effect was observed.  Results of the effect of the HNE on the 
apoptosis in concentrations of 10µM are in concordance with the previous observed HNE 
effect on osteoblast like cells (increased percentage of apoptotic cells). 
The observed bimodal effect of HNE on cellular growth is in concordance with previous 
reports suggesting that in cells exists a very narrow window of physiological levels of HNE. 
Alterations of those levels could strongly change the HNE effect on cell cycle. When 
intracellular HNE levels exceed its physiological range, programmed cell death (apoptosis) is 
triggered. On the contrary cellular proliferation is stimulated when HNE levels drop bellow 
the normal physiological range (Awasthi et al. 2004). The mechanisms through HNE affects 
signaling processes in dose-dependent manner still need to be investigated.  HNE is a strong 
electrophile and as such it reacts with nucleophilic groups of proteins, nucleic acid and lipids. 
It is possible that at low concentrations HNE selectively  affects pathways in favor for cellular 
proliferation by  interacting with nucleophilic groups having high affinity for HNE. At higher 
concentrations HNE could react with low affinity groups of cellular nucleophils thus 
triggering the cellular apoptosis (Awasthi et al. 2004). 
Gluthatione S-transferases (GSTs) can modulate the intracellular concentrations of HNE by 
affecting its generation during lipid peroxidation by reducing hydroperoxides and also by 
converting it into gluthatione (GSH) conjugate (GS-HNE). Previously it was observed that 
otosclerotic cells produce bone matrix glyocosaminoglycans (GAG) with higher level of 
sulfatation (Bodo et al. 1997). Moreover otosclerotic cells express higher activity of the 
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diastrophic dysplasia sulphate transporter (DTDST). Study of Imauchi et al. (2006) showed 
that Ang II in otosclerotic cells stimulate the over expression of IL6 that has stimulatory effect 
on DTDST. This activity could be inhibited with the NaF (Bozorg Grayeli et  al., 2003) and 
Dexamethason (Imauchi et al., 2006).
Regarding our results of the observed interaction between Ang II and HNE  on the cellular 
proliferation, differentiation and apoptosis and with respect to the influence of both on the 
sulfatation of matrix proteins further studies are needed on possible interactions of HNE and 
Ang II and the role of GST in the regulation of these processes. Possible interaction of HNE 
and ANG II on cellular proliferation, differentiation and apoptosis is explained in Figure 6. 
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Figure 6- Possible interaction of HNE and Ang II on cellular proliferation, differentiation 
and apoptosis and necrosis. Ang II interacts with already observed bifunctional growth 
regulating HNE effect in a dose-dependent manner. Higher Ang II concentration (1 nM) 
multiplies the negative effect of supra-physiological concentrations of HNE (5 and 10 µM) on 
cell proliferation, differentiation and stimulates cell apoptosis and necrosis. The best example 
is 10 µM HNE that, as itself, decreases cell proliferation and induces differentiation, 
apoptosis and necrosis whereas in combination with 1 nM Ang II completely directs towards 
necrosis. On the other hand, the physiological concentrations of HNE (1 µM and 2.5 µM) are 
more likely interacting with lower concentration of Ang II (0.1 nM) indicating completely 
opposite effect mostly directed to cell proliferation, and reduction of cell differentiation, 
apoptosis and necrosis.
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In conclusion we showed that there is an interaction between Ang II and oxidative stress on 
the cellular proliferation, differentiation and apoptosis of osteoblast-like cells. The diffuse 
immunostaining of HNE in the otosclerotic stapes indicates the possible role of oxidative 
stress in the otosclerosis.  This phenomenon can explain the differences between normal and 
otosclerotic stapes in terms of response to Ang II. However, further studies on the interaction 
of Ang II and oxidative stress are needed in order to clarify  their role in the pathophysiology 
of the disease.   
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V. PERSPECTIVES 
Ang II and oxidative stress interaction has to be further studied in otosclerosis to clarify their 
role in the pathophysiology of the disease and eventually offer new therapeutic targets. 
1. Angiotensin II and otosclerosis 
Because the vasculature plays an important role in bone remodeling, the effect of renin-
angiotensin system has been largely  studied in this regard. Ang II has been postulated to be 
able to act  on the cells involved in bone metabolism through receptors located in osteoblasts 
and osteoclasts. Ang II inhibited differentiation and bone formation via AT1 receptor in an 
animal model. Moreover AT2 receptor blockade increased bone mass in animal model and in 
addition AT2 receptor knock-out mice revealed also an increase in bone mass. The essential 
signaling pathway for normal osteoclastogenesis is that of RANK-RANKL-OPG system. 
Disruption of this system leads to numerous bone diseases. Osteoblasts express RANKL 
while osteoclasts express RANK that recognize RANKL  through cell-to cell interaction and 
differentiate into mature osteoclasts. Osteoprotegerin (OPG) binds to the RANKL and 
prevents it from binding to RANK. Thus RANKL/OPG ratio is an important regulatory factor 
of bone mass and skeletal integrity. 
Ang II increases RANKL expression in osteoblasts, while the angiotensin receptor blockade 
promotes osteoclastogenesis through down-regulation of RANKL expression. 
The histopathological and pathophysiological findings in osteoprotegerin (OPG) knockout 
mice support the hypothesis that OPG is important in the inhibition of bone remodeling within 
the otic capsule and the maintenance of the normal auditory  function. These mice demonstrate 
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abnormal remodeling of bone within the otic capsule and might be considered in the future  as 
a valuable animal model of human otosclerosis. 
In an animal model of osteoporosis (an otosclerosis like lesion) it  has been shown that 
blocking of the synthesis of Ang II resulted in exacerbation of the low bone mass phenotype. 
Thus, blocking the synthesis of Ang II could be an effective treatment of osteoporosis. Similar 
studies could be done in otosclerosis in order to offer new therapeutical pathways of the 
disease. 
As observed in the present study, Ang II is implicated in inflammation and bone-turnover 
regulation in otosclerosis via different growth factors and cytokines (i.e. IFN-gamma, IL-10, 
TIMP-2). Moreover, gene array analysis showed that Ang II modulated the secretion of 
different pro-inflammatory genes in otosclerotic stapes (i.e. down-regulation of BCL-6 and 
CCL25). The results support  the hypothesis of Ang II implication in inflammation during the 
active phase of otosclerosis, but the exact signaling pathway still remains to be analyzed. 
Future studies need to be more  focused on investigation of the exact signaling pathway on 
how Ang II activates  different  pro-inflammatory  genes particularly the BCL-6. Moreover the 
effect of specific Ang II receptor 1 and 2 antagonists on cytokine production in basal 
condition and upon Ang II stimulation in primary otosclerotic cultures should be evaluated.  
Finally, whether the use of different anti-inflammatory (corticosteroids) and antioxidants 
(gluthation) agents could reduce the oxidative stress and thus the Ang II effect remains to be 
further analyzed. 
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2. Oxidative stress and Angiotensin II
 
As previously discussed, ROS are involved in multiple physiological responses to Ang II. 
Long-term response to Ang II require some level of oxidative stress, and many proteins and 
enzymes that serve as a signal transducers of Ang II are modified by ROS. Furthermore, many 
responses to Ang II share common signaling pathways, and future work should be focused on 
identifying which of these biochemical cascades are redox sensitive. 
So far, studies on the  redox-sensitivity  of Ang II signaling have shown that   Ang II activates 
many enzymes including phospholipase D, phospholipase A2, FAK, Fyn, janus kinase 2 
(JAK2), STAT1 and ras, whose modulation by ROS is unknown,. For some of these proteins 
(JAK2, STAT) potential redox-sensitivity has been demonstrated using exogenous ROS. 
Others (such as Akt and MAP kinase) have still not been studied but their clear relationship 
with ROS suggests that they  are potentially among the protein that mediate redox-sensitive 
physiological response to Ang II. 
Recently, it  has been shown that an isomer (4-ONO) of the so called second messenger of the 
ROS (4-hydroxynonenal, HNE) was formed in the endothelial cell subject to oxidative stress. 
This aldehyde can cause different modifications to the Ang II. Studies are now focused on the 
development of methodology of quantification of 4-ONO derived pyruvamide Ang II in 
biological fluids in order to better understand the influence that lipid peroxidation product 
could have on the role of Ang II in the pathophysiology of different diseases. 
Although the role of ROS in mediating physiological responses to Ang II is currently under 
intense study, much remains to be learned concerning the signaling pathways and genes that 
are regulated by ROS. Animal studies have confirmed that this signal transduction system is 
important in vivo, but the dysregulation of ROS during disease like otosclerosis requires 
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further study. Furthermore, ROS have also been involved in cochlear damage in different 
inner ear pathologies. It is important to identify  the possible source of cochlear ROS 
production and the pathways of ROS-mediated cochlear damage.
Further in vitro studies should be focused on investigating the presence of ROS in otosclerotic 
and control culture media. Furthermore the effect of antioxidants on proliferation, 
differentiation and apoptosis of otosclerotic cell cultures should be determined.
Clinical studies should be focused on evaluating the presence of ROS in stapedial samples 
(control and otosclerotic ones) as a possible prognostic factor for disease activity. Moreover 
measurement of the ROS presence in perilymph samples could be compared with the degree 
of hearing loss in otosclerosis. 
Finally future studies should be focused on developing new approaches for prevention and 
treatment of oxidative stress caused inner ear pathologies (i.e. antioxidant therapy, 
interruption of the lipid peroxidation process, prevention of cochlear ischemia).  
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